documents incorporated reference specified portions registrant 's proxy statement filed commission pursuant regulation connection registrant 's annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrant 's common stock held executive officers directors stockholders whose ownership exceeds registrant 's common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrantgilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures part ii item market registrant 's common equity related stockholder matters issuer purchases equity securities item selected financial data item management 's discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences stribild complera eviplera truvada viread emtriva tybost sovaldi hepsera vitekta letairis ranexa cayston ambisome vistide volibris rapiscan atripla registered trademark belonging bristolmyers squibb gilead sciences llc lexiscan registered trademark belonging astellas us llc macugen registered trademark belonging eyetech inc sustiva registered trademark bristolmyers squibb pharma company tamiflu registered trademark belonging hoffmannla roche inc report also includes trademarks service marks trade names companiesthis annual report including section entitled management 's discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project hope intend plan believe seek estimate continue may could might variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forward looking statements including statements regarding overall trends operating cost revenue trends liquidity capital needs statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forwardlooking statements various reasons including identified risk factors beginning given risks uncertainties cautioned place undue reliance forward looking statements forwardlooking statements included report made date hereof except required federal securities laws rules regulations securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forwardlooking statements distribution report whether result new information future events changes assumptions otherwise part item business overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery experimental drug candidate strive transform simplify care people lifethreatening illnesses around world gilead 's primary areas focus include human immunodeficiency virus hiv liver diseases chronic hepatitis b virus hbv infection chronic hepatitis c virus hcv infection oncologyinflammation serious cardiovascular respiratory conditions headquartered foster city california operations north south america europe asiapacific continue add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategy highlights past year executed strategy bring bestinclass drugs market liver diseases area received approval us food drug administration fda new drug application nda sovaldi sofosbuvir mg sovaldi oncedaily oral nucleotide analog polymerase inhibitor treatment hcv infection component combination antiviral treatment regimen approval sovaldi represents significant improvement treatment paradigm patients hcv shortened duration treatment reduced completely eliminated need pegylated interferon pegifn injections certain viral genotype populations hiv area expanded single tablet regimen product offerings treatment hiv european launch stribild elvitegravir mgcobicistat mgemtricitabine mgtenofovir disoproxil fumarate mg combines four medicines oncedaily single tablet regimen also received approval tybost cobicistat vitekta elvitegravir mg mg component stribild european commission oncologyinflammation area filed fda european medicines agency ema marketing approval idelalisib formerly gs investigational targeted oral inhibitor pik delta treatment patients refractory indolent nonhodgkins lymphoma inhl relapsed chronic lymphocytic leukemia cll also continued advanced research development pipeline active clinical studies end phase clinical trials hiv program substantial portion revenues derived eight marketed hiv products continued forefront advancing hiv treatment development new single tablet regimens longterm goal ensure hiv patients option choose single tablet regimen right single tablet regimens allow patients adhere fully suppressive course therapy easily consistently critical successful management disease continue focus development new hiv medicines coformulations launch stribild united states europe compleraeviplera emtricitabine mgrilpivirine mgtenofovir disoproxil fumarate mg atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg three single tablet regimens available december received fda ema approval compleraeviplera used certain adult patients switching another stable antiretroviral regimen compleraeviplera first approved united states europe patients new antiretroviral therapy september received ema approval tybost pharmacokinetic enhancer boosts blood levels certain hiv medicines tybost indicated boosting agent hiv protease inhibitors atazanavir mg daily darunavir mg daily part antiretroviral combination therapy adults hiv infection approval allows marketing tybost countries european union november ema approved vitekta integrase inhibitor treatment hiv infection adults without known mutations associated resistance elvitegravir active ingredient vitekta vitekta indicated use part hiv treatment regimens include ritonavirboosted protease inhibitor also made important progress clinical development tenofovir alafenamide taf formerly known gs phase study showed taf efficacious fraction dose viread tenofovir disoproxil fumarate mg provides potential safety advantages based results commenced phase trial evaluating single tablet regimen taf elvitegravir cobicistat emtricitabine treatment hiv infection treatmentnave adults agreement janssen rd ireland janssen formerly tibotec pharmaceuticals also conducting phase trials evaluating single tablet regimen taf cobicistat darunavir emtricitabine treatment hiv infection first quarter completed enrollment two phase clinical trials comparing tafbased regimen stribild patients new hiv treatment data studies available first quarter liver diseases hcv therapeutic market continues vastly underserved due limitations available therapies small fraction individuals infected hcv diagnosed even smaller fraction patients treated prior may first protease inhibitors approved half patients responded current standard care involves weeks therapy pegifnribavirin rbv containing regimen addition protease inhibitors standard care resulted incremental response rates patients genotype infection however regimen causes substantial side effects fatigue bone marrow suppression potentially debilitating rash anemia neuropsychiatric effects discontinuation rates triple therapy combinations significant acquisition pharmasset inc pharmasset acquired sofosbuvir nucleotide analog acts inhibit replication hcv december received fda approval sofosbuvir brand name sovaldi treatment hcv component combination antiviral treatment regimen january received european commission approval sovaldi treatment hcv sovaldis efficacy established patients hcv genotypes infection united states europe genotypes infection europe including hepatocellular carcinoma meeting milan criteria awaiting liver transplantation hcvhiv coinfection us recommended regimens treatment duration sovaldi combination therapy hcv monoinfected hcvhiv coinfected patients follows treatment duration genotype sovaldi pegifn rbv weeks genotype sovaldi rbv weeks genotype sovaldi rbv weeks hepatocellular carcinoma awaiting liver transplantation sovaldi rbv weeks liver transplant noted table compared current standard care weeks sovaldi shortened duration treatment little weeks reduced completely eliminated need pegifn injections certain viral genotype populations second generation therapy treatment hcv advancing fixeddose combination ledipasvirsofosbuvir ldvsof treatment genotype patients nda fixeddose combination ldvsof supported three clinical trials filed february first study named ion evaluates fixeddose combination ldvsof without rbv either weeks treatmentnave genotype hcvinfected patients second phase study named ion evaluates fixeddose combination rbv weeks without rbv weeks therapy among treatment experienced genotype hcvinfected patients third study named ion evaluates fixeddose combination ldvsof without rbv eight weeks without rbv weeks noncirrhotic treatmentnave genotype hcvinfected patients japan fully enrolled phase study evaluating sofosbuvir genotype hcvinfected patients expect file regulatory approval sofosbuvir japan mid also completed enrollment phase studies evaluating fixeddose combination ldvsof genotype infected hcv patients sofosbuvir rbv genotype infected hcv patients based results phase studies plan file regulatory approval fixeddose combination ldvsof japan fourth quarter long term goal develop oral pangenotypic oral therapy hcv patients across genotypes fixeddose combination sofosbuvir gs nucleotide nsb inhibitorpangenotypic nsa inhibitor currently phase clinical trials oncologyinflammation last five years worked advance oncology franchise idelalisib pik delta inhibitor antibody formerly known gs evaluated treatment inhl cll september filed nda idelalisib treatment patients inhl refractory non responsive rituximab alkylatingagentcontaining chemotherapy fda set target review date prescription drug user fee act pdufa september december also filed nda idelalisib relapsed cll february fda previously granted breakthrough therapy designation idelalisib cll accepted nda set target review date august pdufa november marketing authorization application idelalisib inhl cll validated ema acquisition ym biosciences inc acquired momelotinib gs formerly known cyt jak inhibitor evaluated treatment myelofibrosis also advanced momelotinib phase trials products hiv stribild oral formulation dosed day treatment hiv infection treatmentnaive adults stribild third complete single regimen treatment hiv fixeddose combination antiretroviral medications vitekta tybost viread emtriva emtricitabine stribild approved fda august ema may compleraeviplera oral formulation dosed day treatment hiv infection adults product marketed united states complera europe eviplera second complete single tablet regimen treatment hiv fixeddose combination antiretroviral medications viread emtriva janssen 's nonnucleoside reverse transcriptase inhibitor edurant rilpivirine atripla oral formulation dosed day treatment hiv infection adults atripla first oncedaily single tablet regimen hiv intended standalone therapy combination antiretrovirals fixeddose combination antiretroviral medications viread emtriva bristol myerssquibb company 's bms nonnucleoside reverse transcriptase inhibitor sustiva efavirenz truvada emtricitabine tenofovir disoproxil fumarate oral formulation dosed day part combination therapy treat hiv infection adults fixeddose combination antiretroviral medications viread emtriva fda also approved truvada combination safer sex practices reduce risk sexually acquired hiv infection adults high risk strategy called preexposure prophylaxis prep viread oral formulation nucleotide analog reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection patients two years age older european commission also approved use viread combination antiretroviral agents treatment hiv infected pediatric patients aged two less years nucleoside reverse transcriptase inhibitor resistance toxicities precluding use first line pediatric agents viread also approved treatment chronic hbv adults emtriva oral formulation nucleoside analog reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults united states europe emtriva also available oral solution approved part combination therapy treat hiv infection children tybost pharmacokinetic enhancer dosed day boosts blood levels certain hiv medicines tybost indicated boosting agent hiv protease inhibitors atazanavir darunavir part antiretroviral combination therapy adults hiv infection received marketing approval tybost countries european union vitekta oral formulation integrase inhibitor dosed day part combination therapy treat hiv infection adults without known mutations associated resistance elvitegravir active ingredient vitekta vitekta indicated use part hiv treatment regimens include ritonavirboosted protease inhibitor received marketing approval vitekta countries european union liver diseases sovaldi oral formulation nucleotide analog polymerase inhibitor dosed day treatment hcv component combination antiviral treatment regimen sovaldi approved fda december european commission january sovaldis efficacy established patients hcv genotypes infection united states europe genotypes infection europe including hepatocellular carcinoma meeting milan criteria awaiting liver transplantation hcvhiv coinfection viread oral formulation nucleotide analog reverse transcriptase inhibitor dosed day treatment chronic hbv adults compensated decompensated liver disease licensed glaxosmithkline inc gsk rights commercialize viread treatment chronic hbv china japan saudi arabia ema approved use viread treatment chronic hbv infection adolescent patients aged less years compensated liver disease evidence immune active disease viread also approved treatment hiv infection patients two years age older combination antiretroviral agents hepsera adefovir dipivoxil oral formulation nucleotide analog polymerase inhibitor dosed day treat chronic hbv patients years age older licensed gsk rights commercialize hepsera treatment chronic hbv asia pacific latin america certain territories cardiovascular letairis ambrisentan oral formulation endothelin receptor antagonist era indicated treatment pulmonary arterial hypertension pah group patients class ii iii symptoms improve exercise capacity delay clinical worsening sublicensed gsk rights ambrisentan marketed gsk volibris ambrisentan pah territories outside united states ranexa ranolazine extendedrelease tablet treatment chronic angina licensed menarini international operations luxembourg sa rights ranexa territories outside united states lexiscanrapiscan regadenoson injection indicated use pharmacologic stress agent radionuclide myocardial perfusion imaging mpi test detects characterizes coronary artery disease patients unable undergo adequate exercise stress astellas us llc astellas exclusive rights manufacture sell regadenoson name lexiscan united states subject obligations pay us royalties based sales lexiscan us rapidscan pharma solutions inc rps holds exclusive right manufacture sell regadenoson name rapiscan europe certain territories outside united states receive royalties astellas rps sales territories respiratory cayston aztreonam inhalation solution inhaled antibiotic treatment respiratory systems cystic fibrosis cf patients seven years age older pseudomonas aeruginosa p aeruginosa tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu approved treatment influenza children adults countries including united states japan european union tamiflu also approved prevention influenza children adults united states japan european union developed tamiflu f hoffmannla roche ltd together hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us royalties based percentage net sales tamiflu ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat serious invasive fungal infections caused various fungal species adults corporate partner astellas pharma us inc promotes sells ambisome united states canada promote sell ambisome europe australia new zealand vistide cidofovir injection antiviral injection treatment cytomegalovirus retinitis adult patients aids macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelated macular degeneration macugen developed eyetech inc eyetech using technology licensed us promoted united states valeant pharmaceuticals inc valeant acquired eyetech valeant holds exclusive rights manufacture sell macugen united states pfizer inc pfizer holds exclusive right manufacture sell macugen rest world receive royalties valeant pfizer based worldwide sales macugen sales antiviral products include products hiv liver diseases areas described billion billion billion represented total revenues total revenues sales products billion billion million represented total revenues see item management 's discussion analysis included annual report information regarding revenues commercialization distribution us international commercial sales operations marketing subsidiaries australia austria belgium brazil canada czech republic denmark finland france germany greece hong kong ireland italy japan netherlands new zealand norway poland portugal russia south korea spain sweden singapore switzerland turkey united kingdom united states products marketed commercial teams andor conjunction thirdparty distributors corporate partners commercial teams promote products direct field contact physicians hospitals clinics healthcare providers generally grant thirdparty distributors exclusive right promote product territory specified period time agreements distributors provide collaborative efforts distributor gilead obtaining maintaining regulatory approval product specified territory sell distribute stribild complera atripla truvada viread hepsera emtriva ranexa sovaldi vistide united states exclusively wholesale channel product sales three large wholesalers cardinal health inc mckesson corp amerisourcebergen corp accounted total revenues years ended december combined basis wholesalers accounted approximately product sales united states approximately total worldwide revenues letairis cayston distributed exclusively specialty pharmacies specialty pharmacies dispense medications complex chronic conditions require high level patient education ongoing counseling sell distribute stribild eviplera atripla truvada sovaldi viread hepsera emtriva vitekta tybost ambisome europe countries outside united states product approved either commercial teams thirdparty distributors corporate partners us patient access make priority increase access medicines people benefit regardless ability pay united states us patient assistance programs help make therapies accessible uninsured individuals need financial assistance also support programs unable afford copayments associated health insurance programs half patients taking hiv medicines united states already receive federal state programs substantially discounted prices long history working state aids drug assistance programs adaps provide lower pricing hiv medicines price freeze instituted adaps extended end providing important support critical programs evolve changing united states healthcare environment access developing world gilead access program established certain products treatment hiv chronic hbv visceral leishmaniasis available substantially reduced prices developing world gilead delivers medicines countries working regional business partners distribute brandname viread truvada prices based country 's ability pay represent little profit gilead also partnerships india based companies expand access generic versions hiv medications leastdeveloped countries world see work closely world health organization nongovernmental organizations provide ambisome treatment leishmaniasis preferential price resource limited settings support numerous clinical studies investigating role ambisome treat visceral cutaneous leishmaniasis developing countries collaborations organizations drugs neglected diseases initiative mdecins sans frontires also support clinical research studies aimed identifying best treatment course visceral leishmaniasis donated ambisome support clinical studies assessing combination therapies costeffectiveness multiple visceral leishmaniasis treatment interventions december signed partnership agreement world health organization donate vials ambisome five years donation used treat patients resourcelimited countries also support many clinical studies donation products help define best treatment strategies developing world countries example donated tenofovir centre aids programme research south africa caprisa microbicide trial assessed effectiveness safety tenofovirbased microbicide gel prevention hiv infection south african women also provide drugs number innovative international studies investigating whether viread truvada prevent hiv transmission among atrisk uninfected adults hiv prevention strategy called prep fda approval prep truvada became first agent indicated uninfected individuals reduce risk acquiring hiv sex also entered number collaborations related access products developing world include pharmachem technologies grand bahama ltd pharmachem pharmachem one commercial manufacturing partners established facility bahamas manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread one active pharmaceutical ingredients atripla truvada resource limited countries cooperative effort pharmachem grand bahama port authority aspen pharmacare holdings ltd aspen entered nonexclusive manufacturing distribution agreement aspen providing manufacture distribution viread truvada treatment hiv infection certain developing world countries included gilead access program amended agreement aspen amended agreement aspen retained right manufacture distribute viread truvada treatment hiv infection developing world countries aspen right purchase viread truvada unlabeled bottles us distribution countries also right manufacture viread truvada using active pharmaceutical ingredient purchased aspen suppliers approved us aspen also granted right manufacture distribute generic versions emtricitabine tenofovir disoproxil fumarate including versions tenofovir disoproxil fumarate combination emtricitabine treatment hiv infection aspen required pay us royalties net sales viread truvada well royalties net sales generic versions tenofovir disoproxil fumarate including versions tenofovir disoproxil fumarate combination generic versions emtricitabine manufactured distributed aspen licenses generic manufacturers entered nonexclusive license agreements indian generic manufacturers granting rights produce distribute generic versions tenofovir disoproxil fumarate treatment hiv infection low income countries around world includes india many low income countries gilead access program agreements require generic manufacturers meet certain national international regulatory quality standards include technology transfers enable expeditious production large volumes high quality generic versions tenofovir disoproxil fumarate addition agreements allow manufacture commercial quantities active pharmaceutical ingredient finished product expanded nonexclusive license agreements increase number countries included license also include rights cobicistat elvitegravir including generic versions combination product containing four active ingredients cobicistat elvitegravir tenofovir disoproxil fumarate emtricitabine also included nonexclusive license agreements ability manufacture distribute generic versions tenofovir disoproxil fumarate treatment hbv countries authorized sell generic versions tenofovir disoproxil fumarate hiv august announced new collaborations indian partners produce distribute generic emtricitabine developing world including single tablet regimens containing emtricitabine fixeddose combinations emtricitabine coformulated gilead hiv medicines merck co inc merck entered agreement affiliate merck pursuant gilead merck provide atripla substantially reduced prices hiv infected patients developing countries africa caribbean latin america southeast asia agreement manufacture atripla using efavirenz supplied merck merck handles distribution product countries covered agreement also entered agreement merck commercialize atripla lowmiddle income countries including brazil egypt mexico international partnership microbicides ipm conrad entered agreement granted rights ipm conrad cooperating agency us agency international development committed improving reproductive health expanding contraceptive choices women men develop manufacture proven efficacious arrange distribution resource limited countries certain formulations tenofovir use topical microbicide prevent hiv infection medicines patent pool pool entered agreement pool organization established united nations increase global access highquality lowcost antiretroviral therapy sharing patents granted pool nonexclusive license identify generic pharmaceutical manufacturers india specialize highquality production generic medicines granted sublicenses indian manufacturers manufacture distribute generic versions antiretrovirals developing world sublicensees pool free develop combination products pediatric formulations hiv medicines also granted pool right grant sublicenses generic versions single tablet regimen consisting elvitegravir cobicistat tenofovir disoproxil fumarate emtricitabine product candidates elvitegravir cobicistat generic pharmaceutical manufacturers india distribution developing world janssen expanded agreement janssen provide distribution compleraeviplera treatment hiv less developed countries enable commercialization generic versions product competition marketed products target number areas including viral cardiovascular respiratory fungal diseases many commercially available products treatment diseases many companies institutions making substantial investments developing additional products treat diseases products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv products hiv landscape becoming competitive complex treatment trends continue evolve growing number hiv drugs currently sold advanced stages clinical development competition current expected competitors may erode revenues receive sales hiv products branded hiv drugs available united states products primarily compete fixeddose combination products nucleotidenucleoside reverse transcriptase inhibitors nrti class including combivir lamivudinezidovudine epzicomkivexa abacavirlamivudine trizivir abacavirlamivudinezidovudine sold joint venture viiv healthcare viiv established gsk pfizer focused hiv therapies products compete stribild compleraeviplera atripla truvada tybost compete ritonavir marketed abbvie inc abbvie hiv products also compete broadly hiv products abbvie boehringer ingelheim gmbh merck roche janssen addition tivicay dolutegravir integrase inhibitor launched fourth quarter viiv could adversely impact sales hiv products also face competition generic hiv products bms 's videx ec didanosine ddi became first generic hiv product united states gsk 's retrovir zidovudine faces competition united states result launch generic zidovudine bms 's zerit stavudine faces competition united states result launch generic stavudine epivir lamivudine marketed viiv competitive emtricitabine active pharmaceutical ingredient emtriva component atripla truvada compleraeviplera stribild may compound patent covering epivir lamivudine expired united states generic lamivudine available united states spain portugal italy expect generic versions lamivudine launched countries within european union may generic version combivir lamivudine zidovudine approved recently launched united states addition late generic tenofovir also became available turkey resulted increase rebate viread turkey generic efavirenz active pharmaceutical ingredient sustiva component atripla available canada europe expect competition generic efavirenz united states may put pricing pressure hiv products liver diseases products hcv product sovaldi competes janssen 's olysio simeprevir united states lesser extent directacting antivirals victrelis boceprevir marketed merck incivek telaprevir marketed vertex pharmaceuticals incorporated hbv products viread hepsera face significant competition existing expected therapies treating patients hbv may erode revenues receive sales hbv products hbv products face competition baraclude entecavir oral nucleoside analog developed bms launched united states europe tyzekasebivo telbivudine oral nucleoside analog developed novartis pharmaceuticals corporation novartis sale united states european union china hbv products also compete epivirhbvzeffix lamivudine developed gsk collaboration shire plc sold major countries throughout north south america europe asia viread hepsera treatment hbv also compete established immunomodulatory therapies including introna interferon alfab sold merck major countries throughout north south america europe asia pegasys pegylated interferon alfaa injectable drug similar introna sold roche treatment hbv cardiovascular products letairis competes directly tracleer bosentan opsumit macitentan drugs sold actelion pharmaceuticals us inc letairis also competes adcirca tadalafil united therapeutics corporation ranexa competes predominantly generic compounds three distinct classes drugs treatment chronic angina united states including generic andor branded betablockers calcium channel blockers longacting nitrates addition surgical treatments interventions coronary artery bypass grafting percutaneous coronary intervention another option angina patients may perceived healthcare practitioners preferred methods treat cardiovascular disease underlies causes angina numerous marketed generic andor branded pharmacologic stress agents compete lexiscanrapiscan respiratory products cayston competes primarily tobi tobramycin inhalation solution inhaled medication sold novartis treatment cf patients whose lungs contain p aeruginosa bacterial infection tamiflu competes relenza zanamivir antiinfluenza drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder generic competitors include amantadine rimantadine oral tablets inhibit replication influenza virus biocryst pharmaceuticals inc developing injectable formulations peramivir influenza neuraminidase inhibitor treatment influenza currently approved japan south korea products ambisome faces strong competition several current expected competitors ambisome faces competition vfend voriconazole developed pfizer caspofungin product developed merck marketed cancidas united states caspofungin elsewhere ambisome also competes lipidbased amphotericin b products including abelcet amphotericin b lipid complex injection sold enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sold three rivers pharmaceuticals llc worldwide anfogen amphotericin b liposomal sold genpharma sa argentina bms numerous generic manufacturers sell conventional amphotericin b also competes ambisome aware least three lipid formulations claim similarity ambisome becoming available outside united states including possible entry formulations taiwan formulations may reduce market demand ambisome manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association vistide competes number drugs also treat cytomegalovirus retinitis including cytovene iv cytovene ganciclovir sold intravenous oral formulations respectively roche ocular implant bausch lomb incorporated valcyte valganciclovir also marketed roche foscavir foscarnet intravenous drug sold astrazeneca plc generic fomivirsen macugen competes primarily visudyne verteporfin injection sold novartis used connection photodynamic therapy lucentis ranibizumab sold genentech inc united states novartis territories outside united states number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs collaborative relationships part business strategy establish collaborations companies universities medical research institutions assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring products rights products technologies complementary business companies universities medical research institutions information regarding certain relationships including ongoing financial accounting impact business see item note collaborative arrangements consolidated financial statements included annual report commercial collaborations although currently number collaborations corporate partners manufacture sale distribution andor marketing products various territories worldwide following commercial collaborations significant us financial statement perspective significant ongoing collaboration activity exists bms entered collaboration arrangement bms develop commercialize single tablet regimen truvada bms 's sustiva efavirenz united states combination approved use united states sold brand name atripla bms structured collaboration joint venture operates limited liability company named bristolmyers squibb gilead sciences llc consolidate bms granted royaltyfree sublicenses joint venture use respective company owned technologies return granted license joint venture use intellectual property results collaboration bms amended joint venture 's collaboration agreement allow joint venture sell atripla canadathe economic interests joint venture held us bms including share revenues outofpocket expenses based portion net selling price atripla attributable efavirenz truvada since net selling price truvada may change time relative net selling price efavirenz bms 's respective economic interests joint venture may vary annually starting except limited number activities jointly managed parties longer coordinate detailing promotional activities united states parties reduced joint promotional efforts since launched complera august stribild august agreement continue terminated mutual agreement parties addition either party may terminate party 's participation collaboration within days launch least one generic version party 's single agent products double agent products terminating party right continue sell atripla become continuing party obligated pay terminated party certain royalties threeyear period following effective date termination gilead sciences limited whollyowned subsidiary ireland bms entered collaboration agreement bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory parties formed limited liability company consolidate manufacture atripla distribution european territory using efavirenz purchases bms bms 's estimated net selling price efavirenz european territory starting except limited number activities jointly managed parties longer coordinate detailing promotional activities region december efavirenz purchased bms bms 's estimated net selling price efavirenz european territory included inventories consolidated balance sheets agreement terminate upon expiration lasttoexpire patent affords market exclusivity atripla one components european territory addition either party may terminate agreement reason termination effective two calendar quarters notice termination nonterminating party right continue sell atripla become continuing party obligated pay terminating party certain royalties threeyear period following effective date termination event continuing party decides sell atripla effective date termination date atripla withdrawn country date third party assumes distribution atripla whichever earlier janssen entered collaboration agreement janssen develop commercialize fixeddose combination truvada janssen 's rilpivirine combination approved united states european union sold brand name complera united states eviplera european union agreement janssen granted us exclusive license compleraeviplera worldwide excluding certain middle income developing world countries japan neither party restricted combining drugs drug products recorded million approximately million reimbursable research development rd expenses incurred janssen development rilpivirine december maximum amount reimbursable terms agreement responsible manufacturing compleraeviplera lead role registration distribution commercialization product licensed countries janssen exercised right codetail combination product countries gilead selling party amended collaboration agreement include distribution compleraeviplera rest world right distribute product north america europe latin america except mexico australia new zealand janssen right distribute product regions including japan russia price product expected sum price truvada price rilpivirine purchased separately cost rilpivirine purchased us janssen compleraeviplera approximately market price rilpivirine less specified percentage major markets either party may terminate collaboration agreement compleraeviplera withdrawn market party materially breaches agreement may terminate agreement united states canada expiration last expire patent tenofovir disoproxil fumarate united states may terminate agreement country expiration last expire patent tenofovir disoproxil fumarate country european union janssen may terminate agreement united states canada expiration last expire patent rilpivirine united states may terminate agreement country expiration last expire patent rilpivirine country european union japan tobacco entered licensing agreement japan tobacco japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco would retain rights agreement responsible seeking regulatory approval territories required use diligent efforts commercialize elvitegravir treatment hiv infection bear costs expenses associated commercialization efforts terms agreement paid upfront license fee million obligated make total potential milestone payments million upon achievement certain clinical regulatory commercial objectives additionally obligated pay royalties based net sales territories market product december made total milestone payments million agreement obligation pay royalties japan tobacco terminate productbyproduct basis patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement reason case license granted japan tobacco us would terminate either party may terminate agreement response material breach party research collaborations also number collaborations partners rd certain compounds drug candidates none research collaborations rose level significant us financial statement perspective significant ongoing collaboration activity exists research development rd philosophy strategy develop bestinclass drugs improve safety efficacy unmet medical needs intend continue committing significant resources rd opportunities business development activity product development efforts cover wide range medical conditions including hivaids liver diseases hbv hcv inflammationoncology serious cardiovascular respiratory conditions research scientists foster city fremont san dimas oceanside california branford connecticut seattle washington alberta canada engaged discovery development new molecules technologies hope lead approval new medicines addressing unmet needs development product candidates subject various risks uncertainties risks uncertainties include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain regulatory approvals result product candidates may never successfully commercialized drug development inherently risky many product candidates fail drug development process summary key product candidates corresponding current stages development additional information development pipeline visit website wwwgileadcom product candidates treatment hiv product candidates description marketing application pending cobicistat cobicistat pharmacokinetic enhancer dosed day boosts blood levels certain hiv medicines approved component stribild september european commission approved cobicistat marketed tybost stand alone boosting agent hiv protease inhibitors atazanavir darunavir part antiretroviral combination therapy adults hiv infection elvitegravir elvitegravir oral integrase inhibitor dosed day part combination therapy treat hiv infection adults approved component stribild november european commission approved elvitegravir marketed vitekta treatment hiv infection adults without known mutations associated resistance elvitegravir vitekta indicated use part hiv treatment regimens include ritonavirboosted protease inhibitor product phase single tablet regimen taf elvitegravir single tablet regimen taf nrti elvitegravir cobicistat emtricitabine evaluated cobicistat emtricitabine treatment hiv infection treatmentnave adults product phase single tablet regimen taf darunavir agreement janssen single tablet regimen taf darunavir cobicistat emtricitabine cobicistat emtricitabine evaluated treatment hiv infection product candidates treatment liver diseases product candidates description marketing application pending fixeddose combination fixeddose combination ledipasvir oral nsa inhibitor sofosbuvir taken without rbv ldvsof evaluation phase trials treatment hcv products phase taf taf nrti evaluation treatment hbv products phase fixeddose combination sofosbuvir gs fixeddose combination sofosbuvir gs nucleotide nsb inhibitorpangenotypic nsa inhibitor evaluated treatment hcv gs gs tarmogen cell immunity stimulator evaluation treatment hbv gs gs oral ns protease inhibitor evaluated treatment hcv gs gs nonnucleoside nsb site polymerase inhibitor evaluation treatment hcv simtuzumab gs simtuzumab monoclonal antibody evaluated treatment liver fibrosis nonalcoholic steatohepatitis primary sclerosing cholangitis products phase gs gs mmp mab inhibitor evaluated treatment ulcerative colitis gs gs oral tlr agonist evaluated treatment hbv hcv product candidates treatment oncologyinflammation product candidates description marketing application pending idelalisib idelalisib pik delta inhibitor antibody treatment inhl cll september submitted nda fda approval idelalisib treatment inhl fda set target review date pdufa september december submitted nda fda approval idelalisib treatment cll pdufa date filing august marketing authorization application idelalisib inhl cll validated ema november products phase momelotinib gscyt momelotinib gs formerly known cyt jak inhibitor evaluated treatment myelofibrosis products phase gs gs pik delta inhibitor evaluated potential treatment lymphoid malignancies gs gs spleen tyrosine kinase syk inhibitor evaluated hematological malignancies simtuzumab simtuzumab monoclonal antibody evaluated treatment myelofibrosis colorectal pancreatic cancer products phase gs gs mmp mab inhibitor evaluated treatment solid tumors product candidates treatment cardiovascular diseases product candidates description product phase ranolazine ranolazine late sodium current inhibitor approved treatment chronic angina evaluated treatment incomplete revascularization postpercutaneous coronary intervention treatment type ii diabetes product phase ranolazine ranolazine also evaluated treatment paroxysmal atrial fibrillation product phase gs gs ask inhibitor evaluated treatment diabetic nephropathy gs gs late sodium current inhibitor evaluated treatment lqt syndrome hypertrophic cardiomyopathy ventricular tachycardiaventricular fibrillation product candidates treatment respiratory diseases product candidates description product phase gs gs inhalable small molecule antiviral fusion inhibitor evaluated treatment respiratory syncytial virus simtuzumab simtuzumab monoclonal antibody evaluated treatment idiopathic pulmonary fibrosis total rd expenses billion compared billion billion addition internal discovery clinical development programs seek add portfolio products product acquisitions licenses collaborations following table shows recent acquisitions year company therapeutic area arresto biosciences inc fibrotic diseases cancer calistoga pharmaceuticals inc cancer inflammatory diseases pharmasset inc chronic hcv ym biosciences inc hematological immune cell disorders inflammatory diseases cancers largest transaction acquisition pharmasset billion pharmasset clinicalstage pharmaceutical company located princeton new jersey committed discovering developing commercializing novel drugs treat viral infections pharmasset 's primary focus development oral therapeutics treatment hcv infection received fda ema approval sovaldi sofosbuvir filed nda fixed dose combination ldvsof treatment hcvinfected patients february patents proprietary rights us european patent expiration number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows estimated expiration dates including patent term extension supplementary protection certificates andor pediatric exclusivity granted united states europe primary typically compound patents phase product candidates patents cover ranolazine compound active ingredient ranexa instead discovered sustained release formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve product candidates single tablet regimens estimated patent expiration date provided corresponds latest expiring compound patent one active ingredients single tablet regimen phase product candidates patent expiration product candidates treatment hiv us eu single tablet regimen taf elvitegravir cobicistat emtricitabine single tablet regimen taf emtricitabine product candidate treatment liver diseases single tablet regimen ldvsof treatment hcv single agent taf treatment hbv product candidate treatment oncologyinflammation idelalisib treatment cll inhl momelotinib treatment myelofibrosis product candidate treatment cardiovascular diseases ranolazine treatment incomplete revascularization postpercutaneous coronary intervention treatment type ii diabetes dates parentheses reflect estimated expiration date patents may issue currently pending applications estimated expiration dates include potential additional exclusivity eg patent term extension supplementary protection certificates pediatric exclusivity yet granted following table shows actual estimated expiration dates including patent term extension supplementary protection certificates andor pediatric exclusivity granted united states europe primary typically compound patents marketed products patents cover ranolazine compound active ingredient ranexa instead discovered sustained release formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve product single tablet regimens eg truvada atripla compleraeviplera stribild estimated patent expiration dates provided correspond latest expiring compound patent one active ingredients single tablet regimen products patent expiration us eu vistide hepsera ambisome macugen tamiflu letairis viread ranexa atripla cayston emtriva truvada lexiscan compleraeviplera vitekta sovaldi stribild tybost dates parentheses reflect estimated expiration date patents may issue currently pending applications estimated expiration dates include potential additional exclusivity eg patent term extension supplementary protection certificates pediatric exclusivity yet granted gilead teva pharmaceuticals teva reached agreement principle settle ongoing patent litigation concerning four patents protect tenofovir disoproxil fumarate viread truvada atripla products agreement teva allowed launch generic version viread december settlement agreement filed federal trade commission department justice required law gilead lupin limited lupin reached agreement settle patent litigation prior issuance courts decision agreement lupin would allowed launch generic version ranexa february settlement agreement filed federal trade commission department justice required law product yet approved us patent protection certain challenges patents proprietary rights important business properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy patents covering certain active pharmaceutical ingredients stribild compleraeviplera atripla truvada emtriva hepsera letairis vistide vitekta held third parties acquired exclusive rights patents agreements parties patents cover ranolazine compound active ingredient ranexa instead discovered sustainedrelease formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve patents cover active ingredients ambisome addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hbv indication hepsera developed may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions supplementary protection certificates countries example extensions patents supplementary protection certificates many products granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain countries also important infringe valid patents third parties infringe valid patents third parties may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware body patents may relate operation letairis education access program leap restricted distribution program designed support letairis patent applications confidential period time patent issued may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete products addition competitors file patent applications covering technology may participate interferencederivation proceedings litigation determine right patent litigation interferencederivation proceedings unpredictable expensive even ultimately successful results operations may adversely affected events patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation proceedings regarding enforcement validity existing patents future patents could result invalidation patents substantially reduce protection time time certain individuals entities may challenge patents pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products closely related developed developing addition certain countries africa asia including china provide effective enforcement patents thirdparty manufacturers able sell generic versions products countries litigation regarding sofosbuvir january acquired pharmasset acquisition acquired sofosbuvir formerly known gs nucleotide analog acts inhibit replication hcv december received fda approval sofosbuvir brandnamed sovaldi received number contractual intellectual property claims regarding sofosbuvir carefully considered claims prior following acquisition believe without merit patents claim sofosbuvir chemical entity metabolites however existence patents necessarily guarantee right practice patented technology commercialize patented product third parties may obtain rights patents allegedly could used prevent attempt prevent us commercializing sofosbuvir example aware patents patent applications owned parties may alleged parties cover use sofosbuvir parties successfully obtain valid enforceable patents successfully prove infringement patents sofosbuvir could prevented selling sofosbuvir unless able obtain license patents license may available commercially reasonable terms party successful establishing exclusive rights sofosbuvir expected revenues earnings sale sofosbuvir would adversely affected contract arbitration jeremy clark march jeremy clark former employee pharmasset inventor us patent patent filed demand arbitration lawsuit pharmasset dr raymond schinazi mr clark initially filed lawsuit pharmasset dr schinazi us district court northern district alabama february seeking void assignment provision employment agreement assert ownership us patent patent claims metabolites sofosbuvir rg december court ordered stay litigation pending outcome arbitration proceeding required mr clark 's employment agreement instead proceeding arbitration mr clark filed two additional lawsuits september june court subsequently dismissed september mr clark filed motion seeking reconsideration court 's december order court denied december mr clark filed motion appoint special prosecutor february court issued order requiring mr clark enter arbitration risk dismissal case mr clark filed demand arbitration march arbitration panel held hearing april june arbitration panel issued decision favor pharmasset gilead dr schinazi august gilead dr schinazi filed motion us district court northern district alabama seeking court confirm arbitration decision mr clark filed motion seeking vacate arbitration decision court yet ruled motions arbitration f hoffmanla roche ltd hoffmanla roche inc collectively roche gilead successor pharmasset party october collaboration agreement roche agreement granted roche rights develop psi cytidine analog prodrugs treatment hcv infection collaborative research efforts agreement ended december roche later asked pharmasset consider whether roche may contributed inventorship sofosbuvir whether pharmasset complied confidentiality provisions collaboration agreement pharmasset advised us carefully considered issues raised roche believed issues without merit also considered issues reached conclusion march roche initiated arbitration us pharmasset predecessor gilead pharmasset llc regarding collaboration agreement arbitration demand roche asserts exclusive license sofosbuvir pursuant collaboration agreement sofosbuvir prodrug uridine monophosphate analog allegedly prodrug psi cytidine analog roche claims exclusive rights sofosbuvir also exclusive license patent covering sofosbuvir infringe patent selling offering sale products containing sofosbuvir gilead gilead pharmasset llc filed response roche 's arbitration demand april interference proceedings litigation idenix pharmaceuticals inc february received notice us patent trademark office uspto declared interference first idenix interference us patent patent idenix pharmaceuticals inc 's idenix pending us patent application interference administrative proceeding uspto designed determine first invent subject matter claimed parties patent covers metabolites sofosbuvir rg prodrug cytidine nucleoside analog pharmasset licensed roche idenix attempting patent class compounds including metabolites purpose first idenix interference determine first invent compounds therefore entitled patent claiming compounds march uspto patent trials appeal board board determined idenix entitled benefit early application filing dates none patent applications including application led idenixs us patent patent patent taught make compounds dispute board also determined entitled filing date earliest application first file patent application compounds dispute therefore senior party first idenix interference january board determined pharmasset idenix first invent compounds dispute accordingly gilead prevailed decision board held idenix failed prove first conceive compounds dispute specifically idenix failed prove idenix inventors identified structure method making use disputed compounds board went conclude idenix failed work diligently toward making testing compounds dispute relevant time period idenix appealed boards decisions us district court district delaware either boards decisions reversed appeal court determines idenix entitled patent claims determined infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg united states decision district court appealed either party us court appeals federal circuit cafcwe believe claims idenix application involved first idenix interference similar us foreign patents claiming compounds metabolites invalid result filed impeachment action federal court canada invalidate idenix canadian patent canadian patent corresponds patent idenix patent application subject first idenix interference idenix asserted canadian patent corresponding us patent patent first idenix interference invalid filed similar legal action norway oslo district court seeking invalidate idenix 's corresponding norwegian patent september idenix filed invalidation action norwegian proceedings norwegian patent patent corresponds us patent patent trial held november court yet issued decision august idenix also filed request invalidation chinese patent office chinese patent cn zl corresponds us patent patent filed legal action federal court australia seeking invalidate idenixs australian p atent corresponding patent april idenix asserted commercialization sofosbuvir infringe australian patent corresponding patent may bring similar action countries future idenix awarded patents compounds european patent office japan china event patents issue expect challenge proceedings similar invoked canada norway australia courts hearing proceedings determine idenix entitled patent claims determined infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg country december receiving gileads request uspto declared interference second idenix interference pending us patent application patent patent includes claims directed methods treating hcv nucleoside compounds similar involved first idenix interference second idenix interference determine first invent claimed methods treating hcv declaration second idenix interference uspto initially designated gilead junior party based upon patent application filing dates appearing face patent february uspto issued order show cause idenix second idenix interference order requires idenix explain judgment entered second idenix interference favor gilead based upon outcome first idenix interference order indicates claims patent involved second idenix interference unpatentable due gilead prevailing first idenix interference idenix allowed claim benefit filing date earlier filed patent applications believe boards determination first idenix interference idenix entitled benefit earlier application filing dates including filing date patent equally applicable second idenix interference correct board may conclude gilead senior party second idenix interference consistent determination first idenix interference light boards conclusion first idenix interference application led patent teach make claimed compounds possible board make determination second idenix interference eliminate need board address first invent claimed methods treating hcv however board consider first invent claimed methods treating hcv ultimately concludes gilead first claims ' patent may revoked board determines idenix first invent entitled patent claims determined proceedings infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg determination board appealed either party us federal court december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sued us us district court district delaware alleging commercialization sofosbuvir infringe patent interference exists patent us patent patent believe claims patent invalid sole right commercialize sofosbuvir however court disagrees view determines patent infringed may required obtain license pay royalties idenix commercialize sofosbuvir decision district court appealed either party cafc also december idenix udsg sued us us district court district massachusetts alleging commercialization sofosbuvir infringe us patent nos patents believe idenixs patents invalid would infringed commercialization sofosbuvir sole right commercialize sofosbuvir however court disagrees view determines patents infringed may required obtain license pay royalties idenix commercialize sofosbuvir decision district court appealed either party cafc expansive patent portfolio covering nsa inhibitors treatment hcv following recent disclosure structure idenixs nsa inhibitor samatasvir also known idx evaluating compound light pending claims us patent application litigation merck co inc august merck co inc merck contacted us requesting pay royalties sales sofosbuvir take license us patent patent us patent patent coowns isis pharmaceuticals inc believe mercks patents invalid would infringed commercialization sofosbuvir sole right commercialize sofosbuvir accordingly august filed lawsuit us district court northern district california seeking declaratory judgment merck patents invalid infringed mercks us patent nos patents cover compounds include may relate sofosbuvir patent prosecution merck amended patent application attempt cover compounds related sofosbuvir ultimately extract royalty payments sofosbuvirs commercialization exclude market court determines mercks patents valid infringed claims may required obtain license pay royalties merck commercialize sofosbuvir either party appeal decision district court cafc litigation abbvie inc abbvie abbvie recently obtained us patent nos patents purport claim use combination ldvsof treatment hcv published pending patent applications directed use combinations treatment hcv specifically combinations ledipasvir sofosbuvir certain applications filed abbvie 's recently issued patents reason others believe abbvie 's patents invalid accordingly december filed lawsuit us district court district delaware seeking declaratory judgment abbvie patents invalid unenforceable well relief believe abbott laboratories inc abbvie conspired eliminate competition hcv market falsely representing pto gilead invented methods treating hcv using combination ldvsof february abbvie responded lawsuit filing lawsuit also us district court district delaware alleging ldvsof product infringe patents expect abbvie 's patents block delay commercialization combination products court determines abbvies patents valid infringed claims may required obtain license pay royalties abbvie commercialize sofosbuvir combination products either party appeal decision district court cafc litigation generic manufacturers part approval process products fda granted new chemical entity nce exclusivity period manufacturers ' applications approval generic versions product approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drugs abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug tenofovir disoproxil fumarate emtricitabine fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz november received notice teva pharmaceuticals teva submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine owned emory university licensed exclusively us invalid unenforceable andor infringed teva 's manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate december filed lawsuit us district court southern district new york teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic fixed dose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva challenged two emtricitabine patents may filed another lawsuit us district court southern district new york teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir disoproxil fumarate patents protecting viread january also received notices teva amending andas related generic versions atripla truvada products notice related teva 's anda generic version atripla teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine two patents related efavirenz notice related teva 's anda generic version truvada teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine march filed lawsuits teva infringement four viread patents two additional emtricitabine patents march bristolmyers squibb company merck filed lawsuit teva infringement patents related efavirenz filed lawsuits within requisite day period provided hatch waxman act stays preventing fda approval teva 's andas months district court decision adverse patents month stay three teva andas expired july april teva reached agreement settle ongoing patent litigation concerning four patents protect tenofovir disoproxil fumarate atripla truvada viread agreement teva allowed launch generic version viread december settlement agreement filed federal trade commission department justice required law october courts dismissal case pursuant settlement agreement parties became final trial lawsuit teva related us patents protecting emtricitabine atripla truvada held october february teva reached agreement principle settle ongoing patent litigation concerning emtricitabine patents protect atripla truvada terms settlement agreement confidential settlement agreement filed federal trade commission department justice required law november received notice teva submitted abbreviated new drug submission ands canadian minister health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate notice teva alleges three patents associated truvada invalid unenforceable andor infringed teva 's manufacture use sale generic version truvada january filed lawsuit teva federal court canada seeking order prohibition approval ands december received notice teva submitted ands canadian minister health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva alleges three patents associated atripla two merck 's patents associated atripla invalid unenforceable andor infringed teva 's manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz february filed lawsuit teva federal court canada seeking order prohibition approval ands august received notice teva submitted ands canadian minister health requesting permission manufacture market generic version viread notice teva alleges two patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed teva 's manufacture use sale generic version viread truvada atripla september filed lawsuit teva federal court canada seeking order prohibition approval ands also august teva filed impeachment action federal court canada seeking invalidation two canadian patents associated viread currently defending impeachment action requests orders prohibition connection three tevas ands filings tevas generic versions viread truvada atripla consolidated hearing consolidated requests orders prohibition took place september december court issued requested order prohibiting canadian minister health issuing notice compliance tevas generic versions viread truvada atripla products expiry patent july teva appealed decision decision ultimately resolve validity challenges raised teva impeachment action teva successful invalidating patents teva may able launch generic versions viread truvada atripla products prior expiry patents trial impeachment action scheduled january july received notice lupin limited lupin submitted anda fda requesting permission manufacture market generic version truvada notice lupin alleges four patents associated emtricitabine four patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed lupin 's manufacture use sale generic version fixeddose combination emtricitabine tenofovir disoproxil fumarate august filed lawsuit lupin us district court southern district new york infringement patents anticipate trial case fourth quarter either party appeal decision district court cafc lupin successful invalidating patents lupin may able launch generic version truvada product prior expiry patents july received notice cipla ltd cipla submitted anda fda requesting permission manufacture market generic version emtriva generic version viread notice cipla alleges two patents associated emtricitabine invalid unenforceable andor infringed cipla 's manufacture use sale generic version emtricitabine four patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed cipla 's manufacture use sale generic version tenofovir disoproxil fumarate august filed lawsuits cipla us district court southern district new york infringement patents anticipate trial case fourth quarter either party appeal decision district court cafc cipla successful invalidating patents cipla may able launch generic versions viread andor emtriva products prior expiry patents october received notice lupin submitted anda fda requesting permission manufacture market generic version viread notice lupin alleges four patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed lupin 's manufacture use sale generic version tenofovir disoproxil fumarate october filed lawsuit lupin us district court southern district new york infringement patents anticipate trial case fourth quarter either party appeal decision district court cafc lupin successful invalidating patents lupin may able launch generic version viread product prior expiry patents ranolazine june received notice lupin submitted anda fda requesting permission manufacture market generic version sustained release ranolazine notice lupin alleged ten patents associated ranexa invalid unenforceable andor infringed lupin 's manufacture use sale generic version ranexa july filed lawsuit lupin us district court district new jersey infringement patents ranexa trial took place april may august parties reached agreement settle patent litigation prior issuance courts decision agreement lupin would allowed launch generic version ranexa february settlement agreement filed federal trade commission department justice required law tamiflu february received notice natco pharma ltd natco submitted anda fda requesting permission manufacture market generic version tamiflu notice natco alleges one patents associated oseltamivir phosphate invalid unenforceable andor infringed natco 's manufacture use sale generic version tamiflu march roche filed lawsuit natco us district court district new jersey infringement one patents associated tamiflu december court issued ruling favor gilead roche patent invalid reasons stated natco 's notice letter natco appealed decision cafc hearing natcos appeal took place january court yet issued decision appeal natco successful appeal case remanded us district court district new jersey full trial merits predict ultimate outcome actions may spend significant resources enforcing defending patents unsuccessful lawsuits claims patents may narrowed invalidated patent protection atripla truvada viread emtriva tamiflu united states atripla truvada viread canada could substantially shortened patents covering one products invalidated fda canadian minister health could approve requests manufacture generic version products united states canada respectively prior expiration date patents sale generic versions products earlier patent expiration would significant negative effect revenues results operations trade secrets also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions manufacturing raw materials manufacturing strategy contract third parties manufacture majority active pharmaceutical ingredients solid dose products also rely corporate partners manufacture certain products additionally lease manufacturing facilities san dimas oceanside california edmonton alberta canada cork ireland manufacture certain products active pharmaceutical ingredients clinical commercial uses manufacturing products contract third parties manufacture certain products clinical commercial purposes including stribild compleraeviplera atripla truvada viread hepsera emtriva tybost vitekta sovaldi ranexa ambisome cayston vistide generally use multiple thirdparty contract manufacturers manufacture active pharmaceutical ingredients products exclusive manufacturer ambrisentan active pharmaceutical ingredient letairis although another supplier qualified make active pharmaceutical ingredient letairis also rely thirdparty contract manufacturers manufacture tablet capsule products example use multiple thirdparty contract manufacturers tablet stribild compleraeviplera atripla truvada viread tybost vitekta sovaldi letairis hepsera ranexa emtriva encapsulation also completed thirdparty contract manufacturers also manufacturing agreements many corporate partners roche third parties responsible manufacturing tamiflu agreement roche joint manufacturing committee composed representatives roche gilead opportunity review roche 's existing manufacturing capacity tamiflu global plans manufacturing tamiflu astellas us llc corporate partner lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan future products continue develop additional manufacturing capabilities establish additional thirdparty suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future products ability conduct large scale clinical trials meet customer demand commercial products adversely affected manufacturing facilities san dimas california manufacturing facility manufacture package label solid dosage oral form products also fill package solid dosage form products including stribild compleraeviplera atripla truvada viread emtriva sovaldi ranexa finished forms label hepsera facilities san dimas manufacture cayston ambisome san dimas facility depend single supplier active pharmaceutical ingredient cayston high quality cholesterol active pharmaceutical ingredient used manufacture ambisome exclusive supplier ambisome event disaster including earthquake equipment failure difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome meet market needs utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral products well product packaging activities fill package drug product stribild compleraeviplera atripla truvada viread tybost tiveka sovaldi label hepsera emtriva facilities cork ireland also perform quality control testing final labeling secondary packaging cayston ambisome final release many products european union elsewhere facility utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral products well product packaging activities distribute products european union international markets dublin ireland site edmonton alberta facility canada carry process research scaleup clinical development candidates manufacture active pharmaceutical ingredients investigational commercial products conduct chemical development activities improve existing commercial manufacturing processes also manufacture active pharmaceutical ingredients hepsera letairis vistide exclusively edmonton site although another supplier qualified make active pharmaceutical ingredient letairis oceanside california facility designed equipped produce biologic compounds toxicological phase phase clinical studies use facility process development manufacture simtuzumab investigational monoclonal antibody candidate development treatment certain cancers fibrotic diseases another antibody currently phase clinical trials thirdparty manufacturers thirdparty manufacturers corporate partners independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected example due unexpected delays qualifying two new external sites expanding cayston manufacturing san dimas unable supply enough cayston fulfill projected demand february september suspended access patients new prescriptions cayston subject certain exceptions specific medical need exists result inability manufacture sufficient cayston meet demand amount revenues received sale cayston reduced believe technology use manufacture products proprietary products manufactured thirdparty contract manufacturers disclosed necessary aspects technology enable manufacture products us agreements thirdparty manufacturers intended restrict manufacturers using revealing technology certain thirdparty manufacturers comply restrictions addition thirdparty manufacturers could develop technology related work perform us may need manufacture products could required enter additional agreements thirdparty manufacturers want use technology allow another manufacturer use technology thirdparty manufacturer could refuse allow us use technology could demand terms use technology acceptable us regulation manufacturing process manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations thirdparty manufacturers corporate partners subject current good manufacturing practices extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda ema similar regulations effect countries manufacturing operations subject routine inspections regulatory agencies example april fda conducted inspection foster city facility issued form inspectional observations noted deficiencies documentation validation certain quality testing procedures methods result observations fda delivered complete response letters notifying us unable approve ndas elvitegravir cobicistat standalone agents midoctober fda completed sofosbuvir preapproval inspection foster city facility following inspection fda issued additional form inspectional observations citing deficiencies related testing reconciliation stability samples testing protocols testing shipping samples procedures calibrating test equipment recently completed filed responses observations fda unable remedy deficiencies cited fda inspections currently marketed products timing regulatory approval products development could adversely affected risk regulatory agencies countries marketing applications pending undertake similar additional reviews apply heightened standard review could delay regulatory approvals products countries approval product candidates including idelalisib fixeddose combination ldvsof delayed production marketed products interrupted anticipated revenues stock price would adversely affected access supplies materials need access certain supplies products manufacture products light global economic downturn increased difficulty purchasing certain raw materials used manufacturing process unable purchase sufficient quantities materials find suitable alternate materials timely manner development efforts product candidates may delayed ability manufacture products would limited would limit ability generate revenues example significant portion raw materials intermediates used manufacture hiv liver disease products stribild compleraeviplera atripla truvada viread emtriva tybost vitekta sovaldi supplied chinesebased companies result international trade dispute china united states actions chinese government would limit prevent chinese companies supplying materials would adversely affect ability manufacture supply hiv products meet market needs material adverse effect operating results seasonal operations backlog worldwide product sales reflect significant degree seasonality however royalty revenues represented approximately total revenues included tamiflu royalties affected seasonality royalty revenue recognize roche 's sales tamiflu impacted severity flu seasons product delivery response influenza pandemics part operate markets characterized short lead times absence significant backlogs believe backlog information material business whole government regulation operations activities subject extensive regulation numerous government authorities united states countries united states drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming fda must approve drug sold united states general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidate 's potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts ind drug candidate studied human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous phase clinical trials phase drug candidate appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials conducted longer term involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials fda approval process believe data phase clinical trials show adequate level safety efficacy submit appropriate filing usually form nda supplemental nda fda seeking approval sell drug candidate particular use fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees compound met required level safety efficacy particular use allow us sell drug candidate united states use unusual however fda reject application believes drug candidate safe enough efficacious enough believe data submitted reliable conclusive point process development drug candidate stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california including oceanside san dimas facilities also must licensed state california compliance local regulatory requirements manufacturing facilities located canada including edmonton alberta facility facilities located near dublin cork ireland also must obtain local licenses permits compliance local regulatory requirements drugs treat serious life threatening diseases conditions adequately addressed existing drugs development program designed address unmet medical need may designated fast track candidates fda may eligible accelerated priority review drugs treatment hiv infection designated use us president 's emergency plan aids relief may also qualify expedited priority review atripla truvada viread complera sovaldi received accelerated approval priority reviews drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug drugs also subject extensive regulation outside united states european union centralized approval procedure authorizes marketing product countries european union includes major countries europe centralized approval procedure used approval one country european union used obtain approval another country european union one two simplified application processes mutual recognition procedure decentralized procedure rely principle mutual recognition receiving regulatory approval european registration procedures separate pricing reimbursement approvals also required countries european union also requirements approval manufacturing facilities products approved sale european regulatory authorities pricing reimbursement successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services particularly new innovative products therapies resulted lower average selling prices significant portion sales majority products subject significant discounts list price rebate obligations united states state adaps purchase significant portion hiv products rely federal supplemental federal state funding help fund purchases products given current economic downturn experienced shift payer mix patients previously covered private insurance move public reimbursement programs require rebates discounts us patients previously covered one public reimbursement program move another public reimbursement program requires greater rebates discounts us result shift revenue growth may lower prescription growth effective march automatic reduction federal spending sequestration effect sequestration acrosstheboard cuts implemented could reduce amount federal state funds support adaps federal state funds available amounts sufficient support number patients rely adaps sales hiv products could negatively impacted would reduce revenues example first quarter state budget crisis florida led temporary movement patients previously covered florida 's adap industrysupported patient assistance programs prior quarters insufficiency federal state funds many states reduced eligibility criteria saw increase number patients state adap wait lists may see similar increases future periods result reduction federal state adap support resulting sequestration patients enrolled adap generally receive product industrysupported patient assistance programs unable access treatment increased emphasis managed healthcare united states country regional pricing reimbursement controls european union put additional pressure product pricing reimbursement usage may adversely affect product sales profitability pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid healthcare reform pharmaceutical reimbursement policies pricing general countries outside united states success commercialized products product candidates may develop depend largely obtaining maintaining government reimbursement many countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices certain governmental authorities delay commercialization months reimbursement policies may adversely affect ability sell products profitable basis many international markets governments control prices prescription pharmaceuticals including implementation reference pricing price cuts rebates revenuerelated taxes tenders profit control expect prices prescription pharmaceuticals decline life product volumes increase recently many countries european union increased amount discounts required products efforts could continue countries attempt manage healthcare expenditures especially light severe fiscal debt crises experienced many countries european union example june spain imposed incremental discount branded drugs august germany increased rebate prescription pharmaceuticals froze price prescription pharmaceuticals generic drugs come market may face price decreases products countries european union cost containment pressures european union especially southern europe could lead delays treatment patients also delay pricing approval could negatively impact commercialization new products government agencies also issue regulations guidelines directly applicable us products addition time time professional societies practice management groups private healthscience foundations organizations publish guidelines recommendations directed certain health care patient communities recommendations guidelines may relate matters product usage dosage route administration use related competing therapies consequently result increased decreased usage products example recent hiv treatment guidelines united states abroad endorsed earlier diagnosis treatment united states healthcare reform legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions march healthcare reform legislation adopted united states result required rebate discount products reimbursed paid various public payers including medicaid entities eligible purchase discounted products b drug pricing program public health service act adaps result legislation discounts rebates fees impacted us include minimum base rebate amount owed medicaid products reimbursed medicaid increased discounts rebates owe adaps public health service entities reimburse purchase products also increased required extend rebates patients receiving products medicaid managed care organizations required provide discount products sold patients medicare part donut hole along pharmaceutical manufacturers branded drug products required pay portion new industry fee also known pharmaceutical excise tax billion calculated based select government sales calendar year percentage total industry government sales amount industry fee imposed pharmaceutical industry whole increase billion billion additional increases next several years peak billion per year decrease billion thereafter amount industry fee increases product sales increase drug patents expire major drugs companies expect portion pharmaceutical excise tax increase well estimate portion pharmaceutical excise tax approximately million compared approximately million approximately million pharmaceutical excise tax tax deductible even though addressed healthcare reform legislation discussions continue federal level legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers set minimum requirements medicare part pricing addition state medicaid programs could request additional supplemental rebates products result increase federal base medicaid rebate private insurers could also use enactment increased rebates exert pricing pressure products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules health care fraud abuse laws antibribery laws subject various federal state laws pertaining health care fraud abuse including antikickback laws false claims laws antikickback laws make illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business including purchase prescription particular drug due breadth statutory provisions increasing attention given law enforcement authorities possible certain practices may challenged antikickback similar laws false claims laws generally prohibit anyone knowingly presenting causing presented false fraudulent claim payment federal certain state payers including medicare medicaid knowingly making using causing made used false record statement material false fraudulent claim sales marketing medical activities may subject scrutiny laws addition us foreign corrupt practices act similar worldwide antibribery laws generally prohibit companies intermediaries making improper payments purpose obtaining retaining business policies mandate compliance antibribery laws operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may state controlled manner different local custom despite training compliance program internal control policies procedures may protect us reckless criminal acts committed employees agents violations fraud abuse laws antibribery laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid violations also lead imposition corporate integrity agreement similar government oversight program government allege convict us violating laws could disruption business material adverse effect results operations compulsory licenses number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread july brazilian patent authority rejected patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread highest level appeal available us within brazilian patent authority currently patent brazil brazilian government purchases supply tenofovir disoproxil fumarate generic manufacturers addition concerns cost availability tamiflu related potential avian flu pandemic hn influenza generated international discussions compulsory licensing tamiflu patents example canadian government considered allowing canadian manufacturers manufacture export active ingredient tamiflu eligible developing least developed countries canada 's access medicines regime furthermore roche issued voluntary licenses permit thirdparty manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense india 's hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit thirdparty manufacturing tamiflu developments could reduce royalties receive roche 's sales tamiflu certain countries permit enforcement patents thirdparty manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales employees january approximately fulltime employees believe good relations employees environment health safety evaluated current level environmental impact identified ways reduce energy consumption factors contribute environmental impact include greenhouse gas emissions produced employee commutes energy water consumed facilities use hazardous materials chemicals viruses radioactive compounds rd facilities pursuant evaluation taken initial measures address impacts example established employee commuter programs evaluated energy efficiency buildings installed lowflow water fixtures also implemented proactive programs minimize occurrence hazardous materials incidents reduce risk accidental environmental contamination worker injury subject number laws regulations require compliance federal state local regulations regarding workplace safety protection environment anticipate additional regulations near future laws regulations implemented consideration mitigate effects climate change mainly caused greenhouse gas emissions business energy intensive therefore anticipate subject cap trade system mitigation measure would materially impact capital expenditures operations competitive position based current information subject finalization proposed regulations believe primary risk related climate change increased energy costs use hazardous materials chemicals viruses various radioactive compounds rd activities eliminate risk accidental contamination injury materials misuse accidents involving hazardous materials could lead significant litigation fines penalties information subject information requirements exchange act therefore file periodic reports proxy statements information sec reports proxy statements information may obtained visiting public reference room sec f street ne washington dc calling sec sec sending electronic message sec publicinfosecgov sending fax sec addition sec maintains website wwwsecgov contains reports proxy information statements information regarding issuers file electronically mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section make available following filings soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act filings available free charge upon request transactions iran transactions iran would require disclosure item risk factors evaluating business carefully consider following risks addition information annual report manifestation following risks could materially adversely affect business results operations financial condition note factors investors permitted private securities litigation reform act possible predict identify factors therefore consider following risks complete statement potential risks uncertainties face substantial portion revenues derived sales hiv products particularly atripla truvada stribild compleraeviplera unable maintain continue increasing sales products results operations may adversely affected currently depend sales products treatment human immunodeficiency virus hiv infection particularly atripla truvada stribild compleraeviplera support existing operations hiv products contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutics treatment paradigm hiv change causing nucleosidebased therapeutics fall favor unable maintain continue increasing hiv product sales results operations would likely suffer would likely need scale back operations including spending research development rd efforts year ended december atripla truvada stribild compleraeviplera product sales together billion total revenues may able sustain increase growth rate sales hiv products especially stribild compleraeviplera atripla truvada tybost number reasons including limited following hiv products used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings contraindications labels narrow approved indications halt sales product could reduce revenues hiv products mature private insurers government payers often reduce amount reimburse patients products increases pressure us reduce prices large part market hiv products consists patients already taking hiv drugs successful encouraging physicians change patients ' regimens include hiv products sales hiv products limited generic hiv products introduced major markets ability maintain pricing market share may affected example generic versions sustiva efavirenz component atripla available canada europe expect competition generic efavirenz united states may increase pricing pressure hiv products tivicay dolutegravir integrase inhibitor launched fourth quarter viiv healthcare viiv could impact sales hiv products fail commercialize new products expand indications existing products prospects future revenues may adversely affected introduce new products market increase sales existing products able increase maintain total revenues continue expand rd efforts drug development inherently risky many product candidates fail drug development process example april announced decision terminate phase clinical trial aztreonam inhalation solution treatment bronchiectasis february filed new drug application nda us food drug administration fda approval fixeddose combination ledipasvirsofosbuvir ldvsof genotype patients represent majority patients infected chronic hepatitis c virus hcv infection united states europe approved ldvsof likely require genotype hcv patients take one pill per day eight weeks without ribavirin rbv pegylated interferon pegifn pegifn expect file approval ldvsof europe first quarter also filed marketing applications idelalisib treatment patients indolent nonhodgkins lymphoma inhl chronic lymphocytic leukemia cll marking applications may approved fda european medicines agency ema foreign regulatory authorities timely basis even marketing approval granted products may significant limitations use may unable file marketing applications new products inability accurately estimate demand products uptake new products timing fluctuations inventories maintained customers makes difficult us accurately forecast sales may cause revenues earnings fluctuate could adversely affect financial results stock price unable accurately estimate demand products including uptake new products demand dependent number factors example hcv products sovaldi ldvsof approved represent significant change treatment paradigm hcv infected patients due shortened duration treatment reduction elimination need pegifn injection rbv products new therapeutic area us patient demand dependent number factors revenues products beyond difficult us investors estimate since sovaldi recently approved clear ldvsof ultimately approved demand products depend part amount coverage private public insurance programs united states ability obtain maintain government reimbursement countries outside united states addition doctors may choose wait treat genotype hcv infected patients later anticipate approval availability ldvsof another competitors alloral regimen treatment genotype hcvinfected patients also hcv products represent significant change treatment paradigm hcv infection highly anticipated medical patient community sales levels prescription growth rates early launch may indicative future results hcvrelated revenues difficult predict investors may widely varying expectations may materially higher lower actual revenues extent sovaldi revenues exceed fall short expectations stock price may experience significant volatility approximately product sales united states three wholesalers cardinal health inc mckesson corp amerisourcebergen corp us wholesalers entered inventory management agreements make estimates determine end user demand may completely effective matching inventory levels actual end user demand result changes inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match end user demand addition inventory held retail pharmacies nonwholesaler locations inventory management agreements control buying patterns adverse changes economic conditions factors may cause retail pharmacies reduce inventories products would reduce orders wholesalers consequently wholesalers ' orders us even end user demand changed example fourth quarter strong wholesaler sub wholesaler purchases may result inventory drawdown wholesalers subwholesalers first quarter inventory distribution channel fluctuates quarter quarter may continue see fluctuations earnings mismatch prescription demand products revenues addition nonretail sector united states includes government institutions including state aids drug assistance programs adaps correctional facilities large health maintenance organizations tends even less consistent terms buying patterns often causes quarter quarter fluctuations necessarily mirror patient demand federal state budget pressures including sequestration well annual grant cycles federal state adap funds may cause adap purchasing patterns reflect patient demand example first quarters certain prior years observed large nonretail purchases number state adaps exceeded patient demand believe purchases driven grant cycle federal adap funds expect continue experience fluctuations purchasing patterns nonretail customers may result fluctuations product sales revenues earnings future light global economic downturn budget crises faced many european countries observed variations purchasing patterns induced cost containment measures europe believe measures caused government agencies purchasers reduce inventory products distribution channels decreased revenues caused fluctuations product sales earnings may continue see trend future results operations adversely affected current potential future healthcare reforms legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions march healthcare reform legislation adopted united states result required rebate discount products reimbursed paid various public payers including medicaid entities eligible purchase discounted products b drug pricing program public health service act adaps result legislation discounts rebates fees impacted us include minimum base rebate amount owed medicaid products reimbursed medicaid increased discounts rebates owe adaps public health service entities reimburse purchase products also increased required extend rebates patients receiving products medicaid managed care organizations required provide discount products sold patients medicare part donut hole along pharmaceutical manufacturers branded drug products required pay portion new industry fee also known pharmaceutical excise tax billion calculated based select government sales calendar year percentage total industry government sales amount industry fee imposed pharmaceutical industry whole increase billion billion additional increases next several years peak billion per year decrease billion thereafter amount industry fee increases product sales increase drug patents expire major drugs companies expect portion pharmaceutical excise tax increase well estimate portion pharmaceutical excise tax approximately million compared approximately million approximately million pharmaceutical excise tax tax deductible even though addressed healthcare reform legislation discussions continue federal level legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers set minimum requirements medicare part pricing addition state medicaid programs could request additional supplemental rebates products result increase federal base medicaid rebate private insurers could also use enactment increased rebates exert pricing pressure products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services particularly new innovative products therapies resulted lower average selling prices significant portion sales majority products subject significant discounts list price rebate obligations united states state adaps purchase significant portion hiv products rely federal supplemental federal state funding help fund purchases products given current economic downturn experienced shift payer mix patients previously covered private insurance move public reimbursement programs require rebates discounts us patients previously covered one public reimbursement program move another public reimbursement program requires greater rebates discounts us result shift revenue growth may lower prescription growth effective march automatic reduction federal spending sequestration effect sequestration acrosstheboard cuts implemented could reduce amount federal state funds support adaps federal state funds available amounts sufficient support number patients rely adaps sales hiv products could negatively impacted would reduce revenues example first quarter state budget crisis florida led temporary movement patients previously covered florida 's adap industrysupported patient assistance programs prior quarters insufficiency federal state funds many states reduced eligibility criteria saw increase number patients state adap wait lists may see similar increases future periods result reduction federal state adap support resulting sequestration patients enrolled adap generally receive product industrysupported patient assistance programs unable access treatment increased emphasis managed healthcare united states country regional pricing reimbursement controls european union put additional pressure product pricing reimbursement usage may adversely affect product sales profitability pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid healthcare reform pharmaceutical reimbursement policies pricing general countries outside united states success commercialized products product candidates may develop depend largely obtaining maintaining government reimbursement many countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices certain governmental authorities delay commercialization months reimbursement policies may adversely affect ability sell products profitable basis many international markets governments control prices prescription pharmaceuticals including implementation reference pricing price cuts rebates revenuerelated taxes tenders profit control expect prices prescription pharmaceuticals decline life product volumes increase recently many countries european union increased amount discounts required products efforts could continue countries attempt manage healthcare expenditures especially light severe fiscal debt crises experienced many countries european union example june spain imposed incremental discount branded drugs august germany increased rebate prescription pharmaceuticals froze price prescription pharmaceuticals generic drugs come market may face price decreases products countries european union cost containment pressures european union especially southern europe could lead delays treatment patients also delay pricing approval could negatively impact commercialization new products government agencies also issue regulations guidelines directly applicable us products addition time time professional societies practice management groups private healthscience foundations organizations publish guidelines recommendations directed certain health care patient communities recommendations guidelines may relate matters product usage dosage route administration use related competing therapies consequently result increased decreased usage products approximately product sales occur outside united states currency fluctuations hedging expenses may cause earnings fluctuate could adversely affect stock price significant percentage product sales denominated foreign currencies primarily euro face exposure adverse movements foreign currency exchange rates us dollar strengthens foreign currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative value sales increases overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business use foreign currency exchange forward option contracts hedge percentage forecasted international sales primarily denominated euro also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid predict future fluctuations foreign currency exchange rate us dollar us dollar appreciates significantly certain currencies hedging program sufficiently offset effects appreciation results operations adversely affected stock price may decline additionally expenses recognize relation hedging activities also cause earnings fluctuate level hedging expenses recognize particular period impacted changes interest rate spreads foreign currencies hedge us dollar face significant competition face significant competition large pharmaceutical biotechnology companies substantially greater resources addition competitors products operated fields compete longer hiv products compete primarily products joint venture established glaxosmithkline incgsk pfizer inc pfizer viiv healthcare viiv markets fixeddose combination products compete stribild compleraeviplera atripla truvada example lamivudine marketed joint venture competitive emtricitabine active pharmaceutical ingredient emtriva component compleraeviplera atripla truvada tybost compete ritonavir marketed abbvie inc abbvie addition tivicay dolutegravir integrase inhibitor launched fourth quarter viiv could adversely impact sales hiv products also face competition generic hiv products may compound patent covering epivir lamivudine expired united states generic lamivudine available united states spain portugal italy expect generic versions lamivudine launched countries within european union may generic version combivir lamivudine zidovudine approved recently launched united states addition late generic tenofovir also became available turkey resulted increase rebate viread turkey generic versions sustiva efavirenz component atripla available canada europe expect competition generic efavirenz united states may increase pricing pressure hiv products hcv product sovaldi competes janssen rd ireland olysio simeprevir united states lesser extent directacting antivirals victrelis boceprevir marketed merck co inc merck incivek telaprevir marketed vertex pharmaceuticals incorporated viread hepsera treatment chronic hepatitis b virus hbv infection compete primarily products produced gsk bristolmyers squibb company bms novartis pharmaceuticals corporation novartis united states european union china ambisome compete primarily products produced merck pfizer addition aware least three lipid formulations claim similarity ambisome becoming available outside united states including possible entry formulations taiwan formulations may reduce market demand ambisome furthermore manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association letairis competes directly products produced actelion pharmaceuticals us inc indirectly pulmonary arterial hypertension products united therapeutics corporation pfizer ranexa competes predominantly generic compounds three distinct classes drugs betablockers calcium channel blockers longacting nitrates treatment chronic angina united states cayston competes product marketed novartis tamiflu competes products sold gsk generic competitors addition number companies pursuing development technologies competitive existing products research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs competitors gain market share products could adversely affect results operations stock price significant safety issues arise marketed products product candidates future sales may reduced would adversely affect results operations data supporting marketing approvals products forming basis safety warnings product labels obtained controlled clinical trials limited duration cases postapproval use products used longer periods time many patients underlying health problems taking numerous medicines expect continue find new issues safety resistance drug interaction issues may require us provide additional warnings contraindications labels narrow approved indications could reduce market acceptance products product letairis approved fda june member class compounds called endothelin receptor antagonists pose specific risks including serious risks birth defects risks letairis available letairis education access program leap restricted distribution program intended help physicians patients learn risks associated product assure appropriate use product product used additional patients may discover new risks associated letairis may result changes distribution program additional restrictions use letairis may decrease demand product regulatory authorities moving towards active transparent pharmacovigilance making greater amounts standalone safety information directly available public websites means eg periodic safety update report summaries risk management plan summaries various adverse event data safety information without appropriate context expertise may misinterpreted lead misperception legal action may potentially cause product sales stock price decline serious safety resistance drug interaction issues arise marketed products sales products could limited halted us regulatory authorities results operations would adversely affected operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis maintain compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda ema comparable regulatory agencies countries continuing clinical trials stribild compleraeviplera atripla truvada viread emtriva tybost vitekta sovaldi hepsera letairis ranexa ambisome cayston currently approved additional uses anticipate file marketing approval additional countries additional indications products next several years products may fail receive marketing approvals timely basis marketed products manufacture sell products subject extensive regulation review discovery previously unknown problems marketed products problems manufacturing promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements including related promotion manufacturing could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution example fda rules often required conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk implement risk evaluation mitigation strategy products could include medication guide patient package insert communication plan healthcare providers elements fda deems necessary assure safe use drug could include imposing certain restrictions distribution use product failure comply requirements imposed sponsor fda could result significant civil monetary penalties operating results may adversely affected results anticipated timelines clinical trials uncertain may support continued development product pipeline would adversely affect prospects future revenue growth required demonstrate safety efficacy products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products product candidates fails achieve primary endpoint clinical trials safety issues arise results clinical trials otherwise inadequate support regulatory approval product candidates commercialization product candidate could delayed halted example april announced decision terminate phase clinical trial aztreonam inhalation solution treatment bronchiectasis addition may also face challenges clinical trial protocol design clinical trials product candidates pipeline delayed terminated prospects future revenue growth would adversely impacted example face numerous risks uncertainties product candidates including ranolazine treatment incomplete revascularization postpercutaneous coronary intervention type ii diabetes single tablet regimen tenofovir alafenamideelvitegravircobicistatemtricitabine currently phase clinical trials could prevent completion development product candidates risks include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain fda regulatory body approvals result product candidates may never successfully commercialized may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline programs others pipeline completed timely basis prospects future revenue growth may adversely impacted addition clinical trials involving commercial products could raise new safety issues existing products could turn decrease revenues harm business due reliance thirdparty contract research organizations conduct clinical trials unable directly control timing conduct expense quality clinical trials extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent third party contract research organizations cros perform clinical studies including document preparation site identification screening preparation prestudy visits training program management bioanalytical analysis many important aspects services performed us cros direct control dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed thirdparty cros cros ' processes methodologies results determined invalid inadequate clinical data results related regulatory approvals could adversely impacted expenses associated clinical trials may cause earnings fluctuate could adversely affect stock price clinical trials required regulatory approval products well clinical trials required conduct approval expensive difficult accurately predict control amount timing expenses quarter quarter fda andor regulatory agencies may require clinical testing originally anticipated uneven unexpected spending programs including clinical trials necessary advance product candidates may cause operating results fluctuate quarter quarter volatility stock price depend relationships companies sales marketing performance development commercialization product candidates revenues failure maintain relationships poor performance companies disputes companies could negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance certain territories include collaborations bms atripla united states europe canada f hoffmannla roche ltd together hoffmannla roche inc roche tamiflu worldwide gsk ambrisentan territories outside united states countries rely international distributors sales truvada viread hepsera emtriva ambisome relationships also involve clinical development products partners reliance collaborative relationships poses number risks including risk unable control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us particularly light current economic conditions given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenues products could decline april licensing agreement gsk gave gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major markets hepsera china japan taiwan south korea november entered agreement gsk provided gsk exclusive commercialization rights registration responsibilities viread treatment chronic hbv china october granted similar rights gsk japan saudi arabia success hepsera viread treatment chronic hbv territories depends almost entirely efforts gsk regard gsk promotes epivirhbvzeffix product competes hepsera viread treatment chronic hbv consequently gsk 's marketing strategy hepsera viread treatment chronic hbv may influenced promotion epivirhbvzeffix receive royalties gsk equal percentage gsk 's net sales hepsera viread treatment chronic hbv well net sales gsk 's epivirhbvzeffix gsk fails devote sufficient resources succeed developing commercializing hepsera viread treatment chronic hbv territories potential revenues territories may substantially reduced addition cayston letairis distributed thirdparty specialty pharmacies pharmacies specializing dispensing medications complex chronic conditions may require high level patient education ongoing counseling use specialty pharmacies requires significant coordination sales marketing medical affairs regulatory affairs legal finance organizations involves risks including limited risks specialty pharmacies provide us accurate timely information regarding inventories patient data safety complaints effectively sell support cayston letairis devote resources necessary sell cayston letairis volumes within time frames expect able satisfy financial obligations us others cease operations also rely third party administer leap restricted distribution program designed support letairis third party provides information education prescribers patients risks letairis confirms insurance coverage investigates alternative sources reimbursement assistance ensures fulfillment risk management requirements mandated letairis fda coordinates controls dispensing patients third party specialty pharmacies failure third party specialty pharmacies distribute letairis perform expected may result regulatory action fda decreased letairis sales either would harm business cayston may taken patients using specific inhalation device delivers drug lungs patients ongoing distribution cayston entirely reliant upon manufacturer device example manufacturer could encounter issues regulatory agencies related device unable supply sufficient quantities device addition manufacturer may able provide adequate warranty support device distributed patients respect distribution drug device patients reliant capabilities specialty pharmacies example distribution channel drug device complicated requires coordination reimbursement approval processes associated drug device similarly complex device manufacturer unable obtain reimbursement approval receives approval lowerthanexpected price sales cayston may adversely affected previously described issues may limit sales cayston would adversely affect financial results success depend significant degree ability defend patents intellectual property rights domestically internationally may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology patents proprietary rights important business success depend significant degree ability obtain patents licenses patent rights preserve trade secrets defend infringement efforts invalidate patents operate without infringing intellectual property others properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents patent applications confidential period time patent issued result may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete products addition competitors file patent applications covering technology may participate litigation interference proceedings determine right patent litigation interference proceedings unpredictable expensive even ultimately successful results operations may adversely affected events patents cover ranolazine compound active ingredient ranexa instead discovered sustainedrelease formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve patents cover active ingredients ambisome addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hbv indication hepsera developed may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions supplementary protection certificates countries generic manufacturers sought may continue seek fda approval market generic versions products abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug see description anda litigation legal proceedings beginning risk factor entitled litigation generic manufacturers reduced may continue reduce earnings unsuccessful lawsuits claims patents may narrowed invalidated generic versions products could launched prior patent expiry beginning success depends large part ability operate without infringing upon patents proprietary rights third parties infringe valid patents third parties may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents may relate operation leap restricted distribution program designed support letairis aware patents patent applications owned parties may claim cover use sofosbuvir see description litigation regarding sofosbuvir risk factor entitled party successful establishing exclusive rights sofosbuvir expected revenues earnings sale sofosbuvir could adversely affected beginning furthermore also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions trade secrets confidential information become known independently discovered competitors enter disputes ownership inventions business results operations could adversely affected party successful establishing exclusive rights sofosbuvir expected revenues earnings sale sofosbuvir could adversely affected patents claim sofosbuvir chemical entity metabolites however existence patents necessarily guarantee right practice patented technology commercialize patented product third parties may obtain rights patents allegedly could used prevent attempt prevent us commercializing sofosbuvir example aware patents patent applications owned parties may alleged parties cover use sofosbuvir parties successfully obtain valid enforceable patents successfully prove infringement patents sofosbuvir could prevented selling sofosbuvir unless able obtain license patents license may available commercially reasonable terms party successful establishing exclusive rights sofosbuvir expected revenues earnings sale sofosbuvir would adversely affected contract arbitration jeremy clark march jeremy clark former employee pharmasset inventor us patent patent filed demand arbitration lawsuit pharmasset dr raymond schinazi mr clark initially filed lawsuit pharmasset dr schinazi us district court northern district alabama february seeking void assignment provision employment agreement assert ownership us patent patent claims metabolites sofosbuvir rg december court ordered stay litigation pending outcome arbitration proceeding required mr clark 's employment agreement instead proceeding arbitration mr clark filed two additional lawsuits september june court subsequently dismissed september mr clark filed motion seeking reconsideration court 's december order court denied december mr clark filed motion appoint special prosecutor february court issued order requiring mr clark enter arbitration risk dismissal case mr clark filed demand arbitration march arbitration panel held hearing april june arbitration panel issued decision favor pharmasset gilead dr schinazi august gilead dr schinazi filed motion us district court northern district alabama seeking court confirm arbitration decision mr clark filed motion seeking vacate arbitration decision court yet ruled motions arbitration f hoffmanla roche ltd hoffmanla roche inc collectively roche gilead successor pharmasset party october collaboration agreement roche agreement granted roche rights develop psi cytidine analog prodrugs treatment hcv infection collaborative research efforts agreement ended december roche later asked pharmasset consider whether roche may contributed inventorship sofosbuvir whether pharmasset complied confidentiality provisions collaboration agreement pharmasset advised us carefully considered issues raised roche believed issues without merit also considered issues reached conclusion march roche initiated arbitration us pharmasset predecessor gilead pharmasset llc regarding collaboration agreement arbitration demand roche asserts exclusive license sofosbuvir pursuant collaboration agreement sofosbuvir prodrug uridine monophosphate analog allegedly prodrug psi cytidine analog roche claims exclusive rights sofosbuvir also exclusive license patent covering sofosbuvir infringe patent selling offering sale products containing sofosbuvir gilead gilead pharmasset llc filed response roche 's arbitration demand april interference proceedings litigation idenix pharmaceuticals inc february received notice us patent trademark office uspto declared interference first idenix interference us patent patent idenix pharmaceuticals inc 's idenix pending us patent application interference administrative proceeding uspto designed determine first invent subject matter claimed parties patent covers metabolites sofosbuvir rg prodrug cytidine nucleoside analog pharmasset licensed roche idenix attempting patent class compounds including metabolites purpose first idenix interference determine first invent compounds therefore entitled patent claiming compounds march uspto patent trials appeal board board determined idenix entitled benefit early application filing dates none patent applications including application led idenixs us patent patent patent taught make compounds dispute board also determined entitled filing date earliest application first file patent application compounds dispute therefore senior party first idenix interference january board determined pharmasset idenix first invent compounds dispute accordingly gilead prevailed decision board held idenix failed prove first conceive compounds dispute specifically idenix failed prove idenix inventors identified structure method making use disputed compounds board went conclude idenix failed work diligently toward making testing compounds dispute relevant time period idenix appealed boards decisions us district court district delaware either boards decisions reversed appeal court determines idenix entitled patent claims determined infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg united states decision district court appealed either party us court appeals federal circuit cafcwe believe claims idenix application involved first idenix interference similar us foreign patents claiming compounds metabolites invalid result filed impeachment action federal court canada invalidate idenix canadian patent canadian patent corresponds patent idenix patent application subject first idenix interference idenix asserted canadian patent corresponding us patent patent first idenix interference invalid filed similar legal action norway oslo district court seeking invalidate idenix 's corresponding norwegian patent september idenix filed invalidation action norwegian proceedings norwegian patent patent corresponds us patent patent trial held november court yet issued decision august idenix also filed request invalidation chinese patent office chinese patent cn zl corresponds us patent patent filed legal action federal court australia seeking invalidate idenixs australian patent corresponding patent april idenix asserted commercialization sofosbuvir infringe australian patent corresponding patent may bring similar action countries future idenix awarded patents compounds european patent office japan china event patents issue expect challenge proceedings si milar invoked canada norway australia courts hearing proceedings determine idenix entitled patent claims determined infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg country december receiving gileads request uspto declared interference second idenix interference pending us patent application patent patent includes claims directed methods treating hcv nucleoside compounds similar involved first idenix interference second idenix interference determine first invent claimed methods treating hcv declaration second idenix interference uspto initially designated gilead junior party based upon patent application filing dates appearing face patent february uspto issued order show cause idenix second idenix interference order requires idenix explain judgment entered second idenix interference favor gilead based upon outcome first idenix interference order indicates claims patent involved second idenix interference unpatentable due gilead prevailing first idenix interference idenix allowed claim benefit filing date earlier filed patent applications believe boards determination first idenix interference idenix entitled benefit earlier application filing dates including filing date patent equally applicable second idenix interference correct board may conclude gilead senior party second idenix interference consistent determination first idenix interference light boards conclusion first idenix interference application led patent teach make claimed compounds possible board make determination second idenix interference eliminate need board address first invent claimed methods treating hcv however board consider first invent claimed methods treating hcv ultimately concludes gilead first claims ' patent may revoked board determines idenix first invent entitled patent claims determined proceedings infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg determination board appealed either party us federal court december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sued us us district court district delaware alleging commercialization sofosbuvir infringe patent interference exists patent us patent patent believe claims patent invalid sole right commercialize sofosbuvir however court disagrees view determines patent infringed may required obtain license pay royalties idenix commercialize sofosbuvir decision district court appealed either party cafc also december idenix udsg sued us us district court district massachusetts alleging commercialization sofosbuvir infringe us patent nos patents believe idenixs patents invalid would infringed commercialization sofosbuvir sole right commercialize sofosbuvir however court disagrees view determines patents infringed may required obtain license pay royalties idenix commercialize sofosbuvir decision district court appealed either party cafc expansive patent portfolio covering nsa inhibitors treatment hcv following recent disclosure structure idenixs nsa inhibitor samatasvir also known idx evaluating compound light pending claims us patent application litigation merck co inc august merck co inc merck contacted us requesting pay royalties sales sofosbuvir take license us patent patent us patent patent coowns isis pharmaceuticals inc believe mercks patents invalid would infringed commercialization sofosbuvir sole right commercialize sofosbuvir accordingly august filed lawsuit us district court northern district california seeking declaratory judgment merck patents invalid infringed mercks us patent nos patents cover compounds include may relate sofosbuvir patent prosecution merck amended patent application attempt cover compounds related sofosbuvir ultimately extract royalty payments sofosbuvirs commercialization exclude market court determines mercks patents valid infringed claims may required obtain license pay royalties merck commercialize sofosbuvir either party appeal decision district court cafc litigation abbvie inc abbvie abbvie recently obtained us patent nos patents purport claim use combination ldvsof treatment hcv published pending patent applications directed use combinations treatment hcv specifically combinations ledipasvir sofosbuvir certain applications filed abbvie 's recently issued patents reason others believe abbvie 's patents invalid accordingly december filed lawsuit us district court district delaware seeking declaratory judgment abbvie patents invalid unenforceable well relief believe abbott laboratories inc abbvie conspired eliminate competition hcv market falsely representing pto gilead invented methods treating hcv using combination ldvsof february abbvie responded lawsuit filing lawsuit also us district court district delaware alleging ldvsof product infringe patents expect abbvie 's patents block delay commercialization combination products court determines abbvies patents valid infringed claims may required obtain license pay royalties abbvie commercialize sofosbuvir combination products either party appeal decision district court cafc manufacturing problems including thirdparty manufacturers corporate partners could cause inventory shortages delay product shipments regulatory approvals may adversely affect results operations order generate revenue products must able produce sufficient quantities products satisfy demand many products result complex manufacturing processes manufacturing process pharmaceutical products also highly regulated regulators may shut manufacturing facilities believe comply regulations products either manufactured facilities thirdparty manufacturers corporate partners depend third parties perform manufacturing activities effectively timely basis majority solid dose products addition roche either third parties responsible manufacturing tamiflu thirdparty manufacturers corporate partners subject current good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda ema similar regulations effect countries thirdparty manufacturers corporate partners independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected addition thirdparty manufacturers corporate partners may able produce products one limited number facilities therefore limited manufacturing capacity certain products example due unexpected delays qualifying two new external sites expanding cayston manufacturing san dimas unable supply enough cayston fulfill projected demand february september suspended access patients new prescriptions cayston subject certain exceptions specific medical need existed result inability manufacture sufficient cayston meet demand amount revenues received sale cayston reduced manufacturing operations subject routine inspections regulatory agencies example april fda conducted inspection foster city facility issued form inspectional observations noted deficiencies documentation validation certain quality testing procedures methods result observations fda delivered complete response letters notifying us unable approve ndas elvitegravir cobicistat standalone agents midoctober fda completed sofosbuvir preapproval inspection foster city facility following inspection fda issued additional form inspectional observations citing deficiencies related testing reconciliation stability samples testing protocols testing shipping samples procedures calibrating test equipment recently completed filed responses observations fda unable remedy deficiencies cited fda inspections currently marketed products timing regulatory approval products development could adversely affected risk regulatory agencies countries marketing applications pending undertake similar additional reviews apply heightened standard review could delay regulatory approvals products countries approval product candidates including idelalisib ldvsof delayed production marketed products interrupted anticipated revenues stock price would adversely affected may able obtain materials supplies necessary conduct clinical trials manufacture sell products would limit ability generate revenues need access certain supplies products conduct clinical trials manufacture products light global economic downturn increased difficulty purchasing certain raw materials used manufacturing processes unable purchase sufficient quantities materials find suitable alternate materials timely manner development efforts product candidates may delayed ability manufacture products would limited would limit ability generate revenues suppliers key components materials must named nda filed fda ema regulatory authority product candidate seeking marketing approval significant delays occur qualification new supplier required even manufacturer qualified regulatory authority manufacturer must continue expend time money effort area production quality control ensure full compliance gmp manufacturers subject regular periodic inspections regulatory authorities following initial approval result inspections regulatory authority determines equipment facilities laboratories processes comply applicable regulations conditions product approval regulatory authority may suspend manufacturing operations manufacturing operations single suppliers products suspended may unable generate sufficient quantities commercial clinical supplies product meet market demand would turn decrease revenues harm business addition delivery material suppliers interrupted reason may unable ship certain products commercial supply supply products development clinical trials addition products materials utilize operations made one facility example manufacture certain drug product intermediates utilized ambisome exclusively facilities san dimas california event disaster including earthquake equipment failure difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome meet market needs addition depend single supplier highquality cholesterol active pharmaceutical ingredient used manufacture ambisome also rely single source active pharmaceutical ingredient letairis astellas us llc markets lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan problems single suppliers depend may negatively impact development commercialization efforts significant portion raw materials intermediates used manufacture hiv products sovaldi stribild compleraeviplera atripla truvada viread emtriva tybost supplied chinesebased companies result international trade dispute china united states actions chinese government would limit prevent chinese companies supplying materials would adversely affect ability manufacture supply hiv products meet market needs material adverse effect operating results litigation generic manufacturers reduced may continue reduce earnings unsuccessful lawsuits claims patents may narrowed invalidated generic versions products could launched prior patent expiry part approval process products fda granted new chemical entity nce exclusivity period manufacturers ' applications approval generic versions product approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drugs anda application form typically used manufacturers seeking approval generic drug received notices generic manufacturers submitted andas manufacture generic version atripla truvada viread emtriva ranexa tamiflu united states atripla truvada viread canada april teva pharmaceuticals teva reached agreement settle ongoing patent litigation concerning four patents protect tenofovir disoproxil fumarate atripla truvada viread products agreement teva allowed launch generic version viread december august lupin limited lupin reached agreement settle patent litigation concerning ten patents protect ranexa agreement lupin would allowed launch generic version ranexa february february teva reached agreement principle settle ongoing patent litigation concerning emtricitabine patents protect atripla truvada terms settlement agreement confidential settlement agreement filed federal trade commission department justice required law also august teva filed impeachment action federal court canada seeking invalidation two canadian patents associated viread september hearing consolidated requests orders prohibition connection three tevas ands filings tevas generic versions viread truvada atripla took place december court issued requested order prohibiting canadian minister health issuing notice compliance tevas generic versions viread truvada atripla products expiry patent july teva appealed decision decision court ultimately resolve validity challenges raised teva impeachment action teva successful invalidating patents teva may able launch generic versions viread truvada atripla products prior expiry patents trial impeachment action scheduled january anticipate trials related lupin 's andas requesting permission make generic version truvada viread anda filed cipla ltd requesting permission make generic versions emtriva viread take place fourth quarter predict ultimate outcome actions may spend significant resources enforcing defending patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection atripla truvada viread emtriva ranexa tamiflu united states atripla truvada viread canada could substantially shortened patents covering one products invalidated fda canadian minister health could approve requests manufacture generic version products united states canada respectively prior expiration date patents sale generic versions products earlier patent expiration would significant negative effect revenues results operations face credit risks southern european customers may adversely affect results operations european product sales governmentowned supported customers southern europe specifically greece italy portugal spain historically continue subject significant payment delays due government funding reimbursement practices resulted may continue result days sales outstanding significantly higher countries due average length time accounts receivable remain outstanding december accounts receivable countries totaled approximately million million past due greater days million past due greater days follows thousands december greater greater days past due days past due spain portugal italy greece total historically receivable balances certain publiclyowned hospitals accumulate period time subsequently settled large lump sum payments pattern also experienced pharmaceutical companies sell directly hospitals significant changes occur reimbursement practices european governments government funding becomes unavailable may able collect amounts due us customers results operations would adversely affected collected million past due accounts receivable customers based spain portugal included million proceeds onetime factoring arrangement sold receivables spain greek government settled substantially outstanding receivables subject bond settlement zerocoupon bonds trade discount face value march greek government restructured sovereign debt impacted holders greek bonds result recorded million loss revenues gross margin could reduced imports countries products available lower prices prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world reexported european countries could resold much higher prices happens products particularly truvada viread agreed make available substantially reduced prices countries participating gilead access program atripla merck distributes substantially reduced prices hiv infected patients developing countries agreement revenues would adversely affected addition established partnerships indian generic manufacturers distribute highquality lowcost generic versions tenofovir disoproxil fumarate developing world countries including india expanded agreements include rights stribild tybost vitekta also entered collaborations certain indian generic manufacturers produce distribute generic emtricitabine developing world including single tablet regimens containing emtricitabine fixeddose combinations emtricitabine co formulated hiv medicines generic versions medications licenses reexported united states europe markets outside countries revenues would adversely affected addition purchases products countries selling prices relatively low resale countries selling prices relatively high may adversely impact revenues gross margin may cause sales fluctuate quarter quarter example european union required permit products purchased one country sold another country purchases products countries selling prices relatively low resale countries selling prices relatively high affect inventory level held wholesalers cause relative sales levels various countries fluctuate quarter quarter reflect actual consumer demand given quarter quarterly fluctuations may impact earnings could adversely affect stock price harm business expensive litigation government investigations reduced may continue reduce earnings involved number litigation investigation disputerelated matters require us expend substantial internal financial resources expect matters continue require high level internal financial resources foreseeable future matters reduced continue reduce earnings please see description litigation regarding sofosbuvir litigation generic manufacturers department justice investigation legal proceedings beginning outcome lawsuits lawsuits may brought us investigation investigations may initiated inherently uncertain adverse developments outcomes result significant expenses monetary damages penalties injunctive relief us could significantly reduce earnings cash flows harm business countries may required grant compulsory licenses products patents may enforced number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread addition concerns cost availability tamiflu related potential avian flu pandemic hn influenza generated international discussions compulsory licensing tamiflu patents example canadian government considered allowing canadian manufacturers manufacture export active ingredient tamiflu eligible developing least developed countries canada 's access medicines regime furthermore roche issued voluntary licenses permit thirdparty manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense india 's hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit thirdparty manufacturing tamiflu developments could reduce royalties receive roche 's sales tamiflu required grant compulsory licenses products could reduce earnings cash flows harm business addition certain countries permit enforcement patents thirdparty manufacturers able sell generic versions products countries example july brazilian patent authority rejected patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread highest level appeal available us within brazilian patent authority currently patent brazil brazilian government purchases supply tenofovir disoproxil fumarate generic manufacturers sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales changes royalty revenue disproportionately affect pretax income earnings per share gross margins portion revenues derived royalty revenues recognized collaboration agreements third parties royalty revenues impact pretax income earnings per share gross margins disproportionately contributions revenues increase decrease royalty revenue could material could significantly impact operating results example roche 's tamiflu sales unpredictable variability due strong relationship seasonal influenza global pandemic planning efforts periods royalty revenue tamiflu increase see disproportionate increase pretax income earnings per share gross margins similarly periods royalty tamiflu decrease see disproportionate decrease pretax income earnings per share gross margins may face significant liability resulting products may covered insurance successful claims could materially reduce earnings testing manufacturing marketing use commercial products well product candidates development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others recent years coverage availability costeffective product liability insurance decreased may unable maintain sufficient coverage product liabilities may arise addition cost defend lawsuits pay damages product liability claims may exceed coverage unable maintain adequate coverage claims exceed coverage financial condition ability clinically test product candidates market products adversely impacted addition negative publicity associated claims regardless merit may decrease future demand products impair financial condition business disruptions natural manmade disasters may harm future revenues worldwide operations could subject business interruptions stemming natural manmade disasters may selfinsured corporate headquarters fremont locations together house majority rd activities san dimas oceanside manufacturing facilities located california seismically active region carry earthquake insurance significant recovery time could required resume operations financial condition operating results could materially adversely affected event major earthquake changes effective income tax rate could reduce earnings various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates portion nontax deductible pharmaceutical excise tax accounting stock options sharebased payments mergers acquisitions ability manufacture product cork ireland facility amortization certain acquisition related intangibles receive tax benefit expiration federal research tax credit future levels rd spending changes accounting standards changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact net income income tax returns audited federal state foreign tax authorities currently examination internal revenue service tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions resolution one exposures reporting period could material impact results operations period fail attract retain highly qualified personnel may unable successfully develop new product candidates conduct clinical trials commercialize product candidates future success depend large part continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization face competition personnel companies universities public private research institutions government entities organizations competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit may able attract retain quality personnel acceptable terms unsuccessful recruitment retention efforts business may harmed item b unresolved staff comments applicable item properties corporate headquarters located foster city california house administrative manufacturing rd activities also rd facilities oceanside fremont california seattle washington branford connecticut alberta canada manufacturing facilities san dimas california cork ireland global commercial operations include offices throughout europe seven asia one south america one north america believe existing properties including owned leased sites good condition suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet expected longterm growth needs item legal proceedings litigation regarding sofosbuvir january acquired pharmasset inc pharmasset acquisition acquired sofosbuvir formerly known gs nucleotide analog acts inhibit replication hcv december received us food drug administration fda approval sofosbuvir brandnamed sovaldi received number contractual intellectual property claims regarding sofosbuvir carefully considered claims prior following acquisition believe without merit patents claim sofosbuvir chemical entity metabolites however existence patents necessarily guarantee right practice patented technology commercialize patented product third parties may obtain rights patents allegedly could used prevent attempt prevent us commercializing sofosbuvir example aware patents patent applications owned parties may alleged parties cover use sofosbuvir parties successfully obtain valid enforceable patents successfully prove infringement patents sofosbuvir could prevented selling sofosbuvir unless able obtain license patents license may available commercially reasonable terms party successful establishing exclusive rights sofosbuvir expected revenues earnings sale sofosbuvir would adversely affected contract arbitration jeremy clark march jeremy clark former employee pharmasset inventor us patent patent filed demand arbitration lawsuit pharmasset dr raymond schinazi mr clark initially filed lawsuit pharmasset dr schinazi us district court northern district alabama february seeking void assignment provision employment agreement assert ownership us patent patent claims metabolites sofosbuvir rg december court ordered stay litigation pending outcome arbitration proceeding required mr clark 's employment agreement instead proceeding arbitration mr clark filed two additional lawsuits september june court subsequently dismissed september mr clark filed motion seeking reconsideration court 's december order court denied december mr clark filed motion appoint special prosecutor february court issued order requiring mr clark enter arbitration risk dismissal case mr clark filed demand arbitration march arbitration panel held hearing april june arbitration panel issued decision favor pharmasset gilead dr schinazi august gilead dr schinazi filed motion us district court northern district alabama seeking court confirm arbitration decision mr clark filed motion seeking vacate arbitration decision court yet ruled motions arbitration f hoffmanla roche ltd hoffmanla roche inc collectively roche gilead successor pharmasset party october collaboration agreement roche agreement granted roche rights develop psi cytidine analog prodrugs treatment hcv infection collaborative research efforts agreement ended december roche later asked pharmasset consider whether roche may contributed inventorship sofosbuvir whether pharmasset complied confidentiality provisions collaboration agreement pharmasset advised us carefully considered issues raised roche believed issues without merit also considered issues reached conclusion march roche initiated arbitration us pharmasset predecessor gilead pharmasset llc regarding collaboration agreement arbitration demand roche asserts exclusive license sofosbuvir pursuant collaboration agreement sofosbuvir prodrug uridine monophosphate analog allegedly prodrug psi cytidine analog roche claims exclusive rights sofosbuvir also exclusive license patent covering sofosbuvir infringe patent selling offering sale products containing sofosbuvir gilead gilead pharmasset llc filed response roche 's arbitration demand april interference proceedings litigation idenix pharmaceuticals inc february received notice us patent trademark office uspto declared interference first idenix interference us patent patent idenix pharmaceuticals inc 's idenix pending us patent application interference administrative proceeding uspto designed determine first invent subject matter claimed parties patent covers metabolites sofosbuvir rg prodrug cytidine nucleoside analog pharmasset licensed roche idenix attempting patent class compounds including metabolites purpose first idenix interference determine first invent compounds therefore entitled patent claiming compounds march uspto patent trials appeal board board determined idenix entitled benefit early application filing dates none patent applications including application led idenixs us patent patent patent taught make compounds dispute board also determined entitled filing date earliest application first file patent application compounds dispute therefore senior party first idenix interference january board determined pharmasset idenix first invent compounds dispute accordingly gilead prevailed decision board held idenix failed prove first conceive compounds dispute specifically idenix failed prove idenix inventors identified structure method making use disputed compounds board went conclude idenix failed work diligently toward making testing compounds dispute relevant time period idenix appealed boards decisions us district court district delaware either boards decisions reversed appeal court determines idenix entitled patent claims determined infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg united states decision district court appealed either party us court appeals federal circuit cafcwe believe claims idenix application involved first idenix interference similar us foreign patents claiming compounds metabolites invalid result filed impeachment action federal court canada invalidate idenix canadian patent canadian patent corresponds patent idenix patent application subject first idenix interference idenix asserted canadian patent corresponding us patent patent first idenix interference invalid filed similar legal action norway oslo district court seeking invalidate idenix 's corresponding norwegian patent september idenix filed invalidation action norwegian proceedings norwegian patent patent corresponds us patent patent trial held november court yet issued decision august idenix also filed request invalidation chinese patent office chinese patent cn zl corresponds us patent patent filed legal action federal court australia seeking invalidate idenixs australian patent corresponding patent april idenix asserted commercialization sofosbuvir infringe australian patent corresponding patent may bring similar action countries future idenix awarded patents compounds european patent office japan china event patents issue expect challenge proceedings similar invoked canada norway australia courts hearing proceedings determine idenix entitled patent claims determined infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg country december receiving gileads request uspto declared interference second idenix interference pending us patent application patent patent includes claims directed methods treating hcv nucleoside compounds similar involved first idenix interference second idenix interference determine first invent claimed methods treating hcv declaration second idenix interference uspto initially designated gilead junior party based upon patent application filing dates appearing face patent february uspto issued order show cause idenix second idenix interference order requires idenix explain judgment entered second idenix interference favor gilead based upon outcome first idenix interference order indicates claims patent involved second idenix interference unpatentable due gilead prevailing first idenix interference idenix allowed claim benefit filing date earlier filed patent applications believe boards determination first idenix interference idenix entitled benefit earlier application filing dates including filing date patent equally applicable second idenix interference correct board may conclude gilead senior party second idenix interference consistent determination first idenix interference light boards conclusion first idenix interference application led patent teach make claimed compounds possible board make determination second idenix interference eliminate need board address first invent claimed methods treating hcv however board consider first invent claimed methods treating hcv ultimately concludes gilead first claims ' patent may revoked board determines idenix first invent entitled patent claims determined proceedings infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg determination board appealed either party us federal court december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sued us us district court district delaware alleging commercialization sofosbuvir infringe patent interference exists patent us patent patent believe claims patent invalid sole right commercialize sofosbuvir however court disagrees view determines patent infringed may required obtain license pay royalties idenix commercialize sofosbuvir decision district court appealed either party cafc also december idenix udsg sued us us district court district massachusetts alleging commercialization sofosbuvir infringe us patent nos patents believe idenixs patents invalid would infringed commercialization sofosbuvir sole right commercialize sofosbuvir however court disagrees view determines patents infringed may required obtain license pay royalties idenix commercialize sofosbuvir decision district court appealed either party cafc expansive patent portfolio covering nsa inhibitors treatment hcv following recent disclosure structure idenixs nsa inhibitor samatasvir also known idx evaluating compound light pending claims us patent application litigation merck co inc august merck co inc merck contacted us requesting pay royalties sales sofosbuvir take license us patent patent us patent patent coowns isis pharmaceuticals inc believe mercks patents invalid would infringed commercialization sofosbuvir sole right commercialize sofosbuvir accordingly august filed lawsuit us district court northern district california seeking declaratory judgment merck patents invalid infringed mercks us patent nos patents cover compounds include may relate sofosbuvir patent prosecution merck amended patent application attempt cover compounds related sofosbuvir ultimately extract royalty payments sofosbuvirs commercialization exclude market court determines mercks patents valid infringed claims may required obtain license pay royalties merck commercialize sofosbuvir either party appeal decision district court cafc litigation abbvie inc abbvie abbvie recently obtained us patent nos patents purport claim use combination ldvsof treatment hcv published pending patent applications directed use combinations treatment hcv specifically combinations ledipasvir sofosbuvir certain applications filed abbvie 's recently issued patents reason others believe abbvie 's patents invalid accordingly december filed lawsuit us district court district delaware seeking declaratory judgment abbvie patents invalid unenforceable well relief believe abbott laboratories inc abbvie conspired eliminate competition hcv market falsely representing pto gilead invented methods treating hcv using combination ldvsof february abbvie responded lawsuit filing lawsuit also us district court district delaware alleging ldvsof product infringe patents expect abbvie 's patents block delay commercialization combination products court determines abbvies patents valid infringed claims may required obtain license pay royalties abbvie commercialize sofosbuvir combination products either party appeal decision district court cafc litigation generic manufacturers part approval process products fda granted new chemical entity nce exclusivity period manufacturers ' applications approval generic versions product approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drugs anda application form typically used manufacturers seeking approval generic drug tenofovir disoproxil fumarate emtricitabine fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz november received notice teva pharmaceuticals teva submitted abbreviated new drug application anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine owned emory university licensed exclusively us invalid unenforceable andor infringed teva 's manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate december filed lawsuit us district court southern district new york teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva challenged two emtricitabine patents may filed another lawsuit us district court southern district new york teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir disoproxil fumarate patents protecting viread january also received notices teva amending andas related generic versions atripla truvada products notice related teva 's anda generic version atripla teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine two patents related efavirenz notice related teva 's anda generic version truvada teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine march filed lawsuits teva infringement four viread patents two additional emtricitabine patents march bristolmyers squibb company merck filed lawsuit teva infringement patents related efavirenz filed lawsuits within requisite day period provided hatch waxman act stays preventing fda approval teva 's andas months district court decision adverse patents month stay three teva andas expired july april teva reached agreement settle ongoing patent litigation concerning four patents protect tenofovir disoproxil fumarate atripla truvada viread agreement teva allowed launch generic version viread december settlement agreement filed federal trade commission department justice required law october courts dismissal case pursuant settlement agreement parties became final trial lawsuit teva related us patents protecting emtricitabine atripla truvada held october february teva reached agreement principle settle ongoing patent litigation concerning emtricitabine patents protect atripla truvada terms settlement agreement confidential settlement agreement filed federal trade commission department justice required law november received notice teva submitted abbreviated new drug submission ands canadian minister health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate notice teva alleges three patents associated truvada invalid unenforceable andor infringed teva 's manufacture use sale generic version truvada january filed lawsuit teva federal court canada seeking order prohibition approval ands december received notice teva submitted ands canadian minister health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva alleges three patents associated atripla two merck 's patents associated atripla invalid unenforceable andor infringed teva 's manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz february filed lawsuit teva federal court canada seeking order prohibition approval ands august received notice teva submitted ands canadian minister health requesting permission manufacture market generic version viread notice teva alleges two patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed teva 's manufacture use sale generic version viread truvada atripla september filed lawsuit teva federal court canada seeking order prohibition approval ands also august teva filed impeachment action federal court canada seeking invalidation two canadian patents associated viread currently defending impeachment action requests orders prohibition connection three tevas ands filings tevas generic versions viread truvada atripla consolidated hearing consolidated requests orders prohibition took place september december court issued requested order prohibiting canadian ministry health issuing notice compliance tevas generic versions viread truvada atripla products expiry patent july teva appealed decision decision ultimately resolve validity challenges raised teva impeachment action teva successful invalidating patents teva may able launch generic versions viread truvada atripla products prior expiry patents trial impeachment action scheduled january july received notice lupin limited lupin submitted anda fda requesting permission manufacture market generic version truvada notice lupin alleges four patents associated emtricitabine four patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed lupin 's manufacture use sale generic version fixeddose combination emtricitabine tenofovir disoproxil fumarate august filed lawsuit lupin us district court southern district new york infringement patents anticipate trial case fourth quarter either party appeal decision district court cafc lupin successful invalidating patents lupin may able launch generic version truvada product prior expiry patents july received notice cipla ltd cipla submitted anda fda requesting permission manufacture market generic version emtriva generic version viread notice cipla alleges two patents associated emtricitabine invalid unenforceable andor infringed cipla 's manufacture use sale generic version emtricitabine four patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed cipla 's manufacture use sale generic version tenofovir disoproxil fumarate august filed lawsuits cipla us district court southern district new york infringement patents anticipate trial case fourth quarter either party appeal decision district court cafc cipla successful invalidating patents cipla may able launch generic versions viread andor emtriva products prior expiry patents october received notice lupin submitted anda fda requesting permission manufacture market generic version viread notice lupin alleges four patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed lupin 's manufacture use sale generic version tenofovir disoproxil fumarate october filed lawsuit lupin us district court southern district new york infringement patents anticipate trial case fourth quarter either party appeal decision district court cafc lupin successful invalidating patents lupin may able launch generic version viread product prior expiry patents ranolazine june received notice lupin submitted anda fda requesting permission manufacture market generic version sustained release ranolazine notice lupin alleged ten patents associated ranexa invalid unenforceable andor infringed lupin 's manufacture use sale generic version ranexa july filed lawsuit lupin us district court district new jersey infringement patents ranexa trial took place april may august parties reached agreement settle patent litigation prior issuance courts decision agreement lupin would allowed launch generic version ranexa february settlement agreement filed federal trade commission department justice required law tamiflu february received notice natco pharma ltd natco submitted anda fda requesting permission manufacture market generic version tamiflu notice natco alleges one patents associated oseltamivir phosphate invalid unenforceable andor infringed natco 's manufacture use sale generic version tamiflu march f hoffmannla roche ltd roche filed lawsuit natco us district court district new jersey infringement one patents associated tamiflu december court issued ruling favor gilead roche patent invalid reasons stated natco 's notice letter natco appealed decision cafc hearing natcos appeal took place january court yet issued decision appeal natco successful appeal case remanded us district court district new jersey full trial merits predict ultimate outcome actions may spend significant resources enforcing defending patents unsuccessful lawsuits claims patents may narrowed invalidated patent protection atripla truvada viread emtriva tamiflu united states atripla truvada viread canada could substantially shortened patents covering one products invalidated fda canadian minister health could approve requests manufacture generic version products united states canada respectively prior expiration date patents sale generic versions products earlier patent expiration would significant negative effect revenues results operations department justice investigation june received subpoena us attorney 's office northern district california requesting documents related manufacture related quality distribution practices complera atripla truvada viread emtriva hepsera letairis cooperating continue cooperate governmental inquiry matters party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations item mine safety disclosures applicable part ii item market registrant 's common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq global select market symbol gild following table sets forth high low intraday sale prices per share common stock nasdaq global select market periods indicated prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter february shares common stock outstanding held approximately stockholders record include shares held broker bank nominee paid cash dividends common stock since inception expect retain earnings primarily use operation expansion business therefore anticipate paying cash dividends near future performance graph following graph compares total stockholder returns past five years two indices standard poor 's stock index labeled sp index nasdaq biotechnology index labeled nbi index total return index assumes reinvestment dividends paid companies included indices calculated december year composite member sp index nbi index intend use indices comparators stock performance purposes following graph going forward composite member sp index required applicable regulations use index comparator believe nbi index relevant comparator since composed peer companies linesofbusiness similar stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years section soliciting material deemed filed sec incorporated reference filings securities act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nbi index sp index december issuer purchases equity securities december repurchased billion common stock january threeyear billion stock repurchase program expire september spent total million repurchase retire approximately million shares common stock average purchase price per share see item note stockholders ' equity consolidated financial statements included annual report information regarding stock repurchase programs table summarizes stock repurchase activity three months ended december thousands except per share amounts total number maximum fair shares purchased value shares part publicly may yet purchased total number average price announced shares purchased paid per share program program october october november november december december total january announced board authorized threeyear billion stock repurchase program expire september difference total number shares purchased total number shares purchased part publicly announced programs due shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data year ended december consolidated statement income data total revenues total costs expenses income operations provision income taxes net income attributable gilead net income per share attributable gilead common stockholdersbasic shares used per share calculationbasic net income per share attributable gilead common stockholdersdiluted shares used per share calculationdiluted december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible senior notes senior unsecured notes credit facility retained earnings total stockholders ' equity recorded million million stockbased compensation research development rd expenses selling general administrative expenses respectively related acquisition pharmasset inc pharmasset recorded million impairment charges rd expenses related certain inprocess research development iprd assets acquired cgi pharmaceuticals inc recorded million impairment charges rd expenses related certain iprd assets acquired cv therapeutics inc cv therapeutics certain prior period amounts reclassified conform current presentation completed acquisition pharmasset recognized consideration transferred billion primarily recorded intangible assets financed transaction approximately billion cash hand billion bank debt issued january billion senior unsecured notes issued december completed acquisition cv therapeutics recognized consideration transferred billion primarily recorded intangible assets repaid billion principal balance convertible senior notes repaid million fiveyear revolving credit facility credit agreement fiveyear revolving credit agreement borrowed million fiveyear revolving credit agreement issued billion principal amount senior unsecured notes registered offerings issued billion principal amount convertible senior notes private placement item management 's discussion analysis financial condition results operations following management 's discussion analysis financial condition results operations mda intended help reader understand results operations financial condition mda provided supplement read conjunction audited consolidated financial statements accompanying notes consolidated financial statements disclosures included annual report including disclosures item risk factors consolidated financial statements prepared accordance us generally accepted accounting principles presented us dollars management overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery experimental drug candidate strive transform simplify care people lifethreatening illnesses around world gilead 's primary areas focus include human immunodeficiency virus hiv liver diseases hepatitis b virus hbv infection hepatitis c virus hcv infection oncologyinflammation serious cardiovascular respiratory conditions headquartered foster city california operations north south america europe asiapacific continue add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategy product portfolio comprised stribild compleraeviplera atripla truvada viread emtriva tybost sovaldi hepsera vitekta letairis ranexa cayston ambisome vistide business highlights continued advance product pipeline across therapeutic areas made significant progress particularly phase studies oncology liver diseases hiv combination existing internal research programs acquisitions partnerships allow us continue bringing innovative therapies individuals living unmet medical needs summary key accomplishments expanded single tablet regimen str products european launch stribild countries received us food drug administration fda european medicines agency ema approval compleraeviplera use among certain adult patients switching another stable antiretroviral regimen received ema approval oncedaily tybost pharmacokinetic enhancer boosts blood levels certain hiv medicines received ema approval vitekta integrase inhibitor treatment hiv infection adults without known mutations associated resistance elvitegravir advanced clinical development tenofovir alafenamide taf oncedaily single tablet regimen treatment hiv infection phase clinical trials received approval fda health canada december sovaldi sofosbuvir daily oral regimen treatment hcv component combination antiviral treatment regimens received approval ema sovaldi january announced positive interim results three phase clinical studies ion ion ion evaluating oncedaily fixeddose combination ledipasvirsofosbuvir ldvsof without ribavirin rbv treatment genotype hcv infection filed new drug application nda fixeddose combination ldvsof february submitted nda fda approval idelalisib treatment patients indolent nonhodgkin 's lymphoma inhl chronic lymphocytic leukemia cll also filed approval idelalisib treatment inhl cll ema october january fda accepted nda inhl set target review date september prescription drug user fee act pdufa february fda previously granted breakthrough therapy designation idelalisib cll accepted nda set target review date august pdufa completed acquisition ym biosciences inc ym acquired momelotinib orally administered oncedaily candidate hematologic cancers advanced clinical development momelotinib phase clinical trials outlook continue focus key operating objectives include continued progression product pipeline continued uptake commercial products research development rd perspective continue invest various ongoing clinical studies support existing products pipeline new drug candidates expect move forward number latestage clinical studies new product candidates plan file marketing applications various therapeutic areas commercial perspective began buildout commercial organization support launch sovaldi united states canada december january received approval ema sovaldi countries european union sovaldi represents significant shift treatment paradigm certain hcv patients around world plan buildout expansion international commercial infrastructure particularly europe asia support sovaldi launches increase marketing sales efforts related anticipated launch first oncology product idelalisib continue monitor conditions macroeconomic environment could affect ability achieve goals changes reimbursement payor landscape well legislation may delay impact funding aids drug assistance programs adaps united states worsening economic conditions certain key markets particularly europe patent expirations competitive products launch generic competitors government pricing pressures internationally potential volatility foreign currency exchange rates adjust business processes appropriate attempt mitigate risks business expect product pipeline investments expanding commercial infrastructure enable us execute operating objectives financial highlights delivered strong financial performance continued invest product pipeline total revenues grew billion total product sales grew billion compared driven primarily increase antiviral product sales rd expenses increased billion compared due progression clinical studies particularly phase studies oncology liver diseases hiv selling general administrative sga expenses increased billion compared due ongoing growth expansion business including commercial expansion related launch sovaldi net income attributable gilead billion per diluted share compared billion per diluted share due increase total revenues partially offset increase rd sga expenses generated billion operating cash flows paid billion warrants related may notes settled august repaid billion debt net proceeds convertible note hedges utilized million acquisition ym net cash acquired results operations total revenues total revenues include product sales royalty revenues contract revenues total revenues increased billion compared increased billion compared billion product sales represented total revenues total revenues royalty revenues represented total revenues product sales total product sales billion increase total product sales billion driven primarily continued uptake str products primarily stribild compleraeviplera cardiovascular product sales consisting letairis ranexa increased million compared million total product sales billion increase total product sales billion driven primarily continued growth sales antiviral products including atripla truvada compleraeviplera product sales united states increased billion compared billion driven sales growth str products specifically stribild complera well launch newest product sovaldi fourth quarters noted strong wholesaler subwholesaler purchases anticipation price increases effective january estimate fourth quarter sales exceeded demand approximately million million period based observations first quarter may result inventory drawdowns first quarter approximately product sales generated outside united states result face exposure adverse movements foreign currency exchange rates primarily euro used foreign currency exchange forward contracts hedge percentage foreign currency exposure foreign currency exchange net hedges unfavorable impact million revenues compared unfavorable impact million revenues compared product sales europe increased billion compared billion driven primarily higher underlying demand antiviral products specifically eviplera partially offset decreases average net selling price product sales europe increased billion compared billion driven primarily higher underlying demand antiviral franchise antiviral product sales europe totaled billion increase compared billion driven primarily sales atripla truvada foreign currency exchange net hedges unfavorable impact million european product sales compared unfavorable impact million european product sales compared light fiscal debt crises experienced several countries european union several governments announced implemented measures manage healthcare expenditures although date paid rebates countries outside united states payments made foreign governments represent significant portion government rebates chargebacks percentage total product sales foreign locations however continue experience pricing pressure increases amount discounts required products delayed reimbursement could negatively impact future product sales results operations expect total product sales grow realize full year impact sales sovaldi continued uptake commercial products primarily single tablet regimens believe growth could tempered pricing pressures certain european territories impact generic efavirenz available canada europe potential volatility foreign currency exchange rates changes macroeconomic environment government rebates chargebacks us government rebates chargebacks deducted gross product sales increased billion billion increased billion representing total gross product sales total gross product sales march healthcare reform legislation adopted united states required rebates discounts products reimbursed paid various public payers medicaid entities eligible purchase discounted products result legislation impact economic downturn total rebates chargebacks increased experienced changes payer mix specifically believe certain patients previously covered private insurance moved public reimbursement programs result expect government rebates chargebacks percentage total gross product sales continue increase following table summarizes period period changes product sales thousands except percentages change change antiviral products atripla truvada viread compleraeviplera stribild sovaldi hepsera emtriva total antiviral products letairis ranexa ambisome products total product sales antiviral products antiviral product sales increased compared compared atripla increases atripla sales driven primarily increase average net selling price atripla sales driven primarily sales volume growth united states atripla sales accounted total antiviral product sales respectively efavirenz component atripla gross margin zero comprised billion billion billion atripla sales respectively generic version bristolmyers squibb company 's sustiva efavirenz component atripla made available canada europe made available united states result expect increased competitive pricing pressure future atripla sales truvada decreases truvada sales due decrease sales volume partially offset increase average net selling price truvada sales driven primarily sales volume growth united states truvada sales accounted total antiviral product sales respectively future sales truvada could impacted patients switching different str regimen compleraeviplera increases compleraeviplera sales driven primarily sales volume growth europe united states compleraeviplera sales increased due primarily sales volume growth united states complera approved united states august eviplera approved european union november estimate complera became number two mostprescribed regimen treatment nave hiv patients united states number one mostprescribed regimen treatment nave hiv patients europe 's big markets united kingdom france germany italy spain stribild increases sales stribild driven primarily sales volume growth united states stribild approved united states august europe may estimate stribild became number one mostprescribed regimen treatment nave hiv patients united states sovaldi december fda approved sovaldi treatment hcv sovaldi sales totaled million estimate approximately half related initial inventory stocking wholesalers subwholesalers cardiovascular products cardiovascular products include letairis ranexa increased due primarily sales volume growth royalty revenues following table summarizes period period changes royalty revenues thousands except percentages change change royalty revenues royalty revenues increased compared due higher royalty revenues f hoffmannla roche ltd roche result increase number patients treated influenza tamiflu royalty revenues increased compared driven primarily higher royalty revenues glaxosmithkline inc japan tobacco inc astellas us llc partially offset lower tamiflu royalties roche tamiflu royalties roche contributed million million million total royalty revenues respectively recognize royalties tamiflu sales roche quarter following quarter corresponding sales occur cost goods sold product gross margin following table summarizes period period changes product sales cost goods sold product gross margin thousands except percentages change change total product sales cost goods sold product gross margin product gross margin consistent product gross margin product gross margin fourth quarter included million amortization expense related transition inprocess research development iprd asset indefinitelived finitelived intangible asset upon fda approval commercial launch sovaldi expect recognize full year impact amortization approximately million related sovaldi research development expenses following table summarizes period period changes rd expenses thousands except percentages change change research development track total rd expenses product candidate therapeutic area development phase however manage rd expenses identifying rd activities anticipate performed given period prioritizing efforts based scientific data probability successful development market potential available human capital resources considerations continually review rd pipeline status development necessary reallocate resources among rd product portfolio believe best support future growth business rd expenses summarized consist primarily clinical studies performed contract research organizations cros materials supplies licenses fees milestone payments collaboration arrangements personnel costs including salaries benefits stockbased compensation overhead allocations consisting various support facilitiesrelated costs following table provides breakout rd expenses major cost type thousands except percentages clinical studies outside services personnel infrastructure expenses facilities costs inprocess research development impairment charges total rd expenses increased million compared due primarily million increase clinical studies million increase personnel infrastructure expenses support continued progression clinical studies particularly phase studies oncology liver diseases hiv increases partially offset million decrease stockbased compensation expense due acceleration vested stock options related acquisition pharmasset inc pharmasset january clinical studies outside services increased million compared due progression expansion phase studies particularly liver diseases oncology additionally personnel expenses increased million due higher headcount support product pipeline study progression recorded million impairment charges related certain iprd assets acquired cgi pharmaceuticals inc impairment charges result changes anticipated market share related spleen tyrosine kinase syk compound expect rd expenses increase due primarily continued investment advancing product pipeline driven primarily progression clinical studies oncology liver diseases hiv selling general administrative expenses following table summarizes period period changes sga expenses thousands except percentages change change selling general administrative sga expenses relate sales marketing finance human resources legal administrative activities expenses primarily comprised facilities overhead costs outside marketing advertising legal expenses general administrative costs sga expenses increased million compared increase due primarily million increase headcountrelated expenses support ongoing growth business legal expenses pharmaceutical excise tax resulting us healthcare reform increase partially offset million decrease stockbased compensation due acceleration vested stock options related acquisition pharmasset january sequentially sga expenses fourth quarter increased million compared third quarter due primarily increased marketing activities related launch sovaldi sga expenses increased million compared increase due primarily million increase costs associated growth business include personnel headcountrelated expenses million increase stockbased compensation expenses primarily resulting acquisition pharmasset increase million pharmaceutical excise tax resulting us healthcare reform increase partially offset reduction bad debt provisions million included gain million related sale accounts receivables balances spain second quarter expect sga expenses increase support continued buildout expansion commercial infrastructure europe asia support sovaldi launches increased sales marketing efforts related anticipated launch first oncology product idelalisib increase pharmaceutical excise tax estimate portion pharmaceutical excise tax approximately million compared approximately million approximately million interest expense interest expense decreased million compared million decrease due primarily repayment may notes conversions convertible senior notes due may may may notes may notes repayment revolving credit facilities interest expense increased million compared million increase due primarily additional debt issued connection acquisition pharmasset included billion senior unsecured notes issued december billion bank debt issued january income expense net income expense net net expense million compared net expense million net income million changes income expense net due primarily million loss greek bonds related greece 's restructuring sovereign debt first quarter provision income taxes provision income taxes billion billion million respectively effective tax rate differed us federal statutory rate due primarily retroactive extension federal research tax credit january federal research tax credit certain operating earnings nonus subsidiaries considered indefinitely reinvested partially offset state taxes portion non tax deductible pharmaceutical excise tax amortization expense related pharmasset acquisition contingent consideration expense related certain acquisitions receive tax benefit provide us income taxes undistributed earnings foreign operations intended indefinitely reinvested foreign subsidiaries effective tax rate differed us federal statutory rate due primarily tax credits certain operating earnings nonus subsidiaries considered indefinitely reinvested partially offset state taxes stockbased compensation expense related pharmasset acquisition contingent consideration expense related certain acquisitions receive tax benefit effective tax rate differed us federal statutory rate due primarily tax credits certain operating earnings nonus subsidiaries considered indefinitely reinvested partially offset state taxes nontax deductible pharmaceutical excise tax future effective tax rate may impacted various factors including amortization certain acquisitionrelated intangibles receive tax benefit acquisitions ym biosciences inc completed acquisition ym biosciences inc ym based canada total consideration transferred million february time ym became whollyowned subsidiary gilead ym drug development company primarily focused advancing momelotinib formerly known cyt orally administered oncedaily candidate hematologic cancers fair values acquired assets assumed liabilities include primarily iprd million goodwill million deferred tax assets million full unrecognized tax benefit deferred tax liabilities million cash acquired million pro forma results operations acquisition ym presented acquisition material consolidated results operations see note intangible assets goodwill description iprd acquired pharmasset inc january completed acquisition pharmasset publiclyheld clinicalstage pharmaceutical company committed discovering developing commercializing novel drugs treat viral infections pharmasset 's primary focus development oral therapeutics treatment hcv infection pharmasset 's lead compound sofosbuvir formerly known gs nucleotide analog december approved fda health canada name sovaldi oncedaily oral regimen treatment hcv patients genotypes infection including hepatocellular carcinoma meeting milan criteria awaiting liver transplantation hcvhiv coinfection january european commission granted marketing authorization sovaldi countries european union acquisition pharmasset allowed us advance effort develop alloral regimens treatment hcv acquired outstanding shares common stock pharmasset per share cash tender offer subsequent merger terms agreement plan merger entered november aggregate cash payment acquire outstanding shares common stock billion financed transaction approximately billion cash hand billion senior unsecured notes issued december billion bank debt issued january pharmasset acquisition accounted business combination results operations pharmasset included consolidated statement income since january date acquired approximately outstanding shares common stock pharmasset cash consideration transferred result obtained effective control pharmasset acquisition completed january time pharmasset became whollyowned subsidiary gilead integrated operations track earnings results product candidate therapeutic area maintain separate earnings results acquired pharmasset business following table summarizes components cash paid acquire pharmasset thousands total consideration transferred stockbased compensation expense total cash paid billion cash payment consisted billion cash payment outstanding common stockholders well million cash payment option holders pharmasset stock option plans billion cash payment outstanding common stockholders million cash payment vested option holders pharmasset stock option plans accounted consideration transferred remaining million cash payment accounted stockbased compensation expense resulting accelerated vesting pharmasset employee options immediately prior acquisition following table summarizes acquisition date fair values assets acquired liabilities assumed consideration transferred thousands identifiable intangible assets cash cash equivalents assets acquired liabilities assumed net total identifiable net assets goodwill total consideration transferred identifiable intangible assets acquired intangible assets primarily comprised sofosbuvir iprd compound estimated fair value billion date acquisition fair value determined using probabilityweighted income approach discounts expected future cash flows present value estimated net cash flows discounted using discount rate based estimated weightedaverage cost capital companies profiles similar pharmasset rate comparable estimated internal rate return acquisition represents rate market participants would use value intangible asset projected cash flows based key assumptions estimates revenues operating profits related project considering stage development acquisition date time resources needed complete development approval product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing product candidate obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived assets amortized completion abandonment associated rd efforts december following approval fda commercialization sofosbuvir sovaldi reclassified billion purchased iprd project sofosbuvir indefinitelived finitelived intangible asset amortizing asset estimated useful life utilizing straightline method goodwill million goodwill represents excess consideration transferred fair values assets acquired liabilities assumed attributable synergies expected combining rd operations pharmasset 's none goodwill expected deductible income tax purposes stockbased compensation expense stockbased compensation expense recognized accelerated vesting employee options immediately prior acquisition reported consolidated statement income follows thousands year ended december research development expense selling general administrative expense total stockbased compensation expense costs costs incurred connection acquisition include thousands year ended december transaction costs eg investment advisory legal accounting fees bridge financing costs restructuring costs total costs following table summarizes costs line item consolidated statement income costs recognized thousands year ended december research development expense selling general administrative expense interest expense total costs liquidity capital resources believe existing capital resources supplemented cash flows generated operating activities adequate satisfy capital needs foreseeable future cash cash equivalents marketable securities working capital decreased significantly compared completed acquisition pharmasset january following table summarizes cash cash equivalents marketable securities working capital cash flow activities end periods presented thousands december cash cash equivalents marketable securities working capital year ended december cash provided used operating activities investing activities financing activities certain prior period amounts reclassified conform current presentation cash cash equivalents marketable securities cash cash equivalents marketable securities remained relatively flat billion december compared billion december generated billion operating cash flows paid billion warrants related may notes settled august repaid billion debt net proceeds convertible note hedges utilized million acquisition ym net cash acquired cash cash equivalents marketable securities totaled billion december decrease billion december primarily due acquisition pharmasset billion january total cash cash equivalents marketable securities december approximately billion generated operations foreign jurisdictions intended use foreign operations rely unrepatriated earnings source funds domestic business expect sufficient cash flow borrowing capacity united states fund domestic operational strategic needs working capital working capital million december decrease million working capital december due increase current portion longterm debt accrued liabilities partially offset increases accounts receivable inventories cash cash equivalents working capital billion december decrease billion working capital december primarily attributable billion cash used pharmasset acquisition increase shortterm debt billion related current portion bank debt issued finance pharmasset acquisition current portion may notes cash provided operating activities cash provided operating activities billion primarily related net income billion adjusted noncash items million depreciation amortization expenses million stockbased compensation expenses partially offset million net cash outflow related changes operating assets liabilities february collected approximately million past due accounts receivable customers based spain cash provided operating activities billion primarily related net income billion adjusted noncash items million depreciation amortization expenses million stockbased compensation expenses million net cash inflow related changes operating assets liabilities million tax benefits employee stock plans cash provided operating activities billion primarily related net income billion adjusted noncash items million depreciation amortization expenses million net cash inflow related changes operating assets liabilities million stockbased compensation expenses cash provided used investing activities cash used investing activities million consisting primarily million used acquisition ym net cash acquired million capital expenditures primarily related construction progress associated new facilities headquarters support ongoing growth business partially offset million net proceeds sales marketable securities cash used investing activities billion consisting primarily billion used acquisition pharmasset net stockbased compensation expense cash acquired million net purchases marketable securities million capital expenditures related primarily purchase office building million million increase construction progress associated new facilities headquarters support ongoing growth business cash provided investing activities billion consisting billion net proceeds related sales marketable securities connection acquisition pharmasset partially offset million used acquisitions arresto biosciences inc calistoga pharmaceuticals inc million capital expenditures cash provided used financing activities cash used financing activities billion consisting primarily billion used repay debt financing includes maturity may notes conversions may notes may notes billion warrants related may notes settled august million used repurchase common stock stock repurchase program cash outflow partially offset proceeds billion related convertible note hedges cash provided financing activities million driven primarily net proceeds billion issuance bank debt conjunction pharmasset acquisition proceeds million issuances common stock employee stock plans million proceeds received related convertible note hedges cash proceeds partially offset billion used repay debt financing year million used repurchase common stock stock repurchase programs cash provided financing activities billion driven primarily issuance billion senior unsecured notes billion raised december partially fund pharmasset acquisition net issuance costs million proceeds issuances common stock employee stock plans cash proceeds partially offset billion used repurchase common stock stock repurchase programs million used repay convertible senior notes due may debt credit facility bank debt january conjunction acquisition pharmasset entered fiveyear billion revolving credit facility credit agreement five year revolving credit agreement million shortterm revolving credit facility credit agreement shortterm revolving credit agreement billion term loan facility term loan credit agreement borrowed million fiveyear revolving credit agreement million shortterm revolving credit agreement billion term loan credit agreement upon close acquisition fully repaid billion outstanding debt term loan credit agreement shortterm revolving credit agreement time agreements terminated repaid million fiveyear revolving credit agreement fiveyear revolving credit agreement contains customary representations warranties affirmative negative financial maintenance covenants events default loan bears interest either eurodollar rate plus applicable margin ii base rate plus applicable margin defined credit agreement may reduce commitments may prepay loan whole part time without premium penalty required comply certain covenants credit agreement note indentures december compliance covenants fiveyear revolving credit agreement inclusive million swing line loan subfacility million letter credit subfacility december million letters credit outstanding fiveyear revolving credit agreement fiveyear revolving credit agreement terminate amounts owed agreement shall due payable january maturity may convertible senior notes portion may notes converted may remainder notes matured repaid aggregate principal balance million also paid million cash related conversion spread notes represents conversion value excess principal amount received million cash convertible note hedges related notes warrants related may notes expired august paid billion settle warrants average market price common stock exceeded warrants ' exercise price convertible senior notes senior unsecured notes portion may notes may notes converted repaid billion principal balance primarily comprised may notes also paid billion cash related conversion spread notes represents conversion value excess principal amount received billion cash convertible note hedges related notes may notes mature settle related warrants stock price currently exceeds conversion warrants exercise prices expect based stock price filing form pay approximately billion settle aggregate principal may notes related warrants following summary borrowings various financing arrangements thousands except percentages interest december type borrowing description issue date due date rate convertible senior may notes april may convertible senior may notes july may convertible senior may notes july may senior unsecured april notes march april senior unsecured december notes december december senior unsecured december notes december december senior unsecured december notes december december senior unsecured december notes december december credit facility fiveyear revolver january january variable total debt net less current portion total longterm debt net believe existing capital resources supplemented cash flows generated operations adequate satisfy capital needs foreseeable future consider financing opportunities better position us growth amount terms potential financing opportunities well factors could affect liquidity financial condition future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities administrative expenses possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products costs associated settlement conversion convertible senior notes related warrants establishment additional collaborative relationships companies costs associated defense settlement adverse results litigation government investigations may future require additional funding could form proceeds equity debt financings funding required guarantee available us favorable terms critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate estimates including related revenue recognition allowance doubtful accounts valuation intangible assets contingent consideration liabilities resulting business combinations tax provision base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements revenue recognition product sales recognize revenues product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectability reasonably assured record estimated reductions revenues government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products estimates deducted gross product sales time revenues recognized reductions gross product sales government rebates significantly impact reported net product sales based upon certain estimates require complex significant judgment management estimates assessed period updated reflect current information actual experience accrued government rebates allowance government chargebacks estimate reductions revenues governmentmanaged medicaid programs well certain qualifying federal state foreign government programs reimbursement portions retail price prescriptions filled covered programs reductions settled either us invoiced directly chargebacks wholesalers qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower contractual government price although may pay rebates countries outside united states date payments made foreign governments represented significant portion total government rebates estimate government rebates invoiced directly us recorded accrued government rebates consolidated balance sheets estimate government rebates charged back wholesalers recorded allowances accounts receivable consolidated accrued government rebates totaled million december million december consolidated allowance government chargebacks totaled million december million december recorded accounts receivable government programs united states rebate allowances estimated based product sold contractual terms historical utilization rates estimated population channel inventory data obtained major us wholesalers accordance inventory management agreements also take consideration new information regarding changes programs ' regulations guidelines would impact amount actual rebates andor expectations regarding future utilization rates programs us accrued government rebates totaled million december million december us allowance government chargebacks totaled million december million december recorded accounts receivable us government rebates chargebacks totaled billion billion representing total gross product sales deducted gross product sales us government rebates chargebacks totaling billion representing total gross product sales deducted gross product sales believe methodology use estimate sales allowances government price reductions reasonable appropriate given current facts circumstances however actual results future periods may differ significantly one provisions affordable care act aca became effective extension medicaid drug rebate program patients medicaid managed care insurance plans rebates previously required estimating rebates implementation aca complex part due delays actual claims data provided medicaid program amounts recorded reduction increase product sales related prior periods million million million respectively increase product sales million approximately million related estimate claims rest related estimates prior years claims resulted part due changes estimates medicaid managed care rebates based current information available us actual government rebates chargebacks claimed prior periods varied less estimates following table summarizes aggregate activity us government rebates allowance accrued government rebate accounts thousands balance deducted balance beginning reductionincrease end accrued government rebates allowance government chargebacks year product sales accruals year year ended december activity related sales activity related sales prior total year ended december activity related sales activity related sales prior total allowance doubtful accounts maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required believe allowance doubtful accounts adequate however significant deterioration factors could materially change expectations may result increase allowance doubtful accounts december allowance doubtful accounts million million respectively valuation intangible assets conjunction business combinations recorded intangible assets primarily related iprd projects total intangible assets billion december billion december part pharmasset acquisition acquired intangible assets primarily comprised sofosbuvir iprd compound estimated fair value billion date acquisition december following approval fda commercialization sofosbuvir sovaldi reclassified billion purchased iprd project indefinitelived finite lived intangible asset amortizing asset estimated useful life utilizing straightline method identifiable intangible assets measured respective fair values acquisition date models used valuing intangible assets require use significant estimates assumptions including limited estimates revenues operating profits related products product candidates probability success unapproved product candidates considering stages development time resources needed complete development approval product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets believe fair values used record intangible assets acquired connection business combination based upon reasonable estimates assumptions given facts circumstances related valuation dates intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts development complete generally occurs regulatory approval market product obtained associated assets would deemed finitelived would amortized based respective estimated useful lives point time period assets considered indefinitelived amortized tested impairment annual basis well annual tests become aware events changes would indicate likely fair value iprd projects respective carrying amounts fair value indefinitelived intangible assets dependent assumptions expected timing probability achieving specified milestones changes projected revenues changes discount rates significant judgment employed determining assumptions changes assumptions could significant impact results operations given period intangible assets finite useful lives amortized estimated useful lives primarily straightline basis intangible assets finite useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable valuation contingent consideration liabilities resulting business combinations conjunction business combinations recorded contingent consideration liabilities payable upon achievement specified development regulatory approval salesbased milestone events contingent consideration liabilities measured respective fair values acquisition date models used valuing contingent consideration liabilities require use significant estimates assumptions including limited estimates revenues operating profits related products product candidates probability success unapproved product candidates considering stages development time resources needed complete development approval product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets revalue contingent consideration obligations quarter following acquisition record increases decreases fair value rd expense within consolidated statement income increases decreases fair value contingent consideration liabilities result updates assumptions expected timing probability achieving specified milestones changes projected revenues changes discount rates significant judgment employed determining assumptions acquisition date subsequent period updates assumptions could significant impact results operations given period actual results may differ estimates total contingent consideration liabilities million december million december tax provision estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization portion deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance reduce valuation allowance period determination first made various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates portion nontax deductible pharmaceutical excise tax accounting stock options sharebased payments mergers acquisitions ability manufacture product cork ireland facility amortization certain acquisition related intangibles receive tax benefit expiration federal research tax credit future levels rd spending changes accounting standards changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact net income record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprise 's financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return believe uncertain tax positions currently pending material adverse effect consolidated financial statements although adverse resolution one uncertain tax positions period could material impact results operations period december total federal state foreign unrecognized tax benefits million million respectively total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification irs tax authorities regarding uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective tax authorities file federal state foreign income tax returns many jurisdictions united states abroad federal income tax purposes statute limitations open onwards certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years california income tax purposes statute limitations open onwards income tax returns audited federal state foreign tax authorities currently examination irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions balance sheet arrangements balance sheet arrangements defined item aii regulation sk contractual obligations contractual obligations consist debt obligations operating leases capital commitments purchase obligations active pharmaceutical ingredients inventoryrelated items clinical trials contracts following table summarizes significant enforceable legally binding obligations future commitments obligations related contracts likely continue regardless fact certain obligations may cancelable december thousands payments due period less one contractual obligations total year years years years debt operating lease obligations capital commitments purchase obligations clinical trials total debt obligations include convertible senior notes senior unsecured notes fiveyear revolving credit agreement incur future interest payments based fixed rates may notes may notes respectively senior unsecured notes due december december april december december respectively fiveyear revolving credit agreement incurs interest based variable interest rates portion interest expense related variable interest totaled million december firm capital project commitments approximately million primarily relating facilities improvement projects december firm purchase commitments related active pharmaceutical ingredients certain inventoryrelated items amounts include minimum purchase requirements actual purchases expected significantly exceed amounts addition committed make potential future milestone payments third parties part licensing collaboration development arrangements payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones achievement milestones neither probable reasonably estimable contingencies recorded consolidated balance sheets included table december several clinical studies various clinical trial phases significant clinical trial expenditures cros although material contracts cros cancelable historically canceled contracts amounts reflect commitments based existing contracts reflect future modifications terminations existing contracts anticipated potential new contracts total gross unrecognized tax benefit liabilities million december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification irs tax authorities regarding uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective tax authorities unrecognized tax benefits included current longterm income taxes payable longterm deferred tax assets consolidated balance sheet included table recent accounting pronouncements february financial accounting standards board fasb issued update existing standard liabilities update provides guidance recognition measurement disclosure obligations resulting joint several liability arrangements obligations total amount fixed reporting date entity required measure obligations sum amount reporting entity agreed pay basis arrangement among coobligors additional amount reporting entity expects pay behalf coobligors entities also required disclose nature amount significant information obligations guidance become effective us beginning first quarter believe adoption update material impact consolidated financial statements july fasb issued update related presentation unrecognized tax benefit net operating loss carryforward similar tax loss tax credit carryforward exists unrecognized tax benefit portion unrecognized tax benefit presented financial statements reduction deferred tax asset net operating loss carryforward similar tax loss tax credit carryforward except follows extent net operating loss carryforward similar tax loss tax credit carryforward available reporting date tax law applicable jurisdiction settle additional income taxes would result disallowance tax position tax law applicable jurisdiction require entity use entity intend use deferred tax asset purpose unrecognized tax benefit presented financial statements liability combined deferred tax assets guidance become effective us beginning first quarter believe adoption update material impact consolidated financial statements item quantitative qualitative disclosures market risk exposed market risks may result changes foreign currency exchange rates interest rates credit risks reduce certain risks enter various types foreign currency interest rate derivative hedging transactions follow investment guidelines monitor outstanding receivables part risk management program foreign currency exchange risk operations include manufacturing sales activities united states canada ireland well sales activities countries outside united states including europe asia pacific result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies significant euro us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business approximately product sales denominated foreign currencies partially mitigate impact changes currency exchange rates net cash flows foreign currency denominated sales may enter foreign currency exchange forward option contracts also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid general market risks contracts offset corresponding gains losses transactions hedged december open foreign currency forward contracts notional amounts billion billion respectively hypothetical adverse movement foreign currency exchange rates compared us dollar relative exchange rates december would resulted reduction fair value contracts approximately million date realized would negatively affect earnings remaining life contracts hypothetical movement foreign currency exchange rates compared us dollar relative exchange rates december would resulted reduction fair value contracts approximately million date realized would negatively affect earnings remaining life contracts analysis consider impact hypothetical changes foreign currency exchange rates would anticipated transactions foreign currency sensitive instruments designed offset interest rate risk portfolio availableforsale marketable securities fixed variable rate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based credit rating maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestgenerating assets fixed interestbearing liabilities december thousands except percentages expected maturity total fair value december thereafter total assets available forsale debt securities average interest rate liabilities debt average interest rate december issued senior unsecured notes due december registered offering notes pay interest fixed annual rates ranging march issued senior unsecured notes due april registered offering notes pay interest fixed annual rate july issued convertible senior notes due may may may notes may notes private placement pursuant rule securities act amended may notes may notes issued par bear interest rates respectively may converted shares common stock subject certain circumstances connection acquisition pharmasset entered credit agreements subject variable interest rates portion interest expense related variable interest totaled million credit risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe second quarter received payment million past due accounts receivable customers based spain included amount proceeds onetime factoring arrangement sold receivables carrying value million net allowance doubtful accounts received proceeds million recorded gain million resulting primarily reversal related allowance doubtful accounts gain recorded offset sga expenses consolidated statement income subsequent transaction continuing involvement transferred receivables derecognized time sale december accounts receivable southern europe specifically greece italy portugal spain totaled approximately million million greater days past due million greater days past due december accounts receivable southern europe specifically greece italy portugal spain totaled approximately million million greater days past due million greater days past due date experienced significant losses respect collection accounts receivable believe allowance doubtful accounts adequate december item financial statements supplementary data financial statements required item set forth beginning annual report incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness disclosure controls procedures defined rule ae securities exchange act amended exchange act controls procedures company designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified securities exchange commission 's rules forms information accumulated communicated company 's management including chief executive officer chief financial officer appropriate allow timely decisions regarding required disclosure based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective december b management 's report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af exchange act internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework coso criteria based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included annual report issued report internal control financial reporting december report audit internal control financial reporting appears c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting report independent registered public accounting firm board directors stockholders gilead sciences inc audited gilead sciences inc 's internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission framework coso criteria gilead sciences inc 's management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's report internal control financial reporting responsibility express opinion company 's internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion company 's internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion gilead sciences inc maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states consolidated financial statements gilead sciences inc report dated february expressed unqualified opinion thereon ernst young llp redwood city california february item b information applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed securities exchange commission pursuant regulation connection annual meeting stockholders proxy statement headings nominees board committees meetings executive officers section beneficial ownership reporting compliance written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website httpwwwgileadcom investors section corporate governance changes waivers code ethics disclosed website intend satisfy disclosure requirement item form k regarding amendment waiver provision code ethics disclosing information website item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee interlocks insider participation compensation committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference sections proxy statement headings security ownership certain beneficial owners management securities authorized issuance equity compensation plans item certain relationships related transactions director independence information required item incorporated reference sections proxy statement headings nominees certain relationships related party transactions item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services part iv item exhibits financial statement schedules following documents filed part annual report index list consolidated financial statements report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements comprehensive income consolidated statements stockholders ' equity consolidated statements cash flows notes consolidated financial statements schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference item exhibits exhibit footnote exhibit number description document agreement plan merger among registrant apex merger sub inc cv therapeutics inc dated march agreement plan merger among registrant merger sub pharmasset inc dated november arrangement agreement among registrant nova scotia limited ym biosciences inc dated december restated certificate incorporation registrant amendment certificate incorporation registrant amended restated bylaws registrant amended restated may reference made exhibit exhibit indenture related convertible senior notes due notes registrant wells fargo bank national association trustee including form convertible senior note due dated april indenture related convertible senior notes due notes registrant wells fargo bank national association trustee including form convertible senior note due dated july indenture related convertible senior notes due notes registrant wells fargo bank national association trustee including form convertible senior note due dated july indenture related senior notes dated march registrant wells fargo national association trustee first supplemental indenture related senior notes dated march registrant wells fargo national association trustee including form senior notes second supplemental indenture related senior notes dated december registrant wells fargo national association trustee including form note form note form note form note confirmation otc convertible note hedge related notes dated april amended restated april registrant bank america na confirmation otc warrant transaction dated april amended restated april registrant bank america na warrants expiring confirmation otc convertible note hedge related notes dated july registrant goldman sachs co confirmation otc convertible note hedge related notes dated july registrant jpmorgan chase bank national association confirmation otc convertible note hedge related notes dated july registrant goldman sachs co confirmation otc convertible note hedge related notes dated july registrant jpmorgan chase bank national association confirmation otc warrant transaction dated july registrant goldman sachs co warrants expiring confirmation otc warrant transaction dated july registrant jpmorgan chase bank national association warrants expiring confirmation otc warrant transaction dated july registrant goldman sachs co warrants expiring confirmation otc warrant transaction dated july registrant jpmorgan chase bank national association warrants expiring confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association confirmation otc additional warrant transaction dated august registrant goldman sachs co warrants expiring confirmation otc additional warrant transaction dated august registrant jpmorgan chase bank national association warrants expiring confirmation otc additional warrant transaction dated august registrant goldman sachs co warrants expiring confirmation otc additional warrant transaction dated august registrant jpmorgan chase bank national association warrants expiring amendment confirmation otc convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc convertible note hedge related notes dated august registrant jpmorgan chase bank national association amendment confirmation otc convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc convertible note hedge related notes dated august registrant jpmorgan chase bank national association amendment confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association amendment confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association year revolving credit facility credit agreement among registrant gilead biopharmaceutics ireland corporation borrowers bank america na administrative agent swing line lender lc issuer certain lenders parties thereto barclays capital syndication agent goldman sachs bank usa jpmorgan chase bank na royal bank canada wells fargo bank na codocumentation agents dated january parent guaranty agreement year revolving credit facility dated january registrant gilead sciences inc equity incentive plan amended may form employee stock option agreement used equity incentive plan grants prior february form employee stock option agreement used equity incentive plan grants made february april form employee stock option agreement used equity incentive plan grants commencing may form employee stock option agreement used equity incentive plan grants commencing february form employee stock option agreement used equity incentive plan subsequent year grants form nonemployee director stock option agreement used equity incentive plan grants prior form nonemployee director option agreement used equity incentive plan initial grants made form nonemployee director option agreement used equity incentive plan annual grants made may may form nonemployee director option agreement used equity incentive plan annual grants commencing may may form nonemployee director option agreement used equity incentive plan annual grants made may form nonemployee director option agreement nonus used equity incentive plan annual grants made may form restricted stock unit issuance agreement used equity incentive plan annual grants nonemployee directors may form restricted stock award agreement used equity incentive plan annual grants certain nonemployee directors prior may form restricted stock unit issuance agreement used equity incentive plan annual grants nonemployee directors commencing may form restricted stock unit issuance agreement nonus used equity incentive plan annual grants non employee directors commencing may form performance share award agreement used equity incentive plan grants certain executive officers made form performance share award agreement used equity incentive plan grants certain executive officers made form performance share award agreement used equity incentive plan grants certain executive officers made form performance share award agreement used equity incentive plan grants certain executive officers made form performance share award agreement used equity incentive plan tsr goals form performance share award agreement used equity incentive plan revenue goals form restricted stock unit issuance agreement used equity incentive plan grants certain executive officers made prior may form restricted stock unit issuance agreement used equity incentive plan grants certain executive officers commencing may form restricted stock unit issuance agreement used equity incentive plan servicebased vesting certain executive officers commencing november form restricted stock unit issuance agreement used equity incentive plan servicebased vesting certain executive officers commencing gilead sciences inc employee stock purchase plan amended restated may gilead sciences inc international employee stock purchase plan amended restated may gilead sciences inc deferred compensation planbasic plan document gilead sciences inc deferred compensation planadoption agreement addendum gilead sciences inc deferred compensation plan gilead sciences inc deferred compensation plan amended restated october gilead sciences inc severance plan amended january gilead sciences inc corporate bonus plan amended restated gilead sciences inc code section bonus plan base salaries named executive officers offer letter dated april registrant robin washington form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees form employee proprietary information invention agreement entered registrant certain officers key employees revised september amended restated collaboration agreement among registrant gilead holdings llc bristolmyers squibb company er squibb sons llc bristolmyers squibb gilead sciences llc dated september commercialization agreement gilead sciences limited bristolmyers squibb company dated december amendment agreement dated october registrant institute organic chemistry biochemistry iocb rega stichting vzw rega together following exhibits license agreement dated december registrant iocb rega license agreement license agreement dated october registrant iocb rega october license agreement license agreement dated december registrant iocb rega december license agreement amendment agreement registrant iocbrega dated december amending license agreement december license agreement sixth amendment agreement license agreement iocbrega registrant dated august amending october license agreement december license agreement seventh amendment agreement license agreement iocbrega registrant dated july amending october license agreement december license agreement development license agreement among registrant f hoffmannla roche ltd hoffmannla roche inc dated september first amendment supplement dated november development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc dated september second amendment dated december development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc dated september third amendment dated october development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc dated september exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university dated may royalty sale agreement among registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july amended restated license agreement registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july license agreement japan tobacco inc registrant dated march first amendment license agreement japan tobacco inc registrant dated may second amendment license agreement japan tobacco inc registrant dated may third amendment license agreement japan tobacco inc registrant dated july fourth amendment license agreement japan tobacco inc registrant dated july fifth amendment license agreement japan tobacco inc registrant dated october license agreement registrant successor myogen inc abbott deutschland holding gmbh dated october license agreement registrant successor myogen inc glaxo group limited dated march license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc dated march first amendment license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc dated july amendment license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc dated november amendment license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc dated june amendment license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc dated december license collaboration agreement among registrant gilead sciences limited janssen rd ireland formerly tibotec pharmaceuticals dated july second amendment license collaboration agreement among registrant gilead sciences limited janssen rd ireland formerly tibotec pharmaceuticals dated july amended restated second amendment license collaboration agreement among registrant gilead sciences limited janssen rd ireland formerly tibotec pharmaceuticals dated february master clinical commercial supply agreement gilead world markets limited registrant patheon inc dated january restated amended toll manufacturing agreement gilead sciences limited registrant takeda gmbh formerly nycomed gmbh altana pharma oranienburg gmbh dated november emtricitabine manufacturing supply agreement gilead sciences limited evonik degussa gmbh formerly known degussa ag dated june amendment emtricitabine manufacturing supply agreement gilead sciences limited evonik degussa gmbh formerly known degussa ag dated april purchase sale agreement joint escrow instructions electronics imaging inc registrant dated july amendment dated october purchase sale agreement joint escrow instructions electronics imaging inc registrant dated july subsidiaries registrant consent independent registered public accounting firm power attorney reference made signature certification chief executive officer required rule aa rule da securities exchange act amended certification chief financial officer required rule aa rule da securities exchange act amended certifications chief executive officer chief financial officer required rule ab rule db section chapter title united states code usc following materials registrant 's annual report year ended december formatted extensible business reporting language xbrl includes consolidated balance sheets december ii consolidated statements income years ended december iii consolidated statements comprehensive income years ended december iv consolidated statements stockholders ' equity years ended december v consolidated statements cash flows years ended december vi notes consolidated financial statements filed exhibit registrant 's current report form k filed march incorporated herein reference filed exhibit registrant 's current report form k filed november incorporated herein reference filed exhibit ym biosciences inc 's report form k filed december incorporated herein reference filed exhibit registrant 's current report form k filed may incorporated herein reference filed exhibit registrant 's current report form k filed may incorporated herein reference filed exhibit registrant 's current report form k filed april incorporated herein reference filed exhibit registrant 's current report form k filed august incorporated herein reference filed exhibit registrant 's current report form k filed april incorporated herein reference filed exhibit registrant 's current report form k filed december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's current report form k filed january incorporated herein reference filed exhibit registrant 's current report form ka filed february incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended march incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended march incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended march incorporated herein reference filed exhibit registrant 's current report form k first filed december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended march incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference information included registrant 's current report form k filed february incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's registration statement form amended incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's annual report fiscal year ended march incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit triangle pharmaceuticals inc 's quarterly report form qa filed november incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended march incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit myogen inc 's registration statement form amended originally filed august incorporated herein reference filed exhibit myogen inc 's quarterly report form q filed may incorporated herein reference filed exhibit cv therapeutics inc 's registration statement form amended originally filed april incorporated herein reference filed exhibit cv therapeutics inc 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference agreement plan merger merger agreement contains representations warranties registrant apex merger sub inc cv therapeutics inc made solely specific dates representations warranties made solely purposes merger agreement may subject important qualifications limitations agreed registrant apex merger sub inc cv therapeutics inc moreover representations warranties may accurate complete specified date may subject standard materiality provided merger agreement used purpose allocating risk among registrant apex merger sub inc cv therapeutics inc rather establishing matters facts agreement plan merger pharmasset merger agreement contains representations warranties registrant merger sub pharmasset inc made solely specific dates representations warranties made solely purposes pharmasset merger agreement may subject important qualifications limitations agreed registrant merger sub pharmasset inc moreover representations warranties may accurate complete specified date may subject standard materiality provided pharmasset merger agreement used purpose allocating risk among registrant merger sub pharmasset inc rather establishing matters facts management contract compensatory plan arrangement certification accompanies form q relates deemed filed securities exchange commission incorporated reference filing registrant securities act amended securities exchange act amended whether made date form q irrespective general incorporation language contained filing xbrl information filed herewith certain confidential portions exhibit omitted means marking portions asterisk mark exhibit filed separately secretary securities exchange commission without mark pursuant registrant 's application requesting confidential treatment rule b securities exchange act amended gilead sciences inc consolidated financial statements years ended december contents report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements comprehensive income consolidated statements stockholders ' equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements income comprehensive income stockholders ' equity cash flows three years period ended december audits also included financial statement schedule listed index item financial statements schedule responsibility company 's management responsibility express opinion financial statements schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity us generally accepted accounting principles also opinion related financial statement schedule considered relation basic financial statements taken whole presents fairly material respects information set forth therein also audited accordance standards public company accounting oversight board united states gilead sciences inc 's internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework coso criteria report dated february expressed unqualified opinion thereon ernst young llp redwood city california february gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents shortterm marketable securities accounts receivable net allowances december december inventories deferred tax assets prepaid taxes prepaid expenses current assets total current assets property plant equipment net longterm portion prepaid royalties longterm deferred tax assets longterm marketable securities intangible assets net goodwill longterm assets total assets liabilities stockholders equity current liabilities accounts payable accrued government rebates accrued compensation employee benefits income taxes payable accrued liabilities deferred revenues current portion longterm debt obligations net total current liabilities longterm deferred revenues longterm debt net longterm income taxes payable longterm deferred tax liabilities longterm obligations commitments contingencies note equity component currently redeemable convertible notes note stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share shares authorized december december shares issued outstanding december december additional paidin capital accumulated comprehensive loss retained earnings total gilead stockholders equity noncontrolling interest total stockholders equity total liabilities stockholders equity common stock shares additional paidin capital periods presented reflect twoforone stock split form stock dividend took effect january see accompanying notes gilead sciences inc consolidated statements income thousands except per share amounts year ended december revenues product sales royalty revenues contract revenues total revenues costs expenses cost goods sold research development expenses selling general administrative expenses total costs expenses income operations interest expense income expense net income provision income taxes provision income taxes net income net loss attributable noncontrolling interest net income attributable gilead net income per share attributable gilead common stockholdersbasic shares used per share calculationbasic net income per share attributable gilead common stockholdersdiluted shares used per share calculationdiluted see accompanying notes gilead sciences inc consolidated statements comprehensive income thousands year ended december net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale securities net unrealized gain loss net tax impact reclassifications net income net tax impact net change cash flow hedges net unrealized gain loss net tax impact reclassification net income net tax impact net change comprehensive income loss comprehensive income comprehensive loss attributable noncontrolling interest comprehensive income attributable gilead see accompanying notes gilead sciences inc consolidated statements stockholders ' equity thousands gilead stockholders ' equity common stock accumulated additional total paidin comprehensive retained noncontrolling stockholders ' shares amount capital income loss earnings interest equity balance december distributions noncontrolling interest net income loss comprehensive income issuances employee stock purchase plan issuances equity incentive plans tax benefits employee stock plans stockbased compensation repurchases common stock convertible notes settlement convertible notes hedge settlement balance december contributions noncontrolling interest net income loss comprehensive loss issuances employee stock purchase plan issuances equity incentive plans tax benefits employee stock plans stockbased compensation repurchases common stock convertible notes settlement convertible notes hedge settlement reclassification equity component currently redeemable convertible notes balance december contributions noncontrolling interest net income loss comprehensive loss issuances employee stock purchase plan issuances equity incentive plans tax benefits employee stock plans stockbased compensation repurchases common stock warrants settlement convertible notes settlement convertible notes hedge settlement reclassification equity component currently redeemable convertible notes balance december common stock shares additional paidin capital periods presented reflect twoforone stock split form stock dividend took effect january see accompanying notes gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income adjustments reconcile net income net cash provided operating activities depreciation expense amortization expense stockbased compensation expense inprocess research development impairment charges excess tax benefits stockbased compensation tax benefits employee stock plans deferred income taxes change fair value contingent consideration changes operating assets liabilities accounts receivable net inventories prepaid expenses assets accounts payable income taxes payable accrued liabilities deferred revenues net cash provided operating activities investing activities purchases marketable securities proceeds sales marketable securities proceeds maturities marketable securities purchases investments acquisitions net cash acquired capital expenditures net cash provided used investing activities financing activities proceeds debt financing net issuance costs proceeds convertible note hedges proceeds issuances common stock repurchases common stock repayments debt financing payments settle warrants repayments longterm obligations excess tax benefits stockbased compensation contributions distributions noncontrolling interest net cash provided used financing activities effect exchange rate changes cash net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid net amounts capitalized income taxes paid see accompanying notes gilead sciences inc notes consolidated financial statements organization summary significant accounting policies overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery experimental drug candidate strive transform simplify care people lifethreatening illnesses around world gilead 's primary areas focus include human immunodeficiency virus hiv liver diseases hepatitis b virus hbv infection hepatitis c virus hcv infection oncologyinflammation serious cardiovascular respiratory conditions continue add existing portfolio products internal discovery clinical development programs product acquisition licensing strategy product portfolio comprised stribild compleraeviplera atripla truvada viread emtriva tybost sovaldi hepsera vitekta letairis ranexa cayston ambisome vistide us international commercial sales operations marketing subsidiaries north south america europe asiapacific addition also sell distribute certain products corporate partners royaltypaying collaborative agreements basis presentation accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries joint ventures bristolmyers squibb company bms primary beneficiary record noncontrolling interest consolidated financial statements reflect bms 's interest joint ventures intercompany transactions eliminated consolidated financial statements include results companies acquired us date acquisition applicable reporting periods january completed twoforone stock split form stock dividend stockholders record january declared december accordingly share per share amounts periods presented consolidated financial statements notes adjusted retroactively reflect stock split additionally certain prior period amounts within consolidated financial statements related notes reclassified conform current presentation significant accounting policies estimates judgments preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis management evaluates significant accounting policies estimates base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates estimates assessed period updated reflect current information actual experience revenue recognition product sales recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectability reasonably assured upon recognition revenue product sales provisions made government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products appropriate items deducted gross product sales government rebates chargebacks estimate reductions revenues governmentmanaged medicaid programs well certain qualifying federal state foreign government programs estimates take consideration contractual terms historical utilization rates available new information regarding changes programs ' regulations guidelines would impact amount actual rebates expectations regarding future utilization rates programs us product sales channel inventory data obtained major us wholesalers accordance inventory management agreements government rebates invoiced directly us recorded accrued government rebates consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower contractual government price record allowances accounts receivable cash discounts estimate cash discounts based contractual terms historical utilization rates available expectations regarding future utilization rates distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractually determined covenants maintenance agreed upon inventory levels distributor fees based contractually determined fixed percentage sales product returns provide customers general right product return typically permit returns product damaged defective received customer case product sold united states certain countries outside united states product expired accept returns product expire within six months expired one year expiration dates estimates expected returns expired products based primarily ongoing analysis historical return patterns royalty revenues royalty revenue sales products generally recognized received generally quarter following quarter corresponding sales occur royalty revenue sales lexiscan ambisome astellas us llc astellas pharma us inc respectively recognized month following month corresponding sales occur contract revenues revenue nonrefundable upfront license fees milestone payments development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms obligations arrangements revenue recognized obligation fulfilled ratably development manufacturing period revenue associated substantive atrisk milestones recognized based upon achievement milestones set forth respective agreements advance payments received excess amounts earned classified deferred revenue consolidated balance sheets shipping handling costs shipping handling costs incurred inventory purchases product shipments recorded cost goods sold consolidated statements income research development expenses research development rd expenses consist primarily personnel costs including salaries benefits stockbased compensation clinical studies performed contract research organizations cros materials supplies licenses fees milestone payments collaboration arrangements overhead allocations consisting various support facilitiesrelated costs charge rd costs including clinical study costs expense incurred clinical study costs significant component rd expenses clinical studies performed thirdparty cros monitor levels performance significant contract including extent patient enrollment activities communications cros accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros material cro contracts terminable us upon written notice generally liable actual services completed cro certain noncancelable expenses incurred point termination amounts paid advance related uncompleted services refunded us contract terminated advertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million stockbased compensation utilize share based compensation form various types equitybased awards including restricted stock units rsus performance units stock options compensation expense recognized consolidated statements income based estimated fair value grant date estimated fair values rsus based closing price common stock performance unit awards based either monte carlo valuation methodology stock price date grant stock option awards based blackscholes option valuation model cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents eligible instruments investment policy included cash equivalents include commercial paper money market funds overnight repurchase agreements repos major banks authorized dealers bank obligations marketable nonmarketable securities determine appropriate classification marketable securities consist primarily debt securities variable rate demand obligations time purchase reevaluate designation balance sheet date marketable securities considered availableforsale carried estimated fair values reported either cash equivalents shortterm marketable securities longterm marketable securities unrealized gains losses availableforsale securities excluded net income reported accumulated comprehensive income loss separate component stockholders ' equity income expense net includes interest dividends amortization purchase premiums discounts realized gains losses sales securities otherthantemporary declines fair value securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value review includes consideration cause impairment including creditworthiness security issuers number securities unrealized loss position severity duration unrealized losses whether intent sell securities whether likely required sell securities recovery amortized cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carrying value security hold record loss amount decline result entering collaborations time time may hold investments nonpublic companies record nonmarketable securities cost longterm assets less amounts otherthantemporary impairment regularly review securities indicators impairment investments nonmarketable securities material periods presented concentrations risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe received payment million past due accounts receivable customers based spain included amount proceeds onetime factoring arrangement sold receivables carrying value million net allowance doubtful accounts received proceeds million recorded gain million resulting primarily reversal related allowance doubtful accounts gain recorded offset selling general administrative sga expenses consolidated statement income subsequent transaction continuing involvement transferred receivables derecognized time sale december accounts receivable southern europe specifically greece italy portugal spain totaled approximately million million greater days past due million greater days past due date experienced significant losses respect collection accounts receivable believe allowance doubtful accounts adequate december certain raw materials components utilize operations obtained single suppliers certain raw materials utilize operations made one facility since suppliers key components raw materials must named new drug application nda filed us food drug administration fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship commercial products supply product candidates clinical trials accounts receivable trade accounts receivable recorded net allowances wholesaler chargebacks related government rebate programs cash discounts prompt payment sales returns doubtful accounts estimates wholesaler chargebacks government rebates cash discounts sales returns based contractual terms historical trends expectations regarding utilization rates programs estimates allowance doubtful accounts determined based existing contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding geographic region review local economic environment potential impact government funding reimbursement practices historically amounts uncollectible accounts receivable written insignificant consistent management 's expectations inventories inventories recorded lower cost market cost determined firstin firstout basis periodically review composition inventories order identify obsolete slowmoving otherwise unsaleable items unsaleable items observed alternate uses inventory record writedown net realizable value period impairment first recognized future commercialization considered probable future economic benefit expected realized based management 's judgment capitalize prelaunch inventory costs prior regulatory approval number factors taken consideration including current status regulatory approval process potential impediments approval process safety efficacy anticipated research development initiatives could impact indication compound used viability commercialization marketplace trends december amount prelaunch inventory consolidated balance sheets significant property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straight line method repairs maintenance costs expensed incurred estimated useful lives years follows description estimated useful life buildings improvements laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term office computer equipment includes capitalized software unamortized capitalized software costs consolidated balance sheets million december million december leasehold improvements capitalized leased equipment amortized shorter lease term asset 's useful life amortization capitalized leased equipment included depreciation expense capitalized interest construction inprogress included property plant equipment interest capitalized significant goodwill intangible assets goodwill represents excess consideration transferred estimated fair value assets acquired liabilities assumed business combination intangible assets indefinite useful lives related purchased inprocess research development iprd projects measured respective fair values acquisition date amortize goodwill intangible assets indefinite useful lives intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts development complete generally occurs regulatory approval market product obtained associated assets would deemed finitelived would amortized based respective estimated useful lives point time test goodwill indefinitelived intangible assets impairment annual basis annual tests become aware events changes would indicate likely fair value assets carrying amounts intangible assets finite useful lives amortized estimated useful lives primarily straightline basis reviewed impairment facts circumstances suggest carrying value assets may recoverable impairment longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment fda another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated income producing asset indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset asset group eventual disposition carrying amount asset asset group excess carrying value asset asset group estimated fair value recognized impairment loss valuation contingent consideration resulting business combination connection certain acquisitions may required pay future consideration contingent upon achievement specified development regulatory approval salesbased milestone events record contingent consideration resulting business combination fair value acquisition date quarter thereafter revalue obligations record increases decreases fair value rd expense within consolidated statement income time related product candidate receives marketing approval increases decreases fair value contingent consideration liabilities result updates assumptions expected timing probability achieving specified milestones changes projected revenues changes discount rates significant judgment employed determining assumptions acquisition date subsequent period updates assumptions could significant impact results operations given period actual results may differ estimates foreign currency translation transaction gains losses hedging contracts nonus entity operations recorded functional currency entity results operations nonus dollar functional currency entities translated us dollars using average currency rates assets liabilities translated using currency rates period end foreign currency translation adjustments recorded component comprehensive income loss within stockholders ' equity foreign currency transaction gains losses recorded income expense net consolidated statements income net foreign currency transaction losses totaled million million million hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes hedge net investment foreign subsidiaries fair value financial instruments apply fair value accounting financial assets liabilities nonfinancial assets liabilities recognized disclosed fair value financial statements recurring basis define fair value price would received selling asset paid transfer liability orderly transaction market participants measurement date determining fair value measurements assets liabilities required recorded fair value consider principal advantageous market would transact marketbased risk measurements assumptions market participants would use pricing asset liability risks inherent valuation techniques transfer restrictions credit risks determine fair value financial nonfinancial assets liabilities using fair value hierarchy establishes three levels inputs may used measure fair value follows level inputs include quoted prices active markets identical assets liabilities level inputs include observable inputs level inputs quoted prices similar assets liabilities quoted prices identical similar assets liabilities markets active inputs observable corroborated observable market data substantially full term asset liability marketable securities review trading activity pricing measurement date sufficient quoted pricing identical securities available use market pricing observable market inputs similar securities obtained various thirdparty data providers inputs either represent quoted prices similar assets active markets derived observable market data level inputs include unobservable inputs supported little market activity significant fair value underlying asset liability level assets liabilities include whose fair value measurements determined using pricing models discounted cash flow methodologies similar valuation techniques significant management judgment estimation derivative financial instruments recognize derivative instruments either assets liabilities fair value consolidated balance sheets changes fair value derivatives recorded period current earnings accumulated comprehensive income loss depending whether derivative designated part hedge transaction type hedge transaction classify cash flows instruments category cash flows hedged items hold issue derivative instruments trading speculative purposes assess inception ongoing basis whether derivatives used hedging transactions highly effective offsetting changes cash flows fair values hedged items also assess hedge ineffectiveness quarterly basis record gain loss related ineffective portion current earnings extent significant determine forecasted transaction longer probable occurring discontinue hedge accounting affected portion hedge instrument related unrealized gain loss contract recognized current earnings income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income taxes estimates based interpretations existing tax laws regulations various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates portion nontax deductible pharmaceutical excise tax accounting stock options sharebased payments mergers acquisitions ability manufacture product cork ireland facility amortization certain acquisition related intangibles receive tax benefit expiration federal research tax credit future levels rd spending changes accounting standards changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact consolidated net income record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprise 's financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return believe uncertain tax positions currently pending material adverse effect consolidated financial statements although adverse resolution one uncertain tax positions period could material impact results operations period recent accounting pronouncements february financial accounting standards board fasb issued update existing standard liabilities update provides guidance recognition measurement disclosure obligations resulting joint several liability arrangements obligations total amount fixed reporting date entity required measure obligations sum amount reporting entity agreed pay basis arrangement among coobligors additional amount reporting entity expects pay behalf coobligors entities also required disclose nature amount significant information obligations guidance become effective us beginning first quarter believe adoption update material impact consolidated financial statements july fasb issued update related presentation unrecognized tax benefit net operating loss carryforward similar tax loss tax credit carryforward exists unrecognized tax benefit portion unrecognized tax benefit presented financial statements reduction deferred tax asset net operating loss carryforward similar tax loss tax credit carryforward except follows extent net operating loss carryforward similar tax loss tax credit carryforward available reporting date tax law applicable jurisdiction settle additional income taxes would result disallowance tax position tax law applicable jurisdiction require entity use entity intend use deferred tax asset purpose unrecognized tax benefit presented financial statements liability combined deferred tax assets guidance become effective us beginning first quarter believe adoption update material impact consolidated financial statements fair value measurements financial instruments consist principally cash cash equivalents marketable securities accounts receivable foreign currency exchange forward contracts accounts payable shortterm longterm debt cash cash equivalents marketable securities foreign currency exchange contracts hedge accounts receivable forecasted sales reported respective fair values consolidated balance sheets shortterm longterm debt reported amortized cost consolidated balance sheets remaining financial instruments reported consolidated balances sheets amounts approximate current fair values fair values convertible senior notes senior unsecured notes determined using level inputs based quoted market values following table summarizes carrying values fair values convertible senior notes senior unsecured notes thousands december december type borrowing description carrying value fair value carrying value fair value convertible senior may notes convertible senior may notes convertible senior may notes senior unsecured april notes senior unsecured december notes senior unsecured december notes senior unsecured december notes senior unsecured december notes following table summarizes assets liabilities recorded fair value respective fair value classification level input within fair value hierarchy thousands december december level level level total level level level total assets debt securities us treasury securities money market funds us government agencies securities municipal debt securities corporate debt securities residential mortgage assetbacked securities total debt securities deferred compensation plan derivatives liabilities contingent consideration deferred compensation plan derivatives maintain deferred compensation plan directors key employees may defer compensation income tax purposes amounts deferred participants deposited rabbi trust amount periodically adjusted reflect earnings losses based participant 's investment elections among select group investment funds consists money market funds mutual funds see note deferred compensation plans information level inputs estimate fair values government related debt corporate debt residential mortgage assetbacked securities taking consideration valuations obtained thirdparty pricing services pricing services utilize industry standard valuation models including income marketbased approaches significant inputs observable either directly indirectly estimate fair value inputs include reported trades brokerdealer quotes similar securities issuer credit spreads benchmark securities prepaymentdefault projections based historical data observable inputs substantially foreign currency derivatives contracts maturities primarily month time horizon counterparties minimum credit rating equivalent standard poor 's moody 's investors service inc fitch inc estimate fair values contracts taking consideration valuations obtained thirdparty valuation service utilizes incomebased industry standard valuation model significant inputs observable either directly indirectly inputs include foreign currency rates london interbank offered rates libor swap rates inputs applicable commonly quoted intervals level inputs december assets liabilities measured using level inputs contingent consideration liabilities held auction rate securities greek government bonds measured fair value using level inputs policy recognize transfers level classification actual date event change circumstances caused transfer following table provides rollforward changes fair value assets measured using level inputs thousands year ended december fair value beginning period total realized unrealized gains losses included income expense net comprehensive income loss net sales marketable securities fair value end period auction rate securities sold remaining portfolio auction rate securities result sale received total proceeds million resulted million loss recognized income expense net consolidated statements income underlying assets auction rate securities consisted student loans although auction rate securities would typically measured using level inputs failure auctions lack market activity liquidity experienced since beginning required securities measured using level inputs fair value auction rate securities determined using discounted cash flow model considered projected cash flows issuing trusts underlying collateral expected yields projected cash flows estimated based underlying loan principal bonds outstanding payout formulas weightedaverage life cash flows projected considered collateral composition securities related historical projected prepayments greek government bonds greek government restructured sovereign debt impacted holders greek bonds result recorded million loss related debt restructuring part income expense net consolidated statements income exchanged greek governmentissued bonds new securities liquidated first quarter estimated fair value greek zerocoupon bonds using level inputs due current lack market activity liquidity discount rates used fair value model bonds based credit default swap rates contingent consideration liabilities connection certain acquisitions may required pay future consideration contingent upon achievement specified development regulatory approval salesbased milestone events estimate fair value contingent consideration liabilities acquisition date reporting period thereafter using probabilityweighted income approach reflects probability timing future payments fair value measurement based significant level inputs anticipated timelines probability achieving development regulatory approval salesbased milestone events projected revenues resulting probabilityweighted cash flows discounted using creditrisk adjusted interest rates reporting period thereafter revalue obligations performing review assumptions listed record increases decreases fair value contingent consideration obligations rd expenses within consolidated statements income time related product candidate receives marketing approval absence significant changes key assumptions quarterly determination fair values contingent consideration obligations would primarily reflect passage time significant judgment employed determining level inputs fair value measurements acquisition date subsequent period updates assumptions could significant impact results operations given period actual results may differ estimates example significant increases probability achieving milestone projected revenues would result significantly higher fair value measurement significant decreases estimated probability achieving milestone projected revenues would result significantly lower fair value measurement significant increases discount rate anticipated timelines would result significantly lower fair value measurement significant decreases discount rate anticipated timelines would result significantly higher fair value measurement potential contingent consideration payments required upon achievement development regulatory approval based milestones related cgi pharmaceuticals inc calistoga pharmaceuticals inc calistoga acquisitions range payment none milestones achieved estimated maximum million undiscounted accrued million december million december remainder contingent consideration liabilities accrual december relates potential future payments resulting acquisition arresto biosciences inc arresto royalty obligations future sales specified salesbased milestones achieved following table provides rollforward contingent consideration liabilities recorded part accrued liabilities longterm obligations consolidated balance sheets thousands year ended december balance beginning period additions new acquisitions net changes valuation balance end period availableforsale securities estimated fair values availableforsale securities generally based prices obtained commercial pricing services following table summary availableforsale debt securities recorded cash cash equivalents marketable securities consolidated balance sheets thousands december december gross gross gross gross amortized unrealized unrealized estimated amortized unrealized unrealized estimated cost gains losses fair value cost gains losses fair value debt securities us treasury securities money market funds us government agencies securities municipal debt securities corporate debt securities residential mortgage assetbacked securities total following table summarizes classification availableforsale debt securities consolidated balance sheets thousands december december cash cash equivalents shortterm marketable securities longterm marketable securities total cash cash equivalents table exclude cash million december million december following table summarizes portfolio availableforsale debt securities contractual maturity thousands december amortized cost fair value less one year greater one year less five years greater five years less ten years greater ten years total following table summarizes gross realized gains losses related sales marketable securities thousands year ended december gross realized gains sales gross realized losses sales cost securities sold determined based specific identification method following table summarizes availableforsale debt securities continuous unrealized loss position deemed otherthan temporarily impaired thousands less months months greater total gross gross gross unrealized estimated unrealized estimated unrealized estimated losses fair value losses fair value losses fair value december debt securities us treasury securities us government agencies securities municipal debt securities corporate debt securities residential mortgage asset backed securities total december debt securities us treasury securities us government agencies securities municipal debt securities corporate debt securities residential mortgage asset backed securities total held total securities december securities december unrealized loss position based review securities believe otherthantemporary impairments securities december intend sell securities believe likely required sell securities recovery amortized cost basis derivative financial instruments operate foreign countries exposes us market risk associated foreign currency exchange rate fluctuations us dollar various foreign currencies significant euro order manage risk may hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes hedge exposure foreign currency exchange rate fluctuations certain monetary assets liabilities foreign subsidiaries denominated nonfunctional currency derivative instruments use hedge exposure designated hedges result changes fair value recorded income expense net consolidated statements income hedge exposure foreign currency exchange rate fluctuations forecasted product sales denominated nonfunctional currency derivative instruments use hedge exposure designated cash flow hedges maturity dates months less upon executing hedging contract quarterly thereafter assess prospective hedge effectiveness using regression analysis calculates change cash flow result hedge instrument monthly basis assess retrospective hedge effectiveness using dollar offset approach exclude time value effectiveness testing recognize changes time value hedge income expense net effective component hedge recorded unrealized gain loss hedging instrument accumulated comprehensive income oci within stockholders ' equity hedged forecasted transaction occurs hedge dedesignated unrealized gains losses reclassified product sales majority gains losses related hedged forecasted transactions reported accumulated oci december reclassified product sales within months cash flow effects derivatives contracts three years ended december included within net cash provided operating activities consolidated statements cash flows notional amounts foreign currency exchange contracts outstanding billion december billion december derivative contracts allow us right offset assets liabilities presented amounts gross basis international swap dealers association inc master agreements respective counterparties foreign currency exchange contracts subject applicable requirements allowed net settle transactions currency single net amount payable one party following table summarizes location fair values derivative instruments consolidated balance sheets thousands december asset derivatives liability derivatives classification fair value classification fair value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities total derivatives designated hedges total derivatives december asset derivatives liability derivatives classification fair value classification fair value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities total derivatives designated hedges total derivatives following table summarizes effect foreign currency exchange contracts consolidated statements income thousands year ended december derivatives designated hedges gains losses recognized oci effective portion gains losses reclassified accumulated oci product sales effective portion gains losses recognized income expense net ineffective portion amounts excluded effectiveness testing derivatives designated hedges gains losses recognized income expense net time time may discontinue cash flow hedges result record related amounts income expense net consolidated statements income material amounts recorded income expense net years ended december result discontinuance cash flow hedges december held one type financial instrument derivative contracts related foreign currency exchange contracts following table summarizes potential effect offsetting derivatives type financial instrument consolidated balance sheets thousands december offsetting derivative assetsliabilities gross amounts offset consolidated balance sheet amounts assetsliabilities gross amounts presented derivative recognized gross amounts offset consolidated financial cash collateral net amount description assetsliabilities consolidated balance sheet balance sheet instruments receivedpledged legal offset derivative assets derivative liabilities december offsetting derivative assetsliabilities gross amounts offset consolidated balance sheet gross amounts amounts assetsliabilities derivative recognized gross amounts offset presented consolidated financial cash collateral net amount description assetsliabilities consolidated balance sheet balance sheet instruments receivedpledged legal offset derivative assets derivative liabilities acquisitions ym biosciences inc completed acquisition ym biosciences inc ym based canada total consideration transferred million february time ym became whollyowned subsidiary gilead ym drug development company primarily focused advancing momelotinib formerly known cyt orally administered oncedaily candidate hematologic cancers fair values acquired assets assumed liabilities include primarily iprd million goodwill million deferred tax assets million full unrecognized tax benefit deferred tax liabilities million cash acquired million pro forma results operations acquisition ym presented acquisition material consolidated results operations see note intangible assets goodwill description iprd acquired pharmasset inc january completed acquisition pharmasset publiclyheld clinicalstage pharmaceutical company committed discovering developing commercializing novel drugs treat viral infections pharmasset 's primary focus development oral therapeutics treatment hcv infection pharmasset 's lead compound sofosbuvir formerly referred gs nucleotide analog december approved fda health canada name sovaldi oncedaily oral regimen treatment hcv patients genotypes infection including hepatocellular carcinoma meeting milan criteria awaiting liver transplantation hcvhic coinfection january european commission granted marketing authorization sovaldi countries european union acquisition pharmasset allowed us advance effort develop alloral regimens treatment hcv acquired outstanding shares common stock pharmasset per share cash tender offer subsequent merger terms agreement plan merger entered november aggregate cash payment acquire outstanding shares common stock billion financed transaction approximately billion cash hand billion senior unsecured notes issued december billion bank debt issued january pharmasset acquisition accounted business combination results operations pharmasset included consolidated statement income since january date acquired approximately outstanding shares common stock pharmasset cash consideration transferred result obtained effective control pharmasset acquisition completed january time pharmasset became whollyowned subsidiary gilead integrated operations track earnings results product candidate therapeutic area maintain separate earnings results acquired pharmasset business following table summarizes components cash paid acquire pharmasset thousands total consideration transferred stockbased compensation expense total cash paid billion cash payment consisted billion cash payment outstanding common stockholders well million cash payment option holders pharmasset stock option plans billion cash payment outstanding common stockholders million cash payment vested option holders pharmasset stock option plans accounted consideration transferred remaining million cash payment accounted stockbased compensation expense resulting accelerated vesting pharmasset employee options immediately prior acquisition following table summarizes acquisition date fair values assets acquired liabilities assumed consideration transferred thousands identifiable intangible assets cash cash equivalents assets acquired liabilities assumed net total identifiable net assets goodwill total consideration transferred identifiable intangible assets acquired intangible assets primarily comprised sofosbuvir iprd compound estimated fair value billion date acquisition fair value asset determined using probabilityweighted income approach discounts expected future cash flows present value estimated net cash flows discounted using discount rate based estimated weightedaverage cost capital companies profiles similar pharmasset rate comparable estimated internal rate return acquisition represents rate market participants would use value intangible asset projected cash flow sofosbuvir based key assumptions estimates revenues operating profits related project considering stage development acquisition date time resources needed complete development approval product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing product candidate obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived assets completion abandonment associated rd efforts december billion purchased iprd project sofosbuvir completed reclassified finitelived intangible asset amortizing asset estimated useful life utilizing straightline method goodwill million goodwill represents excess consideration transferred fair values assets acquired liabilities assumed attributable synergies expected combining rd operations pharmasset 's none goodwill expected deductible income tax purposes stockbased compensation expense stockbased compensation expense recognized accelerated vesting employee options immediately prior acquisition reported consolidated statement income follows thousands year ended december research development expense selling general administrative expense total stockbased compensation expense costs costs incurred connection acquisition include thousands year ended december transaction costs eg investment advisory legal accounting fees bridge financing costs restructuring costs total costs following table summarizes costs line item consolidated statement income costs recognized thousands year ended december research development expense selling general administrative expense interest expense total costs pro forma information following unaudited pro forma information presents combined results operations gilead pharmasset acquisition pharmasset completed january adjustments give effect pro forma events directly attributable acquisition unaudited pro forma results reflect operating efficiencies potential cost savings may result consolidation operations gilead pharmasset accordingly unaudited pro forma results presented informational purposes necessarily indicative actual results operations combined company would acquisition occurred beginning period presented indicative future results operations thousands year ended december total revenues net income attributable gilead unaudited pro forma consolidated results include nonrecurring pro forma adjustments assume acquisition occurred january stock based compensation expenses million incurred included net income attributable gilead year ended december costs million incurred year ended december included net income attributable gilead year ended december calistoga pharmaceuticals inc february entered agreement acquire calistoga million plus potential payments million based achievement certain milestones transaction closed april time calistoga became whollyowned subsidiary calistoga privatelyheld biotechnology company based seattle washington focused development medicines treat cancer inflammatory diseases acquisition provided us portfolio proprietary compounds selectively target isoforms phosphoinositide kinase pik lead product candidate idelalisib formerly referred gs firstinclass specific inhibitor pik delta isoform pik delta preferentially expressed leukocytes involved variety inflammatory autoimmune diseases hematological cancers acquisition accounted business combination calistoga 's results operations since april included consolidated statement income significant acquisitiondate fair value total consideration transferred acquire calistoga million consisted cash paid prior closing million contingent consideration million following table summarizes fair values assets acquired liabilities assumed april thousands iprd net liabilities assumed total identifiable assets goodwill total consideration transferred iprd intangible assets associated iprd projects relate idelalisib product candidate management determined estimated acquisitiondate fair value intangible assets related iprd million estimated fair value determined using income approach discounts expected future cash flows present value estimated fair value using present value discount rate considers estimated weightedaverage cost capital companies profiles substantially similar calistoga well acquirer 's estimated weightedaverage cost capital believe appropriate given unique characteristics acquisition included competitive bidding process rate comparable estimated internal rate return acquisition represents rate market participants would use value intangible assets projected cash flows iprd projects based key assumptions estimates revenues operating profits related project considering stage development acquisition date time resources needed complete development approval product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing product candidate obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts goodwill excess consideration transferred fair values assigned assets acquired liabilities assumed million represents goodwill amount resulting calistoga acquisition management believes goodwill mainly represents synergies expected combining rd operations well acquiring calistoga 's assembled workforce intangible assets qualify separate recognition consider calistoga acquisition material business combination therefore disclosed pro forma results operations required material business combinations arresto biosciences inc december entered agreement acquire arresto million plus potential future payments based achievement certain sales targets transaction closed january time arresto became whollyowned subsidiary arresto privatelyheld developmentstage biotechnology company based palo alto california focused developing antibodies potential treatment fibrotic diseases cancer lead product acquisition arresto simtuzumab formerly referred gs humanized monoclonal antibody mab targeting human lysyl oxidaselike loxl protein addition ongoing phase study simtuzumab patients advanced solid tumors time acquisition phase study also initiated evaluate simtuzumab patients idiopathic pulmonary fibrosis acquisition accounted business combination arresto 's results operations since january included consolidated statement income significant acquisitiondate fair value total consideration transferred acquire arresto million consisted cash paid prior closing million contingent consideration million following table summarizes fair values assets acquired liabilities assumed january thousands iprd deferred tax assets deferred tax liabilities net liabilities assumed total identifiable net assets goodwill total consideration transferred iprd intangible assets associated iprd projects relate simtuzumab product candidate management determined estimated acquisitiondate fair value intangible assets related iprd million estimated fair value determined using income approach discounts expected future cash flows present value estimated fair value using present value discount rate based estimated weightedaverage cost capital companies profiles substantially similar arresto comparable estimated internal rate return acquisition represents rate market participants would use value intangible assets projected cash flows iprd projects based key assumptions estimates revenues operating profits related project considering stage development acquisition date time resources needed complete development approval product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing product candidate obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts goodwill excess consideration transferred fair values assigned assets acquired liabilities assumed million represents goodwill amount resulting arresto acquisition management believes goodwill mainly represents synergies expected combining rd operations well acquiring arresto 's assembled workforce intangible assets qualify separate recognition consider arresto acquisition material business combination therefore disclosed pro forma results operations required material business combinations inventories inventories summarized follows thousands december raw materials work process finished goods total joint ventures formed gilead bms see note collaborative arrangements included consolidated financial statements held efavirenz active pharmaceutical ingredient inventory efavirenz inventory purchased bms bms 's estimated net selling price efavirenz totaled billion december billion december property plant equipment property plant equipment summarized follows thousands december property plant equipment net buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction progress subtotal less accumulated depreciation amortization including relating capitalized leased equipment subtotal land total completed construction new laboratory facility headquarters support ongoing growth business total cost complete facility million intangible assets goodwill intangible assets following table summarizes carrying amount intangible assets thousands december indefinitelived intangible assets finitelived intangible assets total intangible assets indefinitelived intangible assets december indefinitelived intangible assets consisted primarily purchased iprd known commercially sovaldi sofosbuvir acquisition pharmasset upon fda approval commercial launch sovaldi december reclassified iprd related sovaldi finite lived intangible assets also completed acquisition ym total million fair value acquired assets assumed liabilities ym attributed million iprd related momelotinib consolidated balance sheet following table summarizes indefinitelived intangible assets thousands december indefinitelived intangible asset sovaldi sofosbuvir indefinitelived intangible asset momelotinib formerly cyt indefinitelived intangible assets foreign currency translation adjustment total finitelived intangible assets following table summarizes finitelived intangible assets thousands december december gross carrying accumulated gross carrying accumulated amount amortization amount amortization intangible asset sofosbuvir intangible asset ranexa intangible asset lexiscan total upon fda approval commercial launch sovaldi december reclassified iprd related sovaldi finitelived intangible assets amortization expense related finitelived intangible assets included primarily cost goods sold consolidated statements income totaled million million million weightedaverage amortization period finitelived intangible assets approximately years december estimated future amortization expense associated intangible assets five succeeding fiscal years follows thousands fiscal year amount total goodwill upon completing acquisition ym attributed million goodwill consolidated balance sheets following table summarizes changes carrying amount goodwill thousands balance december goodwill resulting acquisition ym foreign currency translation adjustment balance december collaborative arrangements time time result entering strategic collaborations may hold investments nonpublic companies review interests investee companies consolidation andor appropriate disclosure based applicable guidance variable interest entities vies may required consolidate entity contractual terms arrangement essentially provide us control entity even majority voting interest assess whether primary beneficiary vie based power direct activities vie significantly impact vie 's economic performance obligation absorb losses right receive benefits vie could potentially significant vie december determined certain investee companies vies however respect joint ventures bms primary beneficiary therefore consolidate investees bristolmyers squibb company north america entered collaboration arrangement bms develop commercialize single tablet regimen truvada bms 's sustiva efavirenz united states combination approved use united states sold brand name atripla bms structured collaboration joint venture operates limited liability company named bristolmyers squibb gilead sciences llc consolidate bms granted royaltyfree sublicenses joint venture use respective company owned technologies return granted license joint venture use intellectual property results collaboration bms amended joint venture 's collaboration agreement allow joint venture sell atripla canada economic interests joint venture held us bms including share revenues outofpocket expenses based portion net selling price atripla attributable efavirenz truvada since net selling price truvada may change time relative net selling price efavirenz bms 's respective economic interests joint venture may vary annually bms shared marketing sales efforts starting except limited number activities jointly managed parties longer coordinate detailing promotional activities united states parties reduced joint promotional efforts since launched complera august stribild august parties continue collaborate activities manufacturing regulatory compliance pharmacovigilance daily operations joint venture governed four primary joint committees formed bms gilead responsible accounting financial reporting tax reporting manufacturing product distribution joint venture parties provide respective bulk active pharmaceutical ingredients joint venture approximate market values agreement continue terminated mutual agreement parties addition either party may terminate party 's participation collaboration within days launch least one generic version party 's single agent products double agent products terminating party right continue sell atripla become continuing party obligated pay terminated party certain royalties threeyear period following effective date termination december joint venture held efavirenz active pharmaceutical ingredient purchased bms bms 's estimated net selling price efavirenz us market amounts included inventories consolidated balance sheets december total assets held joint venture billion consisted primarily cash cash equivalents million accounts receivable million inventories billion total liabilities billion consisted primarily accounts payable million accrued expenses million december total assets held joint venture billion consisted primarily cash cash equivalents million accounts receivable million inventories billion total liabilities billion consisted primarily accounts payable billion accrued expenses million asset liability amounts reflect impact intercompany eliminations included consolidated balance sheets although consolidate joint venture legal structure joint venture limits recourse creditors general credit assets similarly assets held joint venture used settle obligations joint venture certain prior period amounts reclassified conform current presentation europe gilead sciences limited whollyowned subsidiary ireland bms entered collaboration agreement bms sets forth terms conditions bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory parties formed limited liability company consolidate manufacture atripla distribution european territory using efavirenz purchases bms bms 's estimated net selling price efavirenz european territory responsible manufacturing product distribution inventory management warehousing local subsidiaries primary responsibility order fulfillment collection receivables customer relations handling sales returns territories bms promote atripla general parties share revenues outofpocket expenses proportion net selling prices components atripla truvada efavirenz starting except limited number activities jointly managed parties longer coordinate detailing promotional activities region responsible accounting financial reporting tax reporting collaboration december efavirenz purchased bms bms 's estimated net selling price efavirenz european territory included inventories consolidated balance sheets parties also formed limited liability company hold marketing authorization atripla europe primary responsibility regulatory activities major market countries parties agreed independently continue use commercially reasonable efforts promote atripla agreement terminate upon expiration lasttoexpire patent affords market exclusivity atripla one components european territory addition either party may terminate agreement reason termination effective two calendar quarters notice termination nonterminating party right continue sell atripla become continuing party obligated pay terminating party certain royalties threeyear period following effective date termination event continuing party decides sell atripla effective date termination date atripla withdrawn country date third party assumes distribution atripla whichever earlier japan tobacco inc japan tobacco inc japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco retained rights agreement responsible seeking regulatory approval territories required use diligent efforts commercialize elvitegravir treatment hiv infection november european commission granted us marketing authorization elvitegravir known commercially vitekta also component stribild bear costs expenses associated commercialization efforts terms agreement incurred upfront license fee million included rd expenses future alternative use technology recorded million rd expenses related milestone incurred result dosing first patient phase clinical study recorded million rd expenses related milestone paid related dosing first patient phase clinical study october submitted nda fda approval stribild december submitted marketing authorization application ema marketing approval stribild time recorded million rd expenses related milestones incurred connection filings obligated make additional payments upon achievement milestones total million well pay royalties based net sales territories market product august capitalized million related milestone incurred connection fda approval stribild may capitalized million related milestone incurred connection ema approval stribild milestones amortized useful patent life vitekta approximately years expiring agreement obligation pay royalties japan tobacco terminate productbyproduct basis patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement reason case license granted japan tobacco us would terminate either party may terminate agreement response material breach party janssen rd ireland entered license collaboration agreement janssen rd ireland janssen formerly tibotec pharmaceuticals develop commercialize fixeddose combination truvada janssen 's nonnucleoside reverse transcriptase inhibitor rilpivirine combination approved united states european union sold brand name complera united states eviplera european union agreement janssen granted us exclusive license compleraeviplera worldwide excluding certain middle income developing world countries japan neither party restricted combining drug products drugs accordance terms agreement recorded million approximately million reimbursable research development costs incurred janssen development rilpivirine december responsible manufacturing compleraeviplera lead role registration distribution commercialization product licensed countries janssen exercised right codetail combination product countries gilead selling party amended agreement include distribution compleraeviplera rest world right distribute product north america europe latin america except mexico australia new zealand janssen right distribute product regions including japan russia price product expected sum price truvada price rilpivirine purchased separately cost rilpivirine purchased us janssen compleraeviplera approximately market price rilpivirine less specified percentage major markets either party may terminate collaboration agreement compleraeviplera withdrawn market party materially breaches agreement may terminate agreement united states canada expiration last expire patent tenofovir disoproxil fumarate united states may terminate agreement country expiration last expire patent tenofovir disoproxil fumarate country european union janssen may terminate agreement united states canada expiration last expire patent rilpivirine united states may terminate agreement country expiration last expire patent rilpivirine country european union roche tamiflu entered development license agreement agreement roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped us roche agreement roche exclusive right obligation manufacture sell tamiflu worldwide subject obligation pay us percentage net revenues roche generates tamiflu sales turn subject reduction certain defined manufacturing costs entered first amendment supplement agreement roche amended agreement provided formation joint manufacturing committee review roche 's manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roche 's overall commercial plans tamiflu global basis case consisting representatives roche us amended agreement also option provide specialized sales force supplement roche 's marketing efforts united states tamiflu exercised date agreement roche 's obligation pay royalties us terminate countrybycountry basis patents providing exclusivity tamiflu countries expire roche may terminate agreement reason case rights tamiflu would revert us either party may terminate agreement response material breach party royalties payable us net sales tamiflu sold roche remain amended agreement follows first million worldwide net sales given calendar year b next million worldwide net sales calendar year c worldwide net sales excess million calendar year amended agreement revised provision agreement relating calculation royalty payments given calendar quarter roche pay royalties based actual royalty rates applicable quarter addition amended agreement royalties payable roche us longer subject cost goods sold adjustment provided agreement recorded tamiflu royalties totaling million million million ranexa result acquisition cv therapeutics assumed rights agreement cv therapeutics roche exclusive worldwide license ranexa license agreement paid initial license fee obligated make certain payments roche upon receipt first second product approvals ranexa following major market countries france germany italy united states united kingdom received fda approval ranexa treatment chronic angina paid million roche accordance agreement received marketing authorization european medicines agency ema ranexa treatment chronic angina european union member states paid million roche related approval amount capitalized longterm asset consolidated balance sheet amortized useful us patent life approximately years expiring entered amendment agreement roche related ranexa amendment provided us exclusive worldwide commercial rights ranexa potential indications humans terms amendment made upfront payment roche obligated make royalty payments roche worldwide net product sales licensed products addition obligated make additional milestone payments upon achievement certain regulatory approvals debt credit facility financing arrangements following table summarizes carrying amount borrowings various financing arrangements thousands interest december type borrowing description issue date due date rate convertible senior may notes april may convertible senior may notes july may convertible senior may notes july may senior unsecured april notes march april senior unsecured december notes december december senior unsecured december notes december december senior unsecured december notes december december senior unsecured december notes december december credit facility fiveyear revolver january january variable total debt net less current portion total longterm debt net may convertible senior notes april issued million may notes private placement pursuant rule securities act amended portion may notes converted may remainder matured repaid aggregate principal balance million million also paid million cash million related conversion spread may notes represents conversion value excess principal amount received million cash million convertible note hedges related may notes warrants related may notes expired august paid billion settle warrants average market price common stock exceeded warrants ' exercise price may notes issued par bore interest rate debt issuance costs million recorded longterm assets amortized interest expense contractual term may notes initial conversion rate may notes shares per principal amount represents initial conversion price approximately per share conversion rate subject customary antidilution adjustments prior maturity may notes convertible subject adjustment following circumstances calendar quarter beginning september closing price common stock least trading days last consecutive trading day period previous quarter applicable conversion price per share made specified distributions holders common stock specified corporate transactions occur last month prior maturity applicable notes upon conversion holder received amount cash equal lesser principal amount note ii conversion value note conversion value exceeded principal amount also delivered option cash common stock combination cash common stock conversion value excess principal amount december may notes classified current given maturity date conversion criteria discussed met related unamortized discount million classified equity component currently redeemable convertible notes december consolidated balance sheet may notes converted connection change control could required provide make whole premium form increase conversion rate subject stated maximum amount addition event change control holders could required us purchase portion notes purchase price equal principal amount plus accrued unpaid interest concurrent issuance may notes purchased convertible note hedges private transactions cost million tax deductible life notes also sold warrants private transactions acquire million shares common stock strike price per share received net proceeds million sale warrants convertible note hedges warrants intended reduce potential economic dilution upon future conversions notes effectively increasing conversion price per share may notes net cost million convertible note hedge warrant transactions recorded stockholders ' equity consolidated balance sheets addition contracts classified stockholders equity indexed common stock accounted derivatives convertible note hedges cover subject customary antidilution adjustments million shares common stock strike prices initially correspond initial conversion price may notes subject adjustments similar applicable conversion price related notes market value per share common stock time conversion may notes strike price applicable convertible note hedges would entitled receive counterparties transactions shares common stock extent made corresponding election respect related convertible notes cash combination cash shares common stock option excess market value common stock strike price convertible note hedges convertible note hedges would terminated upon maturity may notes none may notes remained outstanding due conversion otherwise million shares common stock underlying warrants subject customary antidilution adjustments warrants strike price per share exercisable expiration dates market value common stock time exercise applicable warrants exceeded strike prices would required net settle cash shares common stock option counterparties value warrants excess warrant strike prices contemporaneously closing sale may notes portion net proceeds notes issuance proceeds warrant transactions used repurchase shares common stock current accounting guidance bifurcated conversion option may notes debt instrument classified conversion option equity accreted resulting debt discount interest expense contractual terms may notes following table summarizes information equity liability components may notes thousands carrying value net carrying amount unamortized discount equity component liability component liability component december december december may convertible senior notes recognized million million million interest expense related contractual coupon rates amortization debt discount issuance costs may notes effective interest rate liability component may notes may convertible senior notes july issued billion may notes billion may notes private placement pursuant rule securities act amended portion may notes may notes converted repaid billion principal balance primarily comprised may notes also paid billion cash related conversion spread notes represents conversion value excess principal amount received billion cash convertible note hedges related notes may notes may notes issued par bear interest rates respectively debt issuance costs million recorded longterm assets amortized interest expense contractual terms may notes may notes aggregate principal amount may notes may notes sold reflects full exercise initial purchasers option purchase additional notes cover overallotments initial conversion rate may notes shares per principal amount represents initial conversion price approximately per share initial conversion rate may notes shares per principal amount represents initial conversion price approximately per share conversion rates subject customary antidilution adjustments may notes may notes may converted prior april april respectively following circumstances calendar quarter commencing september closing price common stock least trading days whether consecutive period consecutive trading days ending last trading day preceding calendar quarter greater applicable conversion price applicable trading day five business day period measurement period ten consecutive trading days trading day period trading price per principal amount notes less product last reported sale price common stock applicable conversion rate trading day upon occurrence specified corporate transactions distribution certain stock rights cash amounts assets shareholders occurrence change control april case may notes april case may notes holders may convert notes time regardless foregoing circumstances generally upon conversion holder would receive amount cash equal lesser principal amount note ii conversion value note measured indenture governing relevant notes conversion value exceeds principal amount may also deliver option cash common stock combination cash common stock conversion value excess principal amount december may notes classified current given maturity date may notes classified current given conversion criteria discussed met result related unamortized discount million classified equity component currently redeemable convertible notes consolidated balance sheet may notes may notes converted connection change control may required provide make whole premium form increase conversion rate subject stated maximum amount addition event change control holders may require us purchase portion notes purchase price equal principal amount plus accrued unpaid interest december ifconverted value may notes may notes would exceed principal amounts notes million billion respectively concurrent issuance may notes may notes purchased convertible note hedges private transactions cost million tax deductible life notes also sold warrants private transactions acquire million shares common stock received net proceeds million sale warrants convertible note hedges warrants intended reduce potential economic dilution upon future conversions may notes may notes effectively increasing conversion price per share may notes per share may notes net cost million convertible note hedge warrant transactions recorded stockholders ' equity consolidated balance sheets addition contracts classified stockholders equity indexed common stock accounted derivatives convertible note hedges cover subject customary antidilution adjustments million shares common stock strike prices initially correspond initial conversion prices may notes may notes subject adjustments similar applicable conversion price related notes market value per share common stock time conversion may notes may notes strike price applicable convertible note hedges entitled receive counterparties transactions shares common stock extent made corresponding election respect related convertible notes cash combination cash shares common stock option excess market value common stock strike price convertible note hedges convertible note hedges terminate upon maturity may notes may notes none may notes may notes remain outstanding due conversion otherwise million shares common stock underlying warrants subject customary antidilution adjustments warrants strike prices per share warrants expiring per share warrants expiring exercisable respective expiration dates market value common stock time exercise applicable warrants exceeds respective strike prices required net settle cash shares common stock option respective counterparties value warrants excess warrant strike prices used net proceeds issuance convertible notes repurchase shares common stock repay existing indebtedness current accounting guidance bifurcated conversion option may notes may notes debt instrument classified conversion option equity accreting resulting debt discount interest expense contractual terms may notes may notes following table summarizes information equity liability components may notes may notes thousands carrying value net carrying amount unamortized discount equity component liability component liability component december december december may convertible senior notes may convertible senior notes total may convertible senior notes recognized million million million interest expense related contractual coupon rates amortization debt discount issuance costs may notes may notes effective interest rate liability components may notes may notes respectively april senior unsecured notes march issued april notes registered offering aggregate principal amount billion april notes mature april pay interest fixed annual rate debt issuance costs incurred connection issuance debt totaled approximately million amortized interest expense contractual term april notes recognized million million million interest expense related contractual coupon rates amortization debt discount issuance costs april notes april notes may redeemed option time time time redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus basis points plus case accrued unpaid interest notes redeemed date redemption time january may redeem notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption addition event occurrence change control downgrade rating april notes investment grade rating standard poor 's ratings services moody 's investors service inc holders may require us purchase portion notes price equal principal amount plus accrued unpaid interest used net proceeds general corporate purposes include repayment existing indebtedness repurchases common stock december senior unsecured notes december issued december notes december notes december notes december notes december notes registered offering million million billion billion respectively aggregate principal amount billion notes mature december pay interest fixed annual rates respectively debt issuance costs incurred connection issuance debt totaled approximately million amortized interest expense contractual term respective notes recognized million million million interest expense related contractual coupon rates amortization debt discount issuance costs december notes notes may redeemed option time time time redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus basis points case december notes december notes basis points case december notes december notes plus case accrued unpaid interest notes redeemed date redemption time date three months prior maturity date december notes may redeem notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption time date six months prior maturity date december notes may redeem notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption event occurrence change control downgrade rating series notes investment grade rating standard poor 's ratings services moody 's investors service inc holders series notes may require us purchase portion notes series price equal aggregate principal amount notes repurchased plus accrued unpaid interest used net proceeds fund acquisition pharmasset completed january see note credit facilities january conjunction acquisition pharmasset entered fiveyear billion revolving credit facility credit agreement five year revolving credit agreement million shortterm revolving credit facility credit agreement shortterm revolving credit agreement billion term loan facility term loan credit agreement borrowed million fiveyear revolving credit agreement million shortterm revolving credit agreement billion term loan credit agreement upon close acquisition fully repaid outstanding debt term loan credit agreement shortterm revolving credit agreement time agreements terminated repaid million fiveyear revolving credit agreement fiveyear revolving credit agreement contains customary representations warranties affirmative negative financial maintenance covenants events default loan bears interest either eurodollar rate plus applicable margin ii base rate plus applicable margin defined credit agreement may reduce commitments may prepay loan whole part time without premium penalty required comply certain covenants credit agreement notes indentures december compliance covenants fiveyear revolving credit agreement inclusive million swing line loan subfacility million letter credit subfacility december million letters credit outstanding fiveyear revolving credit agreement fiveyear revolving credit agreement terminate amounts owed agreement shall due payable january contractual maturities financing obligations based contractual due dates aggregate maturities financing obligations due subsequent december follows thousands maturity date amount total commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities lease facilities foster city fremont palo alto san dimas california branford connecticut seattle washington dublin cork areas ireland london area united kingdom also operating leases sales marketing administrative facilities europe canada asiapacific leases expire various dates many leases containing options renew certain facility leases also contain rent escalation clauses significant lease related facility seattle washington expires year term lease provides us three consecutive rights extend term lease contains annual three percent rent escalation clause lease also requires us pay additional amounts operating expenses maintenance also leases four corporate aircraft varying terms renewal options upon expiration lease terms lease expense operating leases approximately million million million aggregate noncancelable future minimum rental payments operating leases follows thousands thereafter total legal proceedings department justice investigation june received subpoena us attorney 's office northern district california requesting documents related manufacture related quality distribution practices atripla emtriva hepsera letairis truvada viread complera cooperating continue cooperate governmental inquiry estimate possible loss range losses determined litigation generic manufacturers part approval process products fda granted new chemical entity nce exclusivity period manufacturers ' applications approval generic versions product approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drugs abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug received notices generic manufacturers submitted andas manufacture generic version atripla truvada viread emtriva ranexa tamiflu united states atripla truvada viread canada april teva pharmaceuticals teva reached agreement settle ongoing patent litigation concerning four patents protect tenofovir disoproxil fumarate atripla truvada viread products agreement teva allowed launch generic version viread december august lupin limited lupin reached agreement settle patent litigation concerning ten patents protect ranexa agreement lupin would allowed launch generic version ranexa february february teva reached agreement principle settle ongoing patent litigation concerning emtricitabine patents protect atripla truvada terms settlement agreement confidential settlement agreement filed federal trade commission department justice required law also august teva filed impeachment action federal court canada seeking invalidation two canadian patents associated viread september hearing consolidated requests orders prohibition connection three tevas ands filings tevas generic versions viread truvada atripla took place december court issued requested order prohibiting canadian ministry health issuing notice compliance tevas generic versions viread truvada atripla products expiry patent july teva appealed decision decision court ultimately resolve validity challenges raised teva impeachment action teva successful invalidating patents teva may able launch generic versions viread truvada atripla products prior expiry patents trial impeachment action scheduled january anticipate trials related lupin 's andas requesting permission make generic version truvada viread cipla 's anda requesting permission make generic versions emtriva viread take place fourth quarter predict ultimate outcome actions may spend significant resources enforcing defending patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection atripla truvada viread emtriva ranexa tamiflu united states atripla truvada viread canada could substantially shortened patents covering one products invalidated fda canadian minister health could approve requests manufacture generic version products united states canada respectively prior expiration date patents sale generic versions products earlier patent expiration would significant negative effect revenues results operations litigation related sofosbuvir january acquired pharmasset acquisition acquired sofosbuvir nucleotide analog acts inhibit replication hcv december received fda approval sofosbuvir brandnamed sovaldi received number contractual intellectual property claims regarding sofosbuvir carefully considered claims prior following acquisition believe without merit contract arbitration jeremy clark march jeremy clark former employee pharmasset inventor us patent patent filed demand arbitration lawsuit pharmasset dr raymond schinazi mr clark initially filed lawsuit pharmasset dr schinazi us district court northern district alabama february seeking void assignment provision employment agreement assert ownership us patent patent claims metabolites sofosbuvir rg december court ordered stay litigation pending outcome arbitration proceeding required mr clark 's employment agreement instead proceeding arbitration mr clark filed two additional lawsuits september june court subsequently dismissed september mr clark filed motion seeking reconsideration court 's december order court denied december mr clark filed motion appoint special prosecutor february court issued order requiring mr clark enter arbitration risk dismissal case mr clark filed demand arbitration march arbitration panel held hearing april june arbitration panel issued decision favor pharmasset gilead dr schinazi august gilead dr schinazi filed motion us district court northern district alabama seeking court confirm arbitration decision mr clark filed motion seeking vacate arbitration decision court yet ruled motions arbitration f hoffmanla roche ltd hoffmanla roche inc collectively roche gilead successor pharmasset party october collaboration agreement roche agreement granted roche rights develop psi cytidine analog prodrugs treatment hcv infection collaborative research efforts agreement ended december roche later asked pharmasset consider whether roche may contributed inventorship sofosbuvir whether pharmasset complied confidentiality provisions collaboration agreement pharmasset advised us carefully considered issues raised roche believed issues without merit also considered issues reached conclusion march roche initiated arbitration us pharmasset predecessor gilead pharmasset llc regarding collaboration agreement arbitration demand roche asserts exclusive license sofosbuvir pursuant collaboration agreement sofosbuvir prodrug uridine monophosphate analog allegedly prodrug psi cytidine analog roche claims exclusive rights sofosbuvir also exclusive license patent covering sofosbuvir infringe patent selling offering sale products containing sofosbuvir gilead gilead pharmasset llc filed response roche 's arbitration demand april interference proceedings litigation idenix pharmaceuticals inc february received notice us patent trademark office uspto declared interference first idenix interference us patent patent idenix pharmaceuticals inc 's idenix pending us patent application interference administrative proceeding uspto designed determine first invent subject matter claimed parties patent covers metabolites sofosbuvir rg prodrug cytidine nucleoside analog pharmasset licensed roche idenix attempting patent class compounds including metabolites purpose first idenix interference determine first invent compounds therefore entitled patent claiming compounds march uspto patent trials appeal board board determined idenix entitled benefit early application filing dates none patent applications including application led idenixs us patent patent patent taught make compounds dispute board also determined entitled filing date earliest application first file patent application compounds dispute therefore senior party first idenix interference january board determined pharmasset idenix first invent compounds dispute accordingly gilead prevailed decision board held idenix failed prove first conceive compounds dispute specifically idenix failed prove idenix inventors identified structure method making use disputed compounds board went conclude idenix failed work diligently toward making testing compounds dispute relevant time period idenix appealed boards decisions us district court district delaware either boards decisions reversed appeal court determines idenix entitled patent claims determined infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg united states decision district court appealed either party us court appeals federal circuit cafcwe believe claims idenix application involved first idenix interference similar us foreign patents claiming compounds metabolites invalid result filed impeachment action federal court canada invalidate idenix canadian patent canadian patent corresponds patent idenix patent application subject first idenix interference idenix asserted canadian patent corresponding us patent patent first idenix interference invalid filed similar legal action norway oslo district court seeking invalidate idenix 's corresponding norwegian patent september idenix filed invalidation action norwegian proceedings norwegian patent patent corresponds us patent patent trial held november court yet issued decision august idenix also filed request invalidation chinese patent office chinese patent cn zl corresponds us patent patent filed legal action federal court australia seeking invalidate idenixs australian patent corresponding patent april idenix asserted commercialization sofosbuvir infringe australian patent corresponding patent may bring similar action countries future idenix awarded patents compounds european patent office japan china event patents issue expect challenge proceedings similar invoked canada norway australia courts hearing proceedings determine idenix entitled patent claims determined infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg country december receiving gileads request uspto declared interference second idenix interference pending us patent application patent patent includes claims directed methods treating hcv nucleoside compounds similar involved first idenix interference second idenix interference determine first invent claimed methods treating hcv declaration second idenix interference uspto initially designated gilead junior party based upon patent application filing dates appearing face patent february uspto issued order show cause idenix second idenix interference order requires idenix explain judgment entered second idenix interference favor gilead based upon outcome first idenix interference order indicates claims patent involved second idenix interference unpatentable due gilead prevailing first idenix interference idenix allowed claim benefit filing date earlier filed patent applications believe boards determination first idenix interference idenix entitled benefit earlier application filing dates including filing date patent equally applicable second idenix interference correct board may conclude gilead senior party second idenix interference consistent determination first idenix interference light boards conclusion first idenix interference application led patent teach make claimed compounds possible board make determination second idenix interference eliminate need board address first invent claimed methods treating hcv however board consider first invent claimed methods treating hcv ultimately concludes gilead first claims ' patent may revoked board determines idenix first invent entitled patent claims determined proceedings infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg determination board appealed either party us federal court december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sued us us district court district delaware alleging commercialization sofosbuvir infringe patent interference exists patent us patent patent believe claims patent invalid sole right commercialize sofosbuvir however court disagrees view determines patent infringed may required obtain license pay royalties idenix commercialize sofosbuvir decision district court appealed either party cafc also december idenix udsg sued us us district court district massachusetts alleging commercialization sofosbuvir infringe us patent nos patents believe idenixs patents invalid would infringed commercialization sofosbuvir sole right commercialize sofosbuvir however court disagrees view determines patents infringed may required obtain license pay royalties idenix commercialize sofosbuvir decision district court appealed either party cafc expansive patent portfolio covering nsa inhibitors treatment hcv following recent disclosure structure idenixs nsa inhibitor samatasvir also known idx evaluating compound light pending claims us patent application litigation merck co inc august merck co inc merck contacted us requesting pay royalties sales sofosbuvir take license us patent patent us patent patent coowns isis pharmaceuticals inc believe mercks patents invalid would infringed commercialization sofosbuvir sole right commercialize sofosbuvir accordingly august filed lawsuit us district court northern district california seeking declaratory judgment merck patents invalid infringed mercks us patent nos patents cover compounds include may relate sofosbuvir patent prosecution merck amended patent application attempt cover compounds related sofosbuvir ultimately extract royalty payments sofosbuvirs commercialization exclude market court determines mercks patents valid infringed claims may required obtain license pay royalties merck commercialize sofosbuvir either party appeal decision district court cafc litigation abbvie inc abbvie abbvie recently obtained us patent nos patents purport claim use combination ldvsof treatment hcv published pending patent applications directed use combinations treatment hcv specifically combinations ledipasvir sofosbuvir certain applications filed abbvie 's recently issued patents reason others believe abbvie 's patents invalid accordingly december filed lawsuit us district court district delaware seeking declaratory judgment abbvie patents invalid unenforceable well relief believe abbott laboratories inc abbvie conspired eliminate competition hcv market falsely representing pto gilead invented methods treating hcv using combination ldvsof february abbvie responded lawsuit filing lawsuit also us district court district delaware alleging ldvsof product infringe patents expect abbvie 's patents block delay commercialization combination products court determines abbvies patents valid infringed claims may required obtain license pay royalties abbvie commercialize sofosbuvir combination products either party appeal decision district court cafc predict ultimate outcome actions may spend significant resources enforcing defending patents parties successfully obtain valid enforceable patents successfully prove infringement patents sofosbuvir could prevented selling sofosbuvir unless able obtain license patents license may available commercially reasonable terms party successful establishing exclusive rights sofosbuvir expected revenues earnings sale sofosbuvir would adversely affected range losses estimated time matters party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations commitments normal course business enter various firm purchase commitments primarily related active pharmaceutical ingredients certain inventory related items december commitments next five years approximately billion million million million million amounts related active pharmaceutical ingredients represent minimum purchase requirements actual payments purchases related active pharmaceutical ingredients billion billion billion stockholders ' equity stock repurchase programs may board authorized threeyear billion stock repurchase program completed program september january board authorized another threeyear billion stock repurchase program initiated purchases program september upon completion may stock repurchase program december repurchased million common stock january stock repurchase program remaining authorized amount stock repurchases may made plan billion spent total billion repurchase retire million shares common stock average purchase price per share december repurchased billion common stock january stock repurchase program remaining authorized amount stock repurchases may made plan billion spent total million repurchase retire million shares common stock average purchase price per share december repurchased billion common stock january stock repurchase program remaining authorized amount stock repurchases may made plan billion spent total million repurchase retire million shares common stock average purchase price per share use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated apic based estimated average sales price per issued share excess amounts charged retained earnings addition repurchases stock repurchase program repurchased shares common stock withheld us employee restricted stock awards satisfy applicable tax withholding obligations following table summarizes reduction common stock apic charge retained earnings result stock repurchases thousands year ended december reduction common stock apic charge retained earnings preferred stock million shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series preferred stock outstanding december rights plan september terminated rights plan accumulated comprehensive income following table summarizes changes accumulated oci component net tax thousands unrealized gains unrealized gains foreign losses available losses cash currency items forsale securities flow hedges total balance december comprehensive income loss reclassifications amounts reclassified accumulated comprehensive income net current period comprehensive income loss balance december amounts reclassified gains losses cash flow hedges recorded part product sales consolidated statements income amounts reclassified unrealized gains losses availableforsale securities recorded part income expense net consolidated statements income equity incentive plan may stockholders approved adopted gilead sciences inc equity incentive plan plan replaced existing equity plans prior plans remaining shares available future grants prior plans transferred plan additionally awards granted prior plans expire otherwise terminate without exercised shares common stock reserved awards added back pool available shares common stock plan plan broad based incentive plan provides grant equitybased awards including stock options restricted stock units restricted stock awards performance awards employees directors consultants plan authorized issue maximum million shares fullvalue awards restricted stock restricted stock units performance shares performance units extent settled common stock phantom shares term plan plan authorizes issuance total million shares common stock december total million shares remain available future grant plan stock options plan provides option grants designated either nonqualified incentive stock options prior january granted nonqualified incentive stock options stock options granted january nonqualified stock options plan employee stock options granted prior generally vest five years stock options granted starting generally vest four years options exercisable period exceed contractual term ten years date stock options issued granted prices less fair market value common stock grant date stock option exercises settled common stock plan 's previously authorized available pool shares connection acquisition arresto assumed arresto equity incentive plan arresto plan options issued outstanding arresto plan converted options purchase common stock effective january number converted options purchase common stock significant shares available future grant arresto plan following table summarizes activity related information stock option plans option grants presented table exercise prices less fair value underlying common stock grant date shares aggregate intrinsic value thousands weightedaverage weighted remaining average contractual term aggregate intrinsic shares exercise price years value outstanding december granted assumed forfeited expired exercised outstanding december exercisable december expected vest net estimated forfeitures december aggregate intrinsic value represents value company 's closing stock price last trading day period excess weightedaverage exercise price multiplied number options outstanding exercisable total intrinsic value options exercised million million million weightedaverage grant date fair values stock options granted per share per share per share december million unrecognized compensation cost related stock options expected recognized estimated weightedaverage period years performance awards plan grant performancebased restricted stock units vest upon achievement specified market performance goals could include achieving total shareholder return compared predetermined peer group achieving revenue targets actual number common shares ultimately issued calculated multiplying number performance units payout percentage ranging awards generally vest committee subcommittee board determined specified market performance goals achieved approval committee generally obtained within three year period fair value performance share estimated date grant performance objectives defined grants depending terms award fair value date grant determined based either monte carlo valuation methodology stock price date grant addition also granted performancebased restricted stock awards certain employees plan vesting awards subject achievement specified individual performance goals typically within one year period fair value award equal closing price common stock grant date following table summarizes activity related information performance awards thousands except per share amounts weightedaverage grantdate shares fair value per share outstanding december granted vested forfeited outstanding december weightedaverage grantdate fair value per share excludes shares related grants currently grantdate fair value performance objectives yet defined weightedaverage grant date fair values performance awards granted per share per share per share total fair value performance awards vested million million million recognized stockbased compensation expenses million million million related performance awards december million unrecognized compensation costs related performance awards expected recognized estimated weightedaverage period years restricted stock units grant timebased restricted stock units rsus certain employees part annual employee equity compensation review program well new hire employees nonemployee members board rsus share awards entitle holder receive freely tradable shares common stock upon vesting awards granted prior rsus vest ratably annual basis five years date grant starting january rsus vest four years date grant fair value rsu equal closing price common stock grant date following table summarizes rsu activities related information thousands except per share amounts weightedaverage grantdate shares fair value per share outstanding december granted assumed vested forfeited outstanding december weightedaverage grant date fair values rsus granted per share per share per share total fair value rsus vested million million million december million unrecognized compensation cost related unvested rsus expected recognized weightedaverage period years employee stock purchase plan employee stock purchase plan amended international employee stock purchase plan together espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair market value common stock offering date purchase date espp offers twoyear lookback feature well automatic reset feature provides offering period reset new lowerpriced offering offering price new offering period less current offering period espp purchases settled common stock espp 's previously authorized available pool shares million shares issued espp million total million shares common stock reserved issuance espp million shares available issuance espp december december million unrecognized compensation cost related espp expected recognized estimated weightedaverage period years stockbased compensation following table summarizes stockbased compensation expenses included consolidated statements income thousands year ended december cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense net tax capitalized stockbased compensation costs inventory totaling million million million capitalized stock based compensation costs remaining inventory million december million december million december total stockbased compensation year ended december included million million rd sga expenses respectively related acceleration unvested stock options connection acquisition pharmasset closed first quarter stockbased compensation recognized expense requisite service periods consolidated statements income using graded vesting expense attribution approach unvested stock options granted prior january using straightline expense attribution approach stock options granted adoption new guidance sharebased payments employees directors january stockbased compensation expenses related stock options recognized adoption new guidance based awards ultimately expected vest gross expense reduced estimated forfeitures guidance requires forfeitures estimated time grant revised necessary subsequent periods actual forfeitures differ estimates estimated forfeitures based historical experience prior adoption guidance pro forma information required disclosed included forfeitures occurred result guidance adopted january recognize tax benefit stockbased compensation apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statements income rather apic valuation assumptions fair values options granted plan purchases espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life used following assumptions calculate estimated fair value awards year ended december expected volatility stock options espp expected term years stock options espp riskfree interest rate stock options espp expected dividend yield fair value stock options granted calculated using single option approach use blend historical volatility along implied volatility traded options common stock determine expected volatility expected term stockbased awards represents weightedaverage period awards expected remain outstanding estimate weightedaverage expected term based historical cancellation historical exercise data related stock options well contractual term vesting terms awards riskfree interest rate based upon observed interest rates appropriate term stockbased awards dividend yield based history expectation dividend payouts net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding period diluted net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding dilutive securities outstanding period potential dilutive shares common stock resulting assumed exercise outstanding stock options performance shares assumed exercise warrants relating convertible senior notes due may may notes may notes may notes may notes determined treasury stock method principal amount convertible notes settled cash conversion spread relating convertible notes included calculation diluted net income per share attributable gilead common stockholders common stock resulting assumed settlement conversion spread convertible notes dilutive effect average market price common stock period exceeds conversion price may notes may notes warrants relating convertible notes dilutive effect average market price common stock period exceeds warrants ' exercise price may notes may notes may notes may notes matured result included impact periods outstanding net income per share calculations common stock resulting assumed settlement conversion spread may notes may notes dilutive effect average market price common stock period exceeded conversion price may notes may notes warrants related may notes may notes settled result included impact period outstanding net income per share calculations related warrants dilutive effect average market price common stock period exceeded warrants ' exercise price may notes may notes average market price common stock exceed exercise price warrants related may notes therefore warrants dilutive effect net income per share period excluded stock options purchase approximately million weightedaverage shares common stock outstanding million weightedaverage shares million weightedaverage shares computation diluted net income per share attributable gilead common stockholders effect antidilutive following table reconciliation numerator denominator used calculation basic diluted net income per share attributable gilead common stockholders thousands year ended december numerator net income attributable gilead denominator weightedaverage shares common stock outstanding used calculation basic net income per share attributable gilead common stockholders effect dilutive securities stock options equivalents conversion spread related may notes conversion spread related may notes conversion spread related may notes conversion spread related may notes warrants related convertible notes weightedaverage shares common stock outstanding used calculation diluted net income per share attributable gilead common stockholders net income per share attributable gilead common stockholdersbasic net income per share attributable gilead common stockholdersdiluted segment information product sales operate one business segment primarily focuses discovery development commercialization innovative medicines areas unmet medical need products included one segment majority products similar economic characteristics including nature products production processes type customers distribution methods regulatory environment product sales consist following thousands year ended december antiviral products atripla truvada viread compleraeviplera stribild sovaldi hepsera emtriva total antiviral products letairis ranexa ambisome products total product sales following table summarizes total revenues external customers collaboration partners geographic region thousands product sales productrelated contract revenue attributed regions based shipto location royalty nonproduct related contract revenue attributed regions based location collaboration partner year ended december revenues united states europe countries total revenues following table summarizes revenues customers individually accounted total revenues percentage total revenues year ended december cardinal health inc mckesson corp amerisourcebergen corp property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprised approximately total net book value property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprised approximately total net book value property plant equipment income taxes provision income taxes consists following thousands year ended december federal current deferred state current deferred foreign current deferred provision income taxes foreign pretax income million million billion cumulative unremitted foreign earnings considered indefinitely reinvested foreign subsidiaries us taxes provided approximately billion december billion december residual us tax liability amounts remitted would approximately billion december billion december difference provision income taxes amount computed applying us federal statutory income tax rate income provision income taxes follows thousands year ended december income provision income taxes tax federal statutory rate state taxes net federal benefit foreign earnings different rates research credits net unbenefitted stock compensation nondeductible pharmaceutical excise tax provision income taxes deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities follows thousands december deferred tax assets net operating loss carryforwards stockbased compensation reserves accruals currently deductible deferred revenue depreciation related research credit carryforwards net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities intangibles unremitted foreign earnings total deferred tax liabilities net deferred tax assets valuation allowance decreased million year ended december valuation allowance increased million year ended december decreased million year ended december concluded based standard set forth fasb accounting standards codification related income taxes likely realize benefit deferred tax assets related certain state net operating loss credit carryforwards december us federal net operating loss carryforwards approximately million federal net operating loss carryforwards start expire utilized also federal tax credit carryforwards approximately million start expire utilized addition state net operating loss tax credit carryforwards approximately billion million respectively state net operating loss tax credit carryforwards start expire utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses credits utilization file federal state foreign income tax returns many jurisdictions united states abroad federal income tax purposes statute limitations open onwards certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years california income tax purposes statute limitations open onwards income tax returns audited federal state foreign tax authorities currently examination internal revenue service irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions total federal state foreign unrecognized tax benefits million december million december total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition continued classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements income accrued interest penalties related unrecognized tax benefits million december million december december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification irs tax authorities regarding uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective tax authorities following rollforward total gross unrecognized tax benefit liabilities years ended december thousands december balance beginning period tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations balance end period deferred compensation plans united states maintain retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code gilead plan gilead plan employees may contribute eligible annual compensation subject irs plan limits make matching contributions gilead plan contributed employee 's contributions annual maximum match certain foreign subsidiaries maintain defined benefit plans required local regulatory requirements may deposit funds plans insurance companies third party trustees governmentmanaged accounts consistent local regulatory requirements applicable total matching contribution expense gilead plan defined benefit plans million million million maintain deferred compensation plan directors key employees may defer compensation income tax purposes deferred compensation plan nonqualified deferred compensation plan subject qualification requirements section internal revenue code compensation deferred december subject requirements section internal revenue code plan officers us senior level employees may contribute annual salaries annual bonus commissions directors may contribute annual retainer fee effective nonemployee board members may also defer rsu awards amounts deferred participants deposited rabbi trust corresponding plan assets recorded longterm assets corresponding plan liabilities recorded longterm obligations consolidated balance sheets beginning nonemployee board members could also elect receive portion annual cash retainer phantom shares gives participant right receive amount equal value specified number shares specified period time payable shares common stock fractional shares paid cash established plan administrator december phantom shares outstanding participants elect one several distribution dates events available plan receive deferred compensation payment quarterly results operations unaudited following amounts thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholdersbasic net income per share attributable gilead common stockholdersdiluted total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholdersbasic net income per share attributable gilead common stockholdersdiluted gilead sciences inc schedule ii valuation qualifying accounts thousands balance beginning additionscharged balance end period expense deductions period year ended december accounts receivable allowances valuation allowances deferred tax assets year ended december accounts receivable allowances valuation allowances deferred tax assets year ended december accounts receivable allowances valuation allowances deferred tax assets allowances doubtful accounts sales returns cash discounts government chargebacks valuation allowance deferred tax assets includes million million december respectively related acquisitions